

Bibliography

1. Scientific full-length international papers

Online publications ahead of publication

807. Kroon FPB, Damman W, Liu R, Bijsterbosch J, Meulenbelt I, [van der Heijde D](#), Kloppenburg M. Validity, reliability, responsiveness and feasibility of four hand mobility measures in hand osteoarthritis. *Rheumatology (Oxford)*. 2017 Dec 14. doi: 10.1093/rheumatology/kex438. [Epub ahead of print]

806. [van der Heijde D](#), Gladman DD, Kishimoto M, Okada M, Rathmann SS, Moriarty SR, Shuler CL, Carlier H, Benichou O, Mease PJ. Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1). *J Rheumatol*. 2017 Dec 15. pii: jrheum.170429. doi: 10.3899/jrheum.170429. [Epub ahead of print]

805. van Lunteren M, Ez-Zaitouni Z, Fongen C, Landewé R, Ramonda R, [van der Heijde D](#), van Gaalen FA. Disease activity decrease is associated with improvement in work productivity over 1 year in early axial spondyloarthritis (SPondyloArthritis Caught Early cohort). *Rheumatology (Oxford)*. 2017 Dec 1;56(12):2222-2228. doi: 10.1093/rheumatology/kex365.

804. Fernandes S, Etcheto A, [van der Heijde D](#), Landewé R, van den Bosch F, Dougados M, Moltó A. Vitamin D status in spondyloarthritis: results of the ASAS-COMOSPA international study. *Clin Exp Rheumatol*. 2017 Nov 16. [Epub ahead of print]

803. Bautista-Molano W, Landewé R, Burgos-Vargas R, Maldonado-Cocco J, Moltó A, van den Bosch F, Valle-Oñate R, Dougados M, [van der Heijde D](#). Prevalence of Comorbidities and Risk Factors for Comorbidities in Patients with Spondyloarthritis in Latin America: A Comparative Study with the General Population and Data from the ASAS-COMOSPA Study. DOI: 10.3899/jrheum.170520

802. Nikiphorou E, Ramiro S, [van der Heijde D](#), Norton S, Moltó A, Dougados M, van den Bosch F, Landewé R; ASAS-COMOSPA Task Force. Comorbidities in Spondyloarthritis associate with poor function, work disability and quality of life: Results from the ASAS-COMOSPA study. *Arthritis Care Res (Hoboken)*. 2017 Nov 10. doi: 10.1002/acr.23468. [Epub ahead of print]

801. Charles-Schoeman C, [van der Heijde D](#), Burmester GR, Nash P, Zerbini CAF, Connell CA, Fan H, Kwok K, Bananis E, Fleischmann R. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies. *J Rheumatology* 2017, jrheum.170486; DOI: <https://doi.org/10.3899/jrheum.170486>

800. [van der Heijde D](#), Landewé R. Should radiographic progression still be used as outcome in RA? *Clin Immunology* 2017 <https://doi.org/10.1016/j.clim.2017.07.022>

799. Winthrop KL, Strand V, [van der Heijde D](#), Mease P, Crow M, Weinblatt M, Bathon J, Burmester GR, Dougados M, Kay J, Mariette X, van Vollenhoven R, Sieper J, Melchers F, Breedfeld FC, Kalden J, Smolen JS, Furst DE. The unmet need in rheumatology: Reports from the targeted therapies meeting 2017. *Clin Immunol*. 2017 Aug 12. pii: S1521-6616(17)30543-0. doi: 10.1016/j.clim.2017.08.009. [Epub ahead of print]

798. [van der Heijde D](#), Baraliakos X, Hermann K-GA, Landewé RBM, Machado PM, Maksymowych WP, Davies OR, de Peyrecave N, Hoepken B, Bauer L, Nurminen T, Braun J. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. *Ann Rheum Dis* 2018 Online first

2018

797. Nikiphorou E, [van der Heijde D](#), Norton S, Landewé RBM, Molto A, Dougados M, Van den Bosch FE, Ramiro S. Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study. *Ann Rheum Dis* 2018;77:405–11

796. de Bruin F, de Koning A, van den Berg R, Baraliakos X, Braun J, Ramiro S, van Gaalen FA, Reijnders M, [van der Heijde D](#). Development of the CT Syndesmophyte Score (CTSS) in patients with ankylosing spondylitis: data from the SIAS cohort. *Ann Rheum Dis* 2018;77:371–7

795. Dougados M, Maksymowych WP, Landewé RBM, Moltó A, Claudepierre P, de Hooge M, Lambert RG, Bonin R, Bukowski JF, Jones HE, Logeart I, Pedersen R, Szumski A, Vlahos B, [van der Heijde D](#). Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis. *Ann Rheum Dis* 2018;77:221–27

794. de Koning A, de Bruin F, van den Berg R, Ramiro S, Baraliakos X, Braun J, van Gaalen FA, Reijnders M, [van der Heijde D](#). Low-dose CT detects more progression of bone formation in comparison to conventional radiography in patients with ankylosing spondylitis: results from the SIAS cohort. *Ann Rheum Dis* 2018;77:293–99

793. Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DG, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, de Wit M, Aletaha D, Baraliakos X, Betteridge N, van den Bosch F, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, de Vlam K, [van der Heijde D](#). Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. *Ann Rheum Dis* 2018;77:3-17

792. Molnar C, Scherer A, Baraliakos X, de Hooge M, Micheroli R, Exer P, Kissling RO, Tamborrini G, Wildi LM, Nissen MJ, Zufferey P, Bernhard J, Weber U, Landewé RBM, [van der Heijde D](#), Ciurea A. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. *Ann Rheum Dis* 2018;77:63-9

791. Molto A, Gossec L, Meghnathi B, Landewé RBM, [van der Heijde D](#), Atagunduz P, Elzorkany BK, Akkoc N, Kiltz U, Gu, J, Wei JJC, Dougados M. An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS. *Ann Rheum Dis* 2018;77:124-7

2017

790. de Bruin F, ter Horst S, Bloem JL, van den Berg R, de Hooge M, van Gaalen F, Dagfinrud H, van Oosterhout M, Landewé R, van der Heijde D, Reijnders M. Prevalence and clinical significance of lumbosacral transitional vertebra (LSTV) in a young back pain population with suspected axial spondyloarthritis: results of the SpondyloArthritis Caught Early (SPACE) cohort. *Skeletal Radiol* 2017;46:633–9

789. Orbai AM, de Wit M, Mease PJ, Callis Duffin K, Elmamoun M, Tillett W, Campbell W, FitzGerald O, Gladman DD, Goel N, Gossec L, Hoejgaard P, Leung YY, Lindsay C, Strand V, van der Heijde DM, Shea B, Christensen R, Coates L, Eder L, McHugh N, Kalyoncu U, Steinkoenig I, Ogdie A. Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. *J Rheumatol* 2017;44:1522-8

788. Fleischmann RM, [van der Heijde D](#), Gardiner PV, Szumski A, Marshall L, Bananis E. DAS28-CRP and

DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable.
RMD Open 2017;3:e000382

787. Abawi O, van den Berg R, [van der Heijde D](#), van Gaalen FA. Evaluation of multiple referral strategies for axial spondyloarthritis in the SPondyloArthritis Caught Early (SPACE) cohort.
RMD Open 2017;3:e000389

786. [van der Heijde D](#), Dougados M, Landewé R, Sieper J, Maksymowych WP, Rudwaleit M, Van den Bosch F, Braun J, Mease PJ, Kivitz AJ, Walsh J, Davies O, Bauer L, Hoepken B, Peterson L, Deodhar A. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
Rheumatology 2017;56:1498-509

785. de Hooge M, Pialat JB, Reijnierse M, [van der Heijde D](#), Claudepierre P, Saraux A, Dougados M, Feydy A. Assessment of typical SpA lesions on MRI of the spine: do local readers and central readers agree in the DESIR-cohort at baseline?
Clin Rheumatol. 2017 Jul;36(7):1551-1559

784. Ez-Zaitouni Z, Hilkens A, Gossec L, Berg JJ, Landewé R, Ramonda R, Dougados M, [van der Heijde D](#), van Gaalen F. Is the current ASAS expert definition of a positive family history useful in identifying axial spondyloarthritis? Results from the SPACE and DESIR cohorts.
Arthritis Res Ther 2017;19:118

783. Braun J, Baraliakos X, Hermann KG, Landewé R, Machado PM, Maksymowych WP, Davies O, Hoepken B, Nurminen T, Stach C, [van der Heijde D](#). Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis.
RMD Open 2017;3:e000430

782. Mease P, Gottlieb AB, [van der Heijde D](#), FitzGerald O, Johnsen A, Nys M, Banerjee S, Gladman DD. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.
Ann Rheum Dis 2017;76:1550-8

781. Coates LC, Gossec L, Ramiro S, Mease P, [van der Heijde D](#), Smolen JS, Ritchlin C, Kavanaugh A. New GRAPPA and EULAR recommendations for the management of psoriatic arthritis: Process and challenges faced.
Rheumatology 2017;56:1251-3

780. de Hooge M, de Bruin F, de Beer L, Bakker P, van den Berg R, Ramiro S, van Gaalen F, Fagerli K, Landewé R, van Oosterhout M, Ramonda R, Huizinga T, Bloem H, Reijnierse M, [van der Heijde D](#). Is site of back pain related to location of MRI lesion in patients with chronic back pain included in the SPACE-cohort?
Arthritis Care Res 2017;69:717-23

779. Haugen IK, Slatkowsky-Christensen B, Faraj K, [van der Heijde D](#), Kvien TK. The comparison of magnetic resonance imaging and radiographs to assess structural progression over 5 years in hand osteoarthritis.
Rheumatology 2017;56:371-7

778. van Erp S, Ercan E, Breedveld P, Brakenhoff L, Ghariq E, Schmid S, van Osch M, van Buchem M, Emmer B, van der Grond J, Wolterbeek R, Hommes D, Fidder H, van der Wee N, Huizinga T, [van der Heijde D](#), Middelkoop H, Ronen I, van der Meulen-de Jong A. Cerebral magnetic resonance imaging in quiescent Crohn's disease patients with fatigue.
World Journal of Gastroenterology 2017;23:1018-29

777. van Erp SJ, Verheul MK, Levarht EW, van der Reijden JJ, [van der Heijde D](#), van Gaalen FA, Hommes DW, Norman GL, Shums Z, Mahler M, Verspaget HW, Trouw LA, van der Meulen-de Jong AE. Absence of serological rheumatoid arthritis biomarkers in inflammatory bowel disease patients with arthropathies.

776. van Erp SJF, Brakenhoff LKMP, Vollmann M, van der Heijde D, Veenendaal RA, Fidler HH, Hommes DW, Kaptein AA, van der Meulen-de Jong AE, Scharloo M. Illness Perceptions and Outcomes in Patients with Inflammatory Bowel Disease: Is Coping a Mediator?

Int J Behav Med 2017;24:205-14

775. Bautista-Molano W, Landewé RB, Serna C, Valle-Oñate R, van der Heijde D. Factors associated with the decision of the rheumatologist to order sacroiliac joints magnetic resonance imaging (SI-MRI) or HLA-B27 testing in the diagnostic work-up of patients with spondyloarthritis in clinical practice.

Clin Exp Rheumatol. 2017;35:122-8

774. Thomas GP, Willner D, Robinson PC, Cortes A, Duan R, Rudwaleit M, Akkoc N, Braun J, Chou CT, Maksymowych WP, Ozgocmen S, Roussou E, Sieper J, Valle-Oñate R, van der Heijde D, Wei J, Leo P, Brown MA; and the International Genetics of Ankylosing Spondylitis Consortium. Genetic diagnostic profiling in axial spondyloarthritis: a real world study.

Clin Exp Rheumatol. 2017;35:229-33

773. van der Heijde D, Deodhar A, Fleischmann R, Mease PJ, Rudwaleit M, Nurminen T, Davies O. Early Disease Activity or Clinical Response Predict Long-Term Outcomes with Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis.

Arthritis Care Res 2017;69:1030-9

772. Bautista-Molano W, van der Heijde D, Landewé R, Lafaurie GI, de Ávila J, Valle-Oñate R, Romero-Sanchez C. Is there a relationship between spondyloarthritis and periodontitis? A case-control study.

RMD Open 2017;3:e000547

771. Aizenberg E, van den Berg R, Ez-Zaitouni Z, van der Heijde D, Reijnierse M, Dzyubachyk O, Lelieveldt BPF. Computer-aided evaluation of inflammatory changes over time on MRI of the spine in patients with suspected axial spondyloarthritis: a feasibility study.

BMC Medical Imaging 2017;17:55

770. Jonsson MK, Sundlisæter NP, Nordal HH, Hammer HB, Aga AB, Olsen IC, Brokstad KA, van der Heijde D, Kvien TK, Fevang BS, Lillegraven S, Haavardsholm EA. Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis.

Ann Rheum Dis 2017;76:2031-7

769. Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cieślak D, Graham D, Wang C, Menon S, Hendriks T, Kanik KS. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.

N Engl J Med 2017; 377:1537-50

768. Brinkmann GH, Norli ES, Bøyesen P, van der Heijde D, Grøvlø L, Haugen AJ, Nygaard H, Bjørneboe O, Thunem C, Kvien TK, Mjaavatten MD, Lie E. Role of erosions typical of rheumatoid arthritis in the 2010 ACR/EULAR rheumatoid arthritis classification criteria: results from a very early arthritis cohort.

Ann Rheum Dis 2017;76:1911-4

767. Dougados M, Sepriano A, Molto A, van Lunteren M, Ramiro S, de Hooge M, van den Berg R, Navarro Compan V, Demattei C, Landewé R, van der Heijde D. Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort.

Ann Rheum Dis 2017;76:1823-8

766. Dougados M, van der Heijde D, Sieper J, Braun J, Citera G, Lenaerts J, van den Bosch F, Wei JC, Pedersen R, Bonin R, Jones H, Marshall L, Logeart I, Vlahos B, Bukowski JF, Maksymowych WP. Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study.

Arthritis Care Res 2017;69:1590-98

765. Weinblatt ME, Bingham CO III, Burmester G, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van

Vollenhoven R, VanLunen B, Ecoffet C, Cioffi C, Emery P. A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis
Arthritis Rheum 2017;69:1937-48

764. Keystone EC, Breedveld FC, van der Heijde D, van Vollenhoven RF, Emery P, Smolen JS, Sainsbury I, Florentinus S, Kupper H, Chen K, Kavanaugh A. Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone.
RMD Open 2017; 3:e000445, doi:10.1136/rmdopen-2017-000445

763. Ez-Zaitouni Z, Bakker PAC, van Lunteren M, de Hooge M, van den Berg R, Reijnierse M, Fagerli KM, Landewé RBM, Ramonda R, Jacobsson LTH, Saraux A, Lenczner G, Feydy A, Pialat JB, Thévenin F, van Gaalen FA, van der Heijde D. The yield of a positive MRI of the spine as imaging criterion in the ASAS classification criteria for axial spondyloarthritis: results from the SPACE and DESIR cohorts.
Ann Rheum Dis 2017; 76:1731-6

762. Atsumi T, Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Togo O, Okada T, van der Heijde D, Miyasaka N, Koike T. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.
Ann Rheum Dis 2017;76:1348-56

761. van der Heijde D, Deodhar A, Wei JC, Drescher E, Fleishaker D, Hendrikx T, Li D, Menon S, Kanik KS. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.
Ann Rheum Dis 2017;76:1340-7

760. Bakker P, Moltó A, Etcheto A, Van den Bosch F, Landewé R, van Gaalen F, Dougados M, van der Heijde D. The performance of different classification criteria sets for spondyloarthritis in the worldwide ASAS-COMOSPA study.
Arthritis Res Ther 2017;19:96

759. Ez-Zaitouni Z, Bakker PAC, van Lunteren M, Berg IJ, Landewé R, van Oosterhout M, Lorenzin M, van der Heijde D, van Gaalen FA. Presence of multiple spondyloarthritis (SpA) features is important but not sufficient for a diagnosis of axial spondyloarthritis: data from the SPondyloArthritis Caught Early (SPACE) cohort.
Ann Rheum Dis 2017;76:1086-92

758. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgerit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg J-E, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien TK, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
Ann Rheum Dis 2017;76:960-77

757. Nam JL, Takase-Minegishi K, Ramiro S, Chatzidionysiou K, Smolen JS, van der Heijde D, Bijlsma JW, Burmester GR, Dougados M, Scholte-Voshaar M, van Vollenhoven R, Landewé R. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
Ann Rheum Dis 2017;76:1113-36

756. Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, Bijlsma JW, Burmester GR, Scholte-Voshaar M, Falzon L, Landewé RBM. Safety of synthetic

and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.
Ann Rheum Dis 2017;76:1101-36

755. Chatzidionysiou K, Emamikia S, Nam J, Ramiro S, Smolen J, van der Heijde D, Dougados M, Bijlsma J, Burmester G, Scholte M, van Vollenhoven R, Landewé R. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
Ann Rheum Dis 2017;76:1102-07

754. van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Géher P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compán V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.
Ann Rheum Dis 2017;76:978-91

753. Sepriano A, Rubio R, Ramiro S, Landewé R, van der Heijde D. Performance of the ASAS classification criteria for axial and peripheral spondyloarthritis: a systematic literature review and meta-analysis.
Ann Rheum Dis 2017;76:886-90

752. Dougados M, Wood E, Gossec L, van der Heijde D, Logeart I. Flare in axial spondyloarthritis: investigation of meaningful changes in symptomatic outcome measures.
Clin Exp Rheumatol. 2017;35:209-13

751. Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, Zerbini CA, Gurbuz S, Dickson C, de Bono S, Schlichting D, Beattie S, Kuo WL, Rooney T, Macias W, Takeuchi T. Baricitinib, Methotrexate, or Combination in Patients with Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.
Arthritis Rheumatol 2017;69:506-17

750. Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, del Carmen Morales L, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
N Engl J Med 2017; 376:652-62

749. Regel A, Sepriano A, Baraliakos X, van der Heijde D, Braun J, Landewé R, Van den Bosch F, Falzon L, Ramiro S. Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.
RMD Open 2017;3:e000397

748. Sepriano A, Regel A, van der Heijde D, Braun J, Baraliakos X, Landewé R, Van den Bosch F, Falzon L, Ramiro S. Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.
RMD Open 2017;3:e000396

747. Bakker PAC, van den Berg R, Lenczner G, Thévenin F, Reijnierse M, Claudepierre P, Wendling D, Dougados M, van der Heijde D. Can we use structural lesions seen on MRI of the sacroiliac joints reliably for the classification of patients according to the ASAS axial spondyloarthritis criteria? Data from the DESIR cohort.
Ann Rheum Dis 2017; 76:392-8

746. Nordberg LB, Lillegraven S, Lie E, Aga A-B, Olsen IC, Berner Hammer H, Uhlig T, Jonsson MK, van der Heijde D, Kvien TK, Haavardsholm EA. Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria.
Ann Rheum Dis 2017;76:341-5

745. Emery P, Bingham CO III, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, Arendt C, Moutian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.

Ann Rheum Dis 2017;76:96-104

744. Dougados M, van der Heijde D, Chen Y-C, Greenwald M, Drescher E, Liu J, Beattie S, Witt S, de la Torre I, Gaich C, Rooney T, Schlichting D, de Bono S, Emery P. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.

Ann Rheum Dis 2017;76:88-95

743. Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin C-Y, BraunDK, Lee CH, Gladman DG. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naïve patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.

Ann Rheum Dis 2017;76:79-86

2016

742. Gvozdenović E, Wolterbeek R, van der Heijde D, Huizinga T, Allaart C, Landewé R. DAS steered therapy in clinical practice; cross-sectional results from the METEOR database.

BMC Musculoskelet Disord. 2016 Jan 16;17:33

741. de Winter JJ, van Mens LJ, van der Heijde D, Landewé R, Baeten DL. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis.

Arthritis Res Ther 2016;18:196

740. Haavardsholm EA, Aga A-B, Olsen IC, Lillegraven S, Hammer HB, Uhlig T, Fremstad H, Madland TM, Lexberg AS, Haukeland H, Rodevand E, Hoili C, Stray H, Noraas A, Hansen IJW, Bakland G, Nordberg LB, van der Heijde D, Kvien TK. Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial.

BMJ 2016;354:i4205

739. Jacquemin C, Rubio Vargas R, van den Berg R, Thévenin F, Lenczner G, Reijnierse M, Ferkal S, Le Corvoisier P, Rahmouni A, Loeuille D, Feydy A, Dougados M, van der Heijde D, Claudepierre P. What is the reliability of non-trained investigators in recognising structural MRI lesions of sacroiliac joints in patients with recent inflammatory back pain? Results of the DESIR cohort.

RMD Open 2016;2(2):e000303

738. van Erp SJ, Brakenhoff LK, van Gaalen FA, van den Berg R, Fidder HH, Verspaget HW, Huizinga TW, Veenendaal RA, Wolterbeek R, van der Heijde D, van der Meulen-de Jong AE, Hommes DW. Classifying Back Pain and Peripheral Joint Complaints in Inflammatory Bowel Disease Patients: A Prospective Longitudinal Follow-up Study.

J Crohns Colitis. 2016 Feb;10(2):166-75

737. Haugen IK, Mathiessen A, Slatkowsky-Christensen B, Magnusson K, Bøyesen P, Sesseng S, van der Heijde D, Kvien TK, Hammer HB. Synovitis and radiographic progression in non-erosive and erosive hand osteoarthritis: is erosive hand osteoarthritis a separate inflammatory phenotype?

Osteoarthritis Cartilage 2016;24:647-54

736. Essers I, Ramiro S, Stolwijk C, Blaauw M, Landewé R, van der Heijde D, van den Bosch F, Dougados M, van Tubergen A. Do extra-articular manifestations influence outcome in ankylosing spondylitis? 12-year results from OASIS.

Clin Exp Rheumatol 2016;34:214-21

735. Rudwaleit M, Rosenbaum JT, Landewé R, Marzo-Ortega H, Sieper J, van der Heijde D, Davies O, Bartz

H, Hoepken B, Nurminen T, Deodhar A. Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis. *Arthritis Care Res* 2016;68:838-44

734. van der Heijde D, Landewé RB, Mease PJ, McInnes IB, Conaghan PG, Pricop L, Ligozio G, Richards HB, Mpofo S. Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis. *Arthritis Rheumatol* 2016;68:1914-2

733. Aga A-B, Hammer HB, Olsen IC, Uhlig T, Kvien TK, van der Heijde D, Fremstad H, Madland TM, Lexberg ÅS, Haukeland H, Rødevand E, Høili C, Stray H, Bendvold AN, Soldal DM, Bakland G, Lie E, Haavardsholm EA. First step in the development of an ultrasound joint inflammation score for rheumatoid arthritis using a data-driven approach. *Ann Rheum Dis* 2016;75:1444-51

732. Dougados M, Demattei C, van den Berg R, Vo Hoang V, Thevenin F, Reijnierse M, Loeuille D, Feydy A, Claudepierre P, van der Heijde D. Rate and Predisposing Factors for Sacroiliac Joint Radiographic Progression After a Two-Year Follow-up Period in Recent-Onset Spondyloarthritis. *Arthritis Rheumatol* 2016;68:1904-13

731. Bautista-Molano W, Landewé RBM, Londoño J, Romero-Sanchez C, Valle-Oñate R, van der Heijde D. Analysis and performance of various classification criteria sets in a Colombian cohort of patients with spondyloarthritis. *Clin Rheumatol* 2016;35:1759-67

730. Oude Voshaar M, van Onna M, van Genderen S, van de Laar M, van der Heijde D, Heuft L, Spoorenberg A, Luime J, Gignac M, Boonen A. Development and Validation of a Short Form of the Social Role Participation Questionnaire in Patients with Ankylosing Spondylitis. *J Rheumatol* 2016;43:1386-92

729. Kviatkovsky MJ, Ramiro S, Landewé R, Dougados M, Tubach F, Bellamy N, Hochberg M, Ravaut P, Martin-Mola E, Awada H, Bombardier C, Felson D, Hajjaj-Hassouni N, Logeart I, Matucci-Cerinic M, van de Laar M, van der Heijde D. The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis. *J Rheumatol* 2016;43:1680-6

728. Essers I, Boonen A, Busch M, van der Heijde D, Keszei AP, Landewé R, Ramiro S, van Tubergen A. Fluctuations in patient reported disease activity, pain and global being in patients with ankylosing spondylitis. *Rheumatology* 2016;55:2014-22

727. van Genderen S, Plasqui G, Landewé R, Lacaille D, Arends S, van Gaalen F, van der Heijde D, Heuft L, Luime J, Spoorenberg A, Gignac M, Boonen A. Social Role Participation in Patients With Ankylosing Spondylitis: A Cross-Sectional Comparison With Population Controls. *Arthritis Care Res* 2016;68:1899-1905

726. Gossec L, Coates LC, de Wit M, Kavanaugh A, Ramiro S, Mease PJ, Ritchlin CT, van der Heijde D, Smolen JS. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. *Nat Rev Rheum* 2016;12:743-50

725. Aga A-B, Berner Hammer H, Olsen IC, Uhlig T, Kvien TK, van der Heijde D, Fremstad H, Madland TM, Lexberg ÅS, Haukeland H, Rødevand E, Høili C, Stray H, Noraas AL, Widding Hansen IJ, Bakland G, Lillegraven S, Lie E, Haavardsholm EA. Development of a feasible and responsive ultrasound inflammation score for rheumatoid arthritis through a data-driven approach. *RMD Open* 2016; 2:e000325, doi:10.1136/rmdopen-2016-000325

724. Sepriano A, Ramiro S, van der Heijde D, Ávila-Ribeiro P, Fonseca R, Borges J, Teixeira L, Carvalho PD, Cerqueira M, Neves J, Meirinhos T, Barcelos A, Sequeira G, Salvador MJ, Canas da Silva J, Santos H, Bernardes M, Vieira-Sousa E, Canhão H, Branco JC, Pimentel-Santos F, Landewé R. Effect of Comedication

With Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study.
Arthritis Rheum 2016;68:2671-9

723. Bakker PA, Ez-Zaitouni Z, van Lunteren M, van den Berg R, de Hooge M, Fagerli KM, Landewé R, van Oosterhout M, Ramonda R, Reijniere M, van der Heijde D, van Gaalen FA. Are additional tests needed to rule out axial spondyloarthritis in patients ages 16-45 years with short-duration chronic back pain and maximally one spondyloarthritis feature?
Arthritis Care Res 2016;68:1726-30

722.. Jacquemin C, Rubio Vargas R, van den Berg R, Thévenin F, Lenczner G, Reijniere M, Ferkal S, Le Corvoisier P, Rahmouni A, Loeuille D, Feydy A, Dougados M, van der Heijde D, Claudepierre P. What is the reliability of non-trained investigators in recognising structural MRI lesions of sacroiliac joints in patients with recent inflammatory back pain? Results of the DESIR cohort
RMD Open 2016; 2:e000303, doi:10.1136/rmdopen-2016-000303

721. Huo Y, Veldhuizen RD, van der Heijde D, Besselink NJ, Jacobs JWG, van Laar JM, Viergever MA, Vincken KL, Lafeber FP, de Hair MJH, on behalf of the Society for Rheumatology Research Utrecht investigators. Automated joint space width quantification of hand and wrist joints: a proof of concept study.
Clin Exp Rheumatol 2016;34: S34-S39

720. Lambert RGW, Bakker PAC, van der Heijde D, Weber U, Rudwaleit M, Hermann K-GA, Sieper J, Baraliakos X, Bennett A, Braun J, Burgos-Vargas R, Dougados M, Pedersen SJ, Jurik AG, Maksymowych WP, Marzo-Ortega H, Østergaard M, Poddubnyy D, Reijniere M, van den Bosch F, van der Horst-Bruinsma I, Landewé R. Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group.
Ann Rheum Dis 2016;75:1958-63

719. Kiltz U, van der Heijde D, Boonen A, Bautista-Molano W, Burgos-Vargas R, Chiowchanwisawakit P, Duruoz T, El-Zorkany B, Essers I, Gaydukova I, Géher P, Gossec L, Grazio S, Gu J, Khan MA, Kim TJ, Maksymowych WP, Marzo-Ortega H, Navarro-Compán V, Olivieri I, Patrikos D, Pimentel-Santos FM, Schirmer M, van den Bosch F, Weber U, Zochling J, Braun J. Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS Health Index and the Environmental Item Set: translation and cross-cultural adaptation into 15 languages.
RMD Open 2016; 2:e000311, doi:10.1136/rmdopen-2016-000311

718. Kiltz U, Essers I, Hilgsmann M, Braun J, Maksymowych WP, Taylor WJ, van der Heijde D, Boonen A. Which aspects of health are most important for patients with spondyloarthritis? A best worst scaling based on the ASAS Health index.
Rheumatol 2016;55:1771-6

717. Landewé RBM, Connell CA, Bradley JD, Wilkinson B, Gruben D, Strengholt S, van der Heijde D. Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials.
Arthritis Research & Therapy 2016;18:212 DOI: 10.1186/s13075-016-1106-y

716. Huo Y, Vincken KL, van der Heijde D, De Hair MJH, Lafeber FP, Viergever MA. Automatic Quantification of Radiographic Finger Joint Space Width of Patients With Early Rheumatoid Arthritis.
IEEE Transactions on Biomedical Engineering 2016;63; 10.1109/TBME.2015.2512941

715. Winthrop K, Strand V, van der Heijde DM, Mease PJ, Crow MK, Weinblatt M, Bathon JM, Buch MH, Burmester GR, Dougados M, Kay J, Mariette X, Breedveld FC, Kalden JR, Smolen JS, Furst DE. The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016.
Clin Exp Rheumatol 2016;34(Suppl 98):69-76

714. Machado PM, Baraliakos X, van der Heijde D, Braun J, Landewé R. MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis.
Ann Rheum Dis 2016;75:1486-93

713. Putrik P, Ramiro S, Lie E, Keszei AP, Kvien TK, van der Heijde D, Landewé R, Uhlig T, Boonen A. Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD. *Rheumatology* 2016;55:1217-24
712. Markusse IM, Landewé R, Wolterbeek R, Ho M, Jenkins M, van der Heijde D. Linear extrapolation of missing radiographic change scores in clinical trials does not spuriously overestimate group radiographic changes in rheumatoid arthritis. *Rheumatology* 2016;55:1295-3000
711. Rubio Vargas R, van den Berg R, van Lunteren M, Ez-Zaitouni Z, Bakker PAC, Dagfinrud H, Ramonda R, Landewé R, Molenaar E, van Gaalen FA, van der Heijde D. Does body mass index (BMI) influence the Ankylosing Spondylitis Disease Activity Score in axial spondyloarthritis?: Data from the SPACE cohort. *RMD Open* 2016; 2:e000283, doi:10.1136/rmdopen-2016-000283
710. Maksymowych WP, Dougados M, van der Heijde D, Sieper J, Braun J, Citera G, Van den Bosch F, Logeart I, Wajdula J, Jones H, Marshall L, Bonin R, Pedersen R, Vlahos B, Kotak S, Bukowski JF. Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study. *Ann Rheum Dis* 2016;75:1328-35
709. de Hooge M, van den Berg R, Navarro-Compán V, Reijnders M, van Gaalen F, Fagerli K, Landewé R, van Oosterhout M, Ramonda R, Huizinga T, van der Heijde D. Patients with chronic back pain of short duration from the SPACE cohort: which MRI structural lesions in the sacroiliac joints and inflammatory and structural lesions in the spine are most specific for axial spondyloarthritis? *Ann Rheum Dis* 2016;75:1308-14
708. Dale J, Stirling A, Zhang R, Purves D, Foley J, Sambrook M, Conaghan PG, van der Heijde D, McConnachie A, McInnes IB, Porter D. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. *Ann Rheum Dis* 2016;75:1043-50
707. Sepriano A, Landewé R, van der Heijde D, Sieper J, Akkoc N, Brandt J, Braun J, Collantes-Estevez E, Dougados M, Fitzgerald O, Huang F, Gu J, Kirazli Y, Maksymowych WP, Marzo-Ortega H, Olivieri I, Özgöçmen S, Roussou E, Scarpato S, Sørensen IJ, Valle-Oñate R, Van den Bosch F, van der Horst-Bruinsma I, Weber U, Wei J, Rudwaleit M. Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. *Ann Rheum Dis* 2016;75:1034-42
706. Conaghan PG, Østergaard M, Bowes MA, Wu C, Fuerst T, van der Heijde D, Irazoque-Palazuelos F, Soto-Raices O, Hrycaj P, Xie Z, Zhang R, Wyman BT, Bradley JD, Soma K, Wilkinson B. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. *Ann Rheum Dis* 2016;75:1024-33
705. Moltó A, Etcheto A, van der Heijde D, Landewé R, van den Bosch F, Bautista Molano W, Burgos-Vargas R, Cheung PP, Collantes-Estevez E, Deodhar A, El-Zorkany B, Erdes S, Gu J, Hajjaj-Hassouni N, Kiltz U, Kim T-H, Kishimoto M, Luo S-F, Machado PM, Maksymowych WP, Maldonado-Cocco J, Marzo-Ortega H, Montecucco C-M, Özgöçmen S, van Gaalen F, Dougados M. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. *Ann Rheum Dis* 2016; 75:1016-23
704. Gossec L, Portier A, Landewé R, Etcheto A, Navarro-Compán V, Kroon F, van der Heijde D, Dougados M. Preliminary definitions of 'flare' in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative. *Ann Rheum Dis* 2016;75:991-6
703. Takeuchi T, Tanaka Y, Ishiguro N, Yamanaka H, Yoneda T, Ohira T, Okubo N, Genant HK, van der

Heijde D. Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose–response study of AMG 162 (Denosumab) in patients with Rheumatoid arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)—a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial.

Ann Rheum Dis 2016;75:983-90

702. Baillet A, Gossec L, Carmona L, de Wit M, van Eijk-Hustings Y, Bertheussen H, Kent A, Toft M, Kouloumas M, Ferreira RJO, Oliver S, Rubbert-Roth A, van Assen S, Dixon WG, Finckh A, Zink A, Kremer J, Kvien TK, Nurmohamed M, van der Heijde D, Dougados M. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative.

Ann Rheum Dis 2016;75:965-73

701. Nieuwenhuis WP, van Steenberg HW, Stomp W, Stijnen T, Huizinga TWJ, Bloem, van der Heijde D, Reijnierse M, van der Helm-van Mil AHM. The Course of Bone Marrow Edema in Early Undifferentiated Arthritis and Rheumatoid Arthritis: A Longitudinal Magnetic Resonance Imaging Study at Bone Level. Arthritis Rheum 2016;68:1080–8

700. Gvozdenovic E, Allaart CF, van der Heijde D, Ferraccioli G, Smolen JS, Huizinga TWJ, Landewé R. When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS).

RMD Open 2016;2:e000221.doi:10.1136/rmdopen-2015-000221

699. van der Heijde D, Landewé R. Are conventional radiographs still of value?

Curr Opin Rheum 2016;28:310-5

698. Landewé R, van der Heijde D. New concepts of clinical trials in rheumatoid arthritis: a boom of noninferiority trials.

Curr Opin Rheum 2016;28:316-22

697. Castillo-Ortiz JD, Ramiro S, Landewé R, van der Heijde D, Dougados M, van den Bosch F, Boonen A. Work Outcome in Patients With Ankylosing Spondylitis: Results From a 12-Year Followup of an International Study.

Arthritis Care Res 2016;68:544–52

696. Navarro-Compán V, Ramiro S, Landewé R, Dougados M, Miceli-Richard C, Richette P, van der Heijde D. Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort.

Ann Rheum Dis 2016;75:874-8

695. van der Heijde D, Joshi A, Pangan A, Chen N, Betts K, Mittal M, Bao Y. ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis.

Rheumatology 2016;55:80-8

694. Webers C, Essers I, Ramiro S, Stolwijk C, Landewé R, van der Heijde D, van den Bosch F, Dougados M, van Tubergen A. Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study.

Rheumatology 2016;55:419-28

693. Kroon FP, van der Burg LR, Ramiro S, Landewé RB, Buchbinder R, Falzon L, van der Heijde D. Non-steroidal Antiinflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review.

J Rheumatol 2016;43:607-17

692. de Bruin F, Ter Horst S, Bloem HL, van den Berg R, de Hooge M, van Gaalen F, Fagerli KM, Landewé R, van Oosterhout M, van der Heijde D, Reijnierse M. Prevalence of degenerative changes of the spine on magnetic resonance images and radiographs in patients aged 16-45 years with chronic back pain of short duration in the Spondyloarthritis Caught Early (SPACE) cohort.

Rheumatology 2016;55:56-65

691. de Bruin F, Ter Horst S, van den Berg R, de Hooge M, van Gaalen F, Fagerli KM, Landewé R, van Oosterhout M, Bloem JL, van der Heijde D, Reijnen M. Signal intensity loss of the intervertebral discs in the cervical spine of young patients on fluid sensitive sequences. *Skeletal Radiol* 2016;45:375-81

690. Gherghe AM, Ramiro S, Landewé R, Mihai C, van der Heijde D. Association of the different types of radiographic damage with physical function in patients with rheumatoid arthritis: analysis of the RAPID trials. *RMD Open* 2016;2:e000219.doi:10.1136/rmdopen-2015-000219

689. Combe B, Furst DE, Keystone EC, van der Heijde D, Luijckens K, Ionescu L, Goel N, Emery P. Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials. *Arthritis Care Res* 2016;68:299-307

688. Kavanaugh A, van der Heijde D, Beutler A, Gladman D, Mease P, Krueger GG, McInnes IB, Helliwell P, Coates LC, Xu S. Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Goleimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study. *Arthritis Care Res* 2016;68:267-74

687. Haugen IK, Slatkowsky Christensen B, Bøyesen P, Sesseng S, van der Heijde D, Kvien TK. Increasing synovitis and bone marrow lesions are associated with incident joint tenderness in hand osteoarthritis. *Ann Rheum Dis* 2016;75:702-8

686. Mihai C, Landewé R, van der Heijde D, Walker UA, Constantin PI, Gherghe AM, Ionescu R, Rednic S, Allanore Y, Avouac J, Cziráj L, Hachulla E, Riemekasten G, Cozzi F, Airò P, Cutolo M, Mueller-Ladner U, Matucci-Cerinic M, EUSTAR co-authors. Digital ulcers predict a worse disease course in patients with systemic sclerosis. *Ann Rheum Dis* 2016;75:681-6

685. Ramiro S, Smolen JS, Landewé R, van der Heijde D, Dougados M, Emery P, de Wit M, Cutolo M, Oliver S, Gossec L. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. *Ann Rheum Dis* 2016;75:490-8

684. Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewé R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Cañete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. *Ann Rheum Dis* 2016;75:499-510

683. Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Okada T, van der Heijde D, Miyasaka N, Koike T. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naïve early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. *Ann Rheum Dis* 2016;75:75-83

682. Stoffer MA, Schoels MM, Smolen JA, Aletaha D, Breedveld FC, Burmester G, Bykerk V, Dougados M, Emery P, Haraoui B, Gomez-Reino J, Kvien TK, Nash P, Navarro-Compán V, Scholte-Voshaar M, van Vollenhoven R, van der Heijde D, Stamm TA. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. *Ann Rheum Dis* 2016;75:16-22

681. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Victoria Navarro-Compán M, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewé R, Martin-Mola E, Nash P, Østergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
Ann Rheum Dis 2016;75:3-15

680. Haugen IK, Slatkowsky-Christensen B, Bøyesen P, Sesseng S, van der Heijde D, Kvien TK. MRI findings predict radiographic progression and development of erosions in hand osteoarthritis.
Ann Rheum Dis 2016;75:117-23

679. Inman RD, Baraliakos X, Hermann KA, Braun J, Deodhar A, van der Heijde D, Xu S, Hsu B. Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study.
Arthritis Res Ther. 2016 Dec 28;18(1):304

674. van Genderen S, Plasqui G, Lacaille D, Arends, S van Gaalen F, van der Heijde D, Heuft L, Keszei A, Luime, J Spoorenberg A, Landewé R, Gignac M, Boonen A. Social Role Participation Questionnaire for patients with ankylosing spondylitis: translation into Dutch, reliability and construct validity.
RMD Open 2016; 2:e000177

2015

678. Dougados M, Wood E, Gossec L, Dubanchet A, Logeart I, van der Heijde D. Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drug-sparing Endpoints, Alone or in Combination, in Axial Spondyloarthritis.
J Rheumatol. 2015;42:2361-8

677. Berg IJ, van der Heijde D, Dagfinrud H, Seljeflot I, Olsen IC, Kvien TK, Semb AG, Provan SA. Disease activity in ankylosing spondylitis and associations to markers of vascular pathology and traditional cardiovascular disease risk factors: a cross-sectional study.
J Rheumatol 2015;42:645-53

676. Dougados M, Etchetob A, Molto A, Alonsoc S, Bouvet S, Daurès J-P, Landais P, d'Agostino M-A, Berenbaum F, Breban M, Claudepierre P, Combe B, Fautrel B, Feydy A, Goupille P, Richette P, Pham T, Roux C, Treluyer J-M, Saraux A, van der Heijde D, Wendling D. Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: The DESIR cohort.
Joint Bone Spine 2015;82:345-51

675. Kortekaas MC, Kwok WY, Reijnierse M, Wolterbeek R, Bøyesen P, van der Heijde D, Bloem JL, Kloppenburg M. Magnetic Resonance Imaging in Hand Osteoarthritis: Intraobserver Reliability and Criterion Validity for Clinical and Structural Characteristics.
J Rheumatol 2015;42:1224-30

674. van den Berg R, de Hooge M, Bakker PA, van Gaalen F, Navarro-Compán V, Fagerli KM, Landewé R, van Oosterhout M, Ramonda R, Reijnierse M, van der Heijde D. Metric Properties of the SPARCC Score of the Sacroiliac Joints - Data from Baseline, 3-month, and 12-month Followup in the SPACE Cohort.
J Rheumatol. 2015;42:1186-93

673. Kroon FP, van der Burg LR, Ramiro S, Landewé RB, Buchbinder R, Falzon L, van der Heijde D. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).
Cochrane Database Syst Rev. 2015 Jul 17;7:CD010952

672. Salomon-Escoto KI, van den Berg R, Kay J, van der Heijde D & on behalf of the Merit Foundation.

Utilizing the METEOR initiative to improve rheumatoid arthritis patient care.
Int J Clin Rheumatol 2015;10:425-31

671. Huo Y, De Hair MJH, Shaib YO, van der Heijde D, Kuchuk NO, Viergever MA, van Laar JM, Vincken KL, FP Lafeber. Computerised versus conventional methodology of radiographic joint destruction assessment in early rheumatoid arthritis.
RMD Open 2015; 1:e000148, doi:10.1136/rmdopen-2015-000148

670. Visser AW, Bøyesen P, Haugen IK, Schoones JW, van der Heijde DM, Rosendaal FR, Kloppenburg M. Instruments measuring pain, physical function, or patient's global assessment in hand osteoarthritis: A systematic literature search.
J Rheumatol 2015;42:2118-34

669. Kloppenburg M, Bøyesen P, Visser AW, Haugen IK, Boers M, Boonen A, Conaghan PG, Hawker GA, Kvien TK, Landewé R, Uhlig T, Smeets W, Greibrokk E, van der Heijde DM. Report from the OMERACT hand osteoarthritis working group: Set of core domains and preliminary set of instruments for use in clinical trials and observational studies.
J Rheumatol 2015;42:2190-7

668. Weinblatt ME, Fleischmann R, van Vollenhoven RF, Emery P, Huizinga TWJ, Cutolo M, van der Heijde D, Duncan B, Davies O, Luijckens K, Dougados M. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: Efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
Arthritis Res Ther 2015;17:325

667. Ramiro S, Landewé R, van der Heijde D, Harrison D, Collier D, Michaud K. Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?
RMD Open 2015; 1:e000155, doi:10.1136/rmdopen-2015-000155

666. Ramiro S, Landewé RBM, van der Heijde D, Stolwijk C, Dougados M, van den Bosch F, van Tubergen A. Hierarchy of impairment of spinal mobility measures in ankylosing spondylitis: Twelve-year data.
Arthritis Care and Research 2015;67:1571-7

665. Danila MI, Westfall AO, Raman K, Chen L, Reynolds RJ, Hughes LB, Arnett DK, McGwin G, Szalai AJ, van der Heijde DM, Conn D, Callahan LF, Moreland LW, Bridges Jr SL. The role of genetic variants in CRP in radiographic severity in African Americans with early and established rheumatoid arthritis.
Genes and Immunity 2015;16:446-51

664. Dougados M, Etcheto A, Molto A, Alonso S, Bouvet S, Daurès J-P, Landais P, d'Agostino M-A, Berenbaum F, Breban M, Claudepierre P, Combe B, Fautrel B, Feydy A, Goupille P, Richette P, Pham T, Roux C, Treluyer J-M, Saraux A, van der Heijde D, Wendling D. Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: The DESIR cohort
Joint Bone Spine 2015;82:345-51

663. Navarro-Compán V, Smolen JS, Huizinga TWJ, Landewé R, Ferraccioli G, da Silva J, Moots RJ, Kay J, van der Heijde D. Quality indicators in rheumatoid arthritis: results from the METEOR database.
Rheumatology 2015;54:1630-9

662. Nocturne G, Pavy S, Boudaoud S, Seror R, Goupille P, Chanson P, van der Heijde D, van Gaalen F, Berenbaum F, Mariette X, Briot K, Feydy A, Claudepierre P, Dieudé P, Nithitham J, Taylor KE, Criswell LA, Dougados M, Roux C, Miceli-Richard C. Increase in dickkopf-1 serum level in recent spondyloarthritis. Data from the DESIR cohort.
PLoS ONE 2015;10:e0134974

661. Sieper J, van der Heijde D, Dougados M, Maksymowych WP, Scott BB, Boice JA, Berd Y, Bergman G, Curtis S, Tzontcheva A, Huyck S, Weng HH. A Randomized, Double-Blind, Placebo-Controlled, Sixteen-Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis.
Arthritis Rheum 2015;67:2702-12

660. van den Berg R, Lenczner G, Thévenin F, Claudepierre P, Feydy A, Reijnierse M, Saraux A, Rahmouni A, Dougados M, van der Heijde D. Classification of axial SpA based on positive imaging (radiographs and/or MRI of the sacroiliac joints) by local rheumatologists or radiologists versus central trained readers in the DESIR cohort.
Ann Rheum Dis 2015;74:2016-21
659. Navarro-Compán V, de Miguel E, van der Heijde D, Landewé R, Almodóvar R, Montilla C, Beltrán E, Zarco P. Spondyloarthritis features forecasting the presence of HLA-B27 or sacroiliitis on magnetic resonance imaging in patients with suspected axial spondyloarthritis: Results from a cross-sectional study in the ESPeranza Cohor.
Arthritis Res Ther 2015;17:265
658. Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S, for the FUTURE 1 Study Group. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
N Engl J Med 2015;373:1329-39
657. McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S; FUTURE 2 Study Group. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2015;386:1137-46
656. Gvozdrenović E, Wolterbeek R, Allaart CF, Brenol C, Dougados M, Emery P, Ferraccioli G, van der Heijde D, Huizinga TW, Kay J, Martin Mola E, Moots RJ, da Silva JA, Smolen J, Veale D, Landewé RB. Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians: Differences Across Countries in the METEOR Database.
J Clin Rheumatol 2015;21:349-54
655. Smolen JS, van Vollenhoven R, Kavanaugh A, Strand V, Vencovsky J, Schiff M, Landewé R, Haraoui B, Arendt C, Mountian I, Carter D, van der Heijde D. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
Arthritis Res Ther 2015;17:art no 245
654. Ramiro S, Landewé R, van Tubergen A, Boonen A, Stolwijk C, Dougados M, van den Bosch F, van der Heijde D. Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis.
RMD Open 2015;1:e000153, doi:10.1136/rmdopen-2015-000153
653. Gherghe AM, Dougados M, Combe B, Landewé R, Mihai C, Berenbaum F, Mariette X, Wolterbeek R, van der Heijde D. Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts.
RMD Open 2015;1:e000128, doi:10.1136/rmdopen-2015-000128
652. Maksymowych WP, Boire G, van Schaardenburg D, Wichuk S, Turk S, Boers M, Siminovitch KA, Bykerk V, Keystone E, Tak PP, van Kuijk AW, Landewé R, van der Heijde D, Murphy M, Marotta A. 14-3-3 η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis.
J Rheumatol 2015;42:1587-94
651. de Rooy DPC, Tsonaka R, Andersson MLE, Forslind K, Zhernakova A, Frank-Bertoncelj M, de Kovel CGF, Koeleman BPC, van der Heijde DMFM, Huizinga TWJ, Toes REM, Houwing-Duistermaat JJ, Ospelt C, Svensson B, van der Helm-van Mil AHM. Genetic factors for the severity of ACPA-negative rheumatoid arthritis in 2 cohorts of early disease: A genome-wide study.
J Rheumatology 2015;42:1383-91
650. Mangnus L, van Steenberg HW, Lindqvist E, Brouwer E, Reijnierse M, Huizinga TWJ, Gregersen PK, Berglin E, Rantapää-Dahlqvist S, van der Heijde D, van der Helm-van Mil, A.H.M. Studies on ageing and the severity of radiographic joint damage in rheumatoid arthritis.

649. Barnabe C, Sun Y, Boire G, Hitchon CA, Haraoui B, Carter Thorne J, Tin D, [van der Heijde D](#), Curtis JR, Jamal S, Pope JE, Keystone EC, Bartlett S, Bykerk VP, CATCH Investigators. Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH). *PLoS ONE* 10(8): e0135327
648. Fleischmann R, [van der Heijde D](#), Koenig AS, Pedersen R, Szumski A, Marshall L, Bananis E, Kvien TK. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index? *Ann Rheum Dis* 2015;74:1327-39
647. [van der Heijde D](#), Breban M, Halter D, Divittorio G, Bratt J, Cantini F, Kary S, Pangan AL, Kupper H, Rathmann SS, Sieper J, Mease PJ. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab. *Rheumatology* 2015;54:1210-9
646. Magnusson K, Slatkowsky-Christensen B, [van der Heijde D](#), Kvien TK, Hagen KB, Haugen IK. Body mass index and progressive hand osteoarthritis: Data from the Oslo hand osteoarthritis cohort. *Scand J Rheumatol* 2015;44:331-6
645. Bellamy N, Hochberg M, Tubach F, Martin-Mola E, Awada H, Bombardier C, Hajjaj-Hassouni N, Logeart I, Matucci-Cerinic M, van de Laar M, [van der Heijde D](#), Dougados M. Development of Multinational Definitions of Minimal Clinically Important Improvement and Patient Acceptable Symptomatic State in Osteoarthritis. *Arthritis Care Res* 2015;67:972-80
644. Smolen JS, Weinblatt ME, [van der Heijde D](#), Rigby WFC, van Vollenhoven R, Bingham III CO, Veenhuizen M, Gill A, Zhao F, Komocsar WJ, Berclaz P-Y, Ortmann R, Lee C. Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. *Ann Rheum Dis* 2015;74:1567-70
643. Berg IJ, Semb AG, [van der Heijde D](#), Kvien TK, Olsen IC, Dagfinrud H, Provan SA. CRP and ASDAS are associated with future elevated arterial stiffness, a risk marker of cardiovascular disease, in patients with ankylosing spondylitis: results after 5-year follow-up. *Ann Rheum Dis* 2015;74:1562-6
642. Poddubnyy D, van Tubergen A, Landewé R, Sieper J, [van der Heijde D](#). Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis *Ann Rheum Dis* 2015;74:1483-7
641. Mease P, Deodhar A, Fleischmann R, Wollenhaupt J, Gladman D, Leszczyński P, Vitek P, Turkiewicz A, Khraishi M, FitzGerald O, Landewé R, de Longueville M, Hoepken B, Peterson L, [van der Heijde D](#). Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. *RMD Open* 2015;1:e000119.doi:10.1136/rmdopen-2015-000119
640. Mandl P, Navarro-Compán V, Terslev L, Aegerter P, [van der Heijde D](#), D'Agostino MA, Baraliakos X, Pedersen SJ, Jurik AG, Naredo E, Schueller-Weidekamm C, Weber U, Wick MC, Bakker PAC, Filippucci E, Conaghan PG, Rudwaleit M, Schett G, Sieper J, Tarp S, Marzo-Ortega H, Østergaard M. EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. *Ann Rheum Dis* 2015;74:1327-39
639. Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, Rohane P, van Hoogstraten H, Garg A, Fan C, van Adelsberg J, Weinstein SP, Graham NMH, Stahl N, Yancopoulos G,

Huizinga TWJ, [van der Heijde D](#). Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. *Arthritis Rheumatol* 2015;67:1424-37

638. Landewé R, Smolen JS, Florentinus S, Chen S, Guérette B, [van der Heijde D](#). Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis. *Arthritis Res Ther* 2015;17:133

637. Navarro-Compán V, Gherghe AM, Smolen JS, Aletaha D, Landewé R, [van der Heijde D](#). Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review. *Rheumatology* 2015;54:83-90

636. Vendelbosch S, de Boer M, van der Heijde D, van den Berg TK, van Gaalen FA, Kuijpers TW. KIR3DL1 and KIR3DL2 gen copy number variation in axial spondyloarthritis. *Tissue Antigens* 2015;85:497-8

635. Ramiro S, van Tubergen A, Stolwijk C, [van der Heijde D](#), Royston P, Landewé R. Reference intervals of spinal mobility measures in normal individuals: the mobility study. *Ann Rheum Dis* 2015; 74:1218-24

634. Fleischmann R, [van der Heijde D](#), Koenig AS, Pedersen R, Szumski A, Marshall L, Bananis E. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index? *Ann Rheum Dis* 2015;74:1132-7

633. Buch MH, Silva-Fernandez L, Carmona L, Aletaha D, Christensen R, Combe B, Emery P, Ferraccioli G, Guillemin F, Kvien TK, Landewé R, Pavelka K, Saag K, Smolen JS, Symmons D, [van der Heijde D](#), Welling J, Wells G, Westhovens R, Zink A, Boers M. Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. *Ann Rheum Dis* 2015;74:963-9

632. Hemke R, Nusman CM, [van der Heijde DMFM](#), Doria AS, Kuijpers TW, Maas M, van Rossum MAJ. Frequency of joint involvement in juvenile idiopathic arthritis during a 5-year follow-up of newly diagnosed patients: implications for MR imaging as outcome measure. *Rheumatol Int* 2015;35:351-7

631. van der Have MV, Brakenhoff LK, van Erp SJ, Kaptein AA, Leenders M, Scharloo M, Veenendaal RA, [van der Heijde DM](#), van der Meulen-de Jong AE, Hommes DW, Fidder HH. Back/Joint Pain, Illness Perceptions and Coping are Important Predictors of Quality of Life and Work Productivity in Patients With Inflammatory Bowel Disease: A 12-Month Longitudinal Study. *J Crohns Colitis*. 2015;9:276-83

630. Stomp W, Krabben A, [van der Heijde D](#), Huizinga TWJ, Bloem JL, Østergaard M, van der Helm-van Mil, AHM, Reijnen M. Aiming for a simpler early arthritis MRI protocol: can Gd contrast administration be eliminated? *European Radiology* 2015;25:1520-7

629. Boonen A, Sieper J, [van der Heijde D](#), Dougados M, Bukowski JF, Valluri S, Vlahos B, Kotak S. The burden of non-radiographic axial spondyloarthritis. *Sem Arthritis Rheum* 2015;44:558-62

628. Stolwijk C, Ramiro S, Vosse D, Landewé R, [van der Heijde D](#), van Tubergen A. Comparison of tests for lumbar flexion and hip function in patients with axial spondyloarthritis and in normal individuals. *Arthritis Care Res* 2015;67:538-45

627. Nieuwenhuis WP, Krabben A, Stomp W, Huizinga TWJ, van der Heijde D, Bloem JL, van der Helm-van Mil AHM, Reijnierse M. Evaluation of Magnetic Resonance Imaging-Detected Tenosynovitis in the Hand and Wrist in Early Arthritis. *Arthritis Rheumatol* 2015;67:869-76
626. Kiltz U, van der Heijde D, Boonen A, Cieza A, Stucki G, Khan MA, Maksymowych WP, Marzo-Ortega H, Reveille J, Stebbings S, Bostan C, Braun J. Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. *Ann Rheum Dis* 2015;74:830-5
625. van Onna M, van Tubergen A, Jurik A, van der Heijde D, Landewé R. Natural course of bone marrow oedema on magnetic resonance imaging of the sacroiliac joints in patients with early inflammatory back pain: a 2-year follow-up study. *Scand J Rheumatol* 2015;44:129-34
624. Rauscher V, Englbrecht M, van der Heijde D, Schett G, Hueber AJ. High degree of nonadherence to oral disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. *J Rheumatol* 2015;42:386-90
623. Sieper J, Landewé R, Rudwaleit M, van der Heijde D, Dougados M, Mease PJ, Braun J, Deodhar A, Kivitz A, Walsh J, Hoepken B, Nurminen T, Maksymowych WP. Effect of Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis: Results from a Phase 3 Randomized Trial. *Arthritis Rheumatol* 2015;67:668-77
622. Deodhar A, Braun J, Inman RD, van der Heijde D, Zhou Y, Xu S, Han C, Hsu B. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study *Ann Rheum Dis* 2015;74:757-61
621. Moltó A, Paternotte S, van der Heijde D, Claudepierre P, Rudwaleit M, Dougados M. Evaluation of the validity of the different arms of the ASAS set of criteria for axial spondyloarthritis and description of the different imaging abnormalities suggestive of spondyloarthritis: data from the DESIR cohort. *Ann Rheum Dis* 2015;74:746-51
620. Krabben A, Stomp W, Huizinga TWJ, van der Heijde D, Bloem JL, Reijnierse M, van der Helm-van Mil AHM. Concordance between inflammation at physical examination and on MRI in patients with early arthritis. *Ann Rheum Dis* 2015; 74:506-512
619. Landewé R, Østergaard M, Keystone EC, Florentinus S, Liu S, van der Heijde D. Analysis of integrated radiographic data from two long-term, open-label extension studies of adalimumab for the treatment of rheumatoid arthritis. *Arthritis Care Res* 2015;2:108-6
618. Machado P, Navarro-Compán V, Landewé R, van Gaalen FA, Roux C, van der Heijde D. How to calculate the ASDAS if the conventional CRP is below the limit of detection or if using high sensitivity CRP? - An analysis in the DESIR cohort. *Arthritis Rheumatol* 2015;2:408-13
617. Navarro-Compán V, Landewé R, Provan SA, Ødegard S, Uhlig T, Kvien TK, Keszei AP, Ramiro S, van der Heijde D. Relationship between types of radiographic damage and disability in patients with rheumatoid arthritis in the EURIDISS cohort: a longitudinal study. *Rheumatology* 2015;54:83-90
616. Ramiro S, Stolwijk C, van Tubergen A, van der Heijde D, Dougados M, van den Bosch F, Landewé R. Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. *Ann Rheum Dis* 2015;74:52-9

615. Kavanaugh A, Gladman D, [van der Heijde D](#), Purcaru O, Mease P. Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study.
Ann Rheum Dis 2015;74:44-51

614. [van der Heijde D](#), Aletaha D, Carmona L, Edwards CJ, Kvien TK, Kouloumas M, Machado P, Oliver S, de Wit M, Dougados M. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations.
Ann Rheum Dis 2015;74:8-13

2014

613. Stomp W, Krabben A, [van der Heijde D](#), Huizinga TW, Bloem JL, van der Helm-van Mil AH, Reijnen M. Are rheumatoid arthritis patients discernible from other early arthritis patients using 1.5T extremity magnetic resonance imaging? A large cross-sectional study
J Rheumatol 2014;41:1630-7

612. Essers I, Ramiro S, Stolwijk C, Blaauw M, Landewé R, [van der Heijde D](#), Van den Bosch F, Dougados M, van Tubergen A. Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS.
Rheumatology 2014;54:633-40

611. Jansen DT, Hameetman M, van Bergen J, Huizinga TW, [van der Heijde D](#), Toes RE, van Gaalen FA. IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities.
Rheumatology 2014;54:728-35

610. Ramiro S, [van der Heijde D](#), van Tubergen A, Stolwijk C, Dougados M, van den Bosch F, Landewé R. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort.
Ann Rheum Dis. 2014;73:1455-61

609. Kirwan JR, Boers M, Hewlett S, Beaton D, Bingham CO, Choy E, Conaghan PG, D'Agostino MA, Dougados M, Furst DE, Guillemin F, Gossec L, [van der Heijde DM](#), Kloppenburg M, Kvien TK, Landewé RB, Mackie SL, Matteson EL, Mease PJ, Merkel PA, Ostergaard M, Saketkoo LA, Simon L, Singh JA, Strand V, Tugwell P. Updating the OMERACT Filter: Core Areas as a Basis for Defining Core Outcome Sets.
J Rheumatol 2014;41:994-9.

608. Hemke R, Doria AS, Tzaribachev N, Maas M, [van der Heijde DM](#), van Rossum MA. Selecting Magnetic Resonance Imaging (MRI) Outcome Measures for Juvenile Idiopathic Arthritis (JIA) Clinical Trials: First Report of the MRI in JIA Special Interest Group.
J Rheumatol 2014;41:354-8

607. Baraliakos X, Heldmann F, Callhoff J, Listing J, Appelboom T, Brandt J, Van den Bosch F, Breban M, Burmester GR, Dougados M, Emery P, Gaston H, Grunke M, van der Horst-Bruinsma IE, Landewé R, Leirisalo-Repo M, Sieper J, De Vlam K, Pappas D, Kiltz U, [van der Heijde D](#), Braun J. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography.
Ann Rheum Dis 2014;73:1819-25

606. Brakenhoff L, Stomp W, van Gaalen F, Hommes D, Bloem J, [van der Heijde D](#), Fidler H, Reijnen M. Magnetic resonance imaging of the hand joints in patients with inflammatory bowel disease and arthralgia: a pilot study.
Scand J Rheumatol 2014;43:416-8

605. Bautista-Molano W, Navarro-Compán V, Landewé RBM, Boers M, Kirkham JJ, [van der Heijde D](#). How well are the ASAS/OMERACT Core Outcome Sets for Ankylosing Spondylitis implemented in randomized

clinical trials? A systematic literature review.
Clin Rheumatol 2014;33:1313-22

604. Maksymowych WP, Naides SJ, Bykerk V, Siminovitch KA, van Schaardenburg D, Boers M, Landewé R, van der Heijde D, Tak PP, Genovese MC, Weinblatt ME, Keystone EC, Zhukov OS, Abolhosn RW, Popov JM, Britsemmer K, van Kuijk AW, Marotta A. Serum 14-3-3 η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis.
J Rheumatol. 2014;41:2104-13

603. van Gaalen F, van den Berg R, Verhoog I, Schonkeren J, van der Helm-van Mil A, Huizinga T, van der Heijde DM. Is HLA-B27 increased in patients diagnosed with undifferentiated arthritis? Results from the Leiden early arthritis cohort.
J Rheumatol. 2014;41:1948-51

602. Nieuwenhuis WP, van Nies JA, Reijnierse M, van der Heijde D, van der Helm-Van Mil AH. Is the modified disease activity score superior to the disease activity score in early arthritis and rheumatoid arthritis? Comment on the article by Baker et al.
Arthritis Rheumatol. 2014;66:3244-5

601. Genovese MC, van der Heijde DM, Keystone E, Spindler AJ, Benhamou C, Kavanaugh A, Fudman E, Lampl K, O'Brien C, Duffield EL, Poiley J, Weinblatt ME. A Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor- α antagonist.
J Rheumatol 2014;41:2120-8

600. van Durme CM, Wechalekar MD, Buchbinder R, Schlesinger N, van der Heijde D, Landewé RB. Non-steroidal anti-inflammatory drugs for acute gout.
Cochrane Database Syst Rev. 2014 Sep 16;9:CD010120. doi: 10.1002/14651858.CD010120.pub2.

599. Berg IJ, Semb AG, van der Heijde D, Kvien TK, Hisdal J, Olsen IC, Dagfinrud H, Provan SA. Uveitis is associated with hypertension and atherosclerosis in patients with ankylosing spondylitis: A cross-sectional study.
Sem Arthritis Rheum 2014;44:309-13

598. van der Heijde D, Sieper J, Elewaut D, Deodhar A, Pangan AL, Dorr AP. Referral patterns, diagnosis, and disease management of patients with axial spondyloarthritis: Results of an international survey.
J Clin Rheumatol 2014;20:411-7

597. Weinblatt ME, Genovese MC, Ho M, Hollis S, Rosiak-Jedrychowicz K, Kavanaugh A, Millson DS, Leon G, Wang M, van der Heijde D. Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study.
Arthritis Rheum 2014;66:3255-64

596. Visser AW, Bøyesen P, Haugen IK, Schoones JW, van der Heijde DM, Rosendaal FR, Kloppenburg M. Radiographic scoring methods in hand osteoarthritis - a systematic literature search and descriptive review.
Osteoarthritis Cartilage 2014;22:1710-23

595. Keystone E, Landewé, van Vollenhoven R, Combe B, Strand V, Mease P, Shaughnessy L, VanLunen B, van der Heijde D. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.
Ann Rheum Dis 2014; 73:2094-100

594. Landewé RB, van der Heijde DM. Optimisation of rheumatic disease assessments in clinical trials, clinical care, and long-term databases.
Clin Exp Rheumatol ;32 Suppl 85(5):2-6

593. Braun J, Kiltz U, Baraliakos X, van der Heijde DM. Optimisation of rheumatology assessments - the

actual situation in axial spondyloarthritis including ankylosing spondylitis.
Clin Exp Rheumatol ;32 Suppl 85(5):96-104

592. Kiltz U, van der Heijde DM, Boonen A, Braun J. The ASAS Health Index (ASAS HI) - a new tool to assess the health status of patients with spondyloarthritis.
Clin Exp Rheumatol ;32 Suppl 85(5):105-08

591. van den Berg R, van der Heijde DM, Landewé RB, van Lambalgen K, Huizinga TW. The METEOR initiative: the way forward for optimal, worldwide data integration to improve care for RA patients.
Clin Exp Rheumatol ;32 Suppl 85(5):135-40

590. Dougados MR, van der Heijde DM, Brault Y, Koenig AS, Logeart IS. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: Findings from a randomized study (COMET).
J Rheumatol 2014;41:1922-34

589. Krabben A, Stomp W, van Nies JAB, Huizinga TWJ, van der Heijde D, Bloem JL, Reijnen M, van der Helm-van Mil AHM. MRI-detected subclinical joint inflammation is associated with radiographic progression.
Ann Rheum Dis 2014;73:2034-7

588. Ramiro S, van Tubergen A, van der Heijde D, Stolwijk C, Bookelman G, Dougados M, van den Bosch F, Landewé RBM. Erosions and sclerosis on radiographs precede the subsequent development of syndesmophytes at the same site: a twelve-year prospective followup of patients with ankylosing spondylitis.
Arthritis Rheumatology 2014;66:2773-2779

587. Deodhar A, Reveille JD, van den Bosch F, Braun J, Burgos-Vargas R, Caplan L, Clegg DO, Colbert RA, Gensler LS, van der Heijde D, van der Horst-Bruinsma IE, Inman RD, Maksymowych WP, Mease PJ, Raychaudhuri S, Reimold A, Rudwaleit M, Sieper J, Weisman MH, Landewé RBM. The concept of axial spondyloarthritis: joint statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns.
Arthritis Rheumatology 2014;66:2649-56

586. Landewé RBM, Smolen JS, Weinblatt ME, Emery P, Dougados M, Fleischmann R, Aletaha D, Kavanaugh A, van der Heijde D. Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example.
Ann Rheum Dis 2014;73:1755-60

585. van den Berg R, Lenczner G, Feydy A, van der Heijde D, Reijnen M, Saraux A, Rahmouni A, Dougados M, Claudepierre P. Reading of sacroiliac joints on plain pelvic radiographs: Agreement between clinical practice and trained central reading. Results of the DESIR-cohort.
Arthritis Rheumatol 2014;66:2403-11

584. Stomp W, Krabben A, van der Heijde D, Huizinga TWJ, Bloem JL, van der Helm-van Mil AHM, Reijnen M. Aiming for a shorter rheumatoid arthritis MRI protocol: can contrast-enhanced MRI replace T2 for the detection of bone marrow oedema?
Eur Radiol 2014;24:2614-22

583. Vinik O, Wechalekar MD, Falzon L, Buchbinder R, van der Heijde DM, Bombardier C. Treatment of asymptomatic hyperuricemia for the prevention of gouty arthritis, renal disease, and cardiovascular events: a systematic literature review.
J Rheumatol 2014;suppl 92:70-4

582. Sriranganathan MK, Vinik O, Falzon L, Bombardier C, van der Heijde DM, Edwards CJ. Interventions for tophi in gout: a cochrane systematic literature review.
J Rheumatol 2014;suppl 92:63-9

581. Andrés M, Sivera F, Falzon L, van der Heijde DM, Carmona L. Treatment target and followup measures for patients with gout: a systematic literature review.
J Rheumatol 2014;suppl 92:55-62
580. van Echteld IA, van Durme C, Falzon L, Landewé RB, van der Heijde DM, Aletaha D. Treatment of gout patients with impairment of renal function: a systematic literature review.
J Rheumatol 2014;suppl 92:48-54
579. Seth R, Kydd ASR, Falzon L, Bombardier C, van der Heijde DM, Edwards CJ. Preventing attacks of acute gout when introducing urate-lowering therapy: a systematic literature review.
J Rheumatol 2014;suppl 92:42-7
578. Kydd AS, Seth R, Buchbinder R, Falzon L, Edwards CJ, van der Heijde DM, Bombardier C. Urate-lowering therapy for the management of gout: summary of 2 cochrane reviews.
J Rheumatol 2014;suppl 92:33-41
577. Moi JHY, Sriranganathan MK, Falzon L, Edwards CJ, van der Heijde DM, Buchbinder R. Lifestyle interventions for the treatment of gout: a summary of 2 cochrane systematic reviews.
J Rheumatol 2014;suppl 92:26-32
576. Wechalekar MD, Vinik O, Moi JHY, Sivera F, van Echteld IAAM, van Durme C, Falzon L, Bombardier C, Carmona L, Aletaha D, Landewé RB, van der Heijde DMFM, Buchbinder R. The efficacy and safety of treatments for acute gout: results from a series of systematic literature reviews including cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors.
J Rheumatol 2014;suppl 92:15-25
575. van Durme C, van Echteld IAAM, Falzon L, Aletaha D, van der Heijde DMFM, Landewé RB. Cardiovascular risk factors and comorbidities in patients with hyperuricemia and/or gout: a systematic review of the literature.
J Rheumatol 2014;suppl 92:9-14
574. Sivera F, Andrés M, Falzon L, van der Heijde DMFM, Carmona L. Diagnostic value of clinical, laboratory, and imaging findings in patients with a clinical suspicion of gout: a systematic literature review.
J Rheumatol 2014;92:3-8
573. van der Heijde D, Buchbinder R. Introduction diagnosis and management of gout. systematic literature reviews of the 3e initiative, 2011–2012.
J Rheumatol 2014;ppl 92:1-2
572. Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Iwai K, Sakamaki Y, van der Heijde D, Miyasaka N, Koike T. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.
Mod Rheumatol 2014;24:715-24
571. Hafström I, Engvall I-L, Rönnelid J, Boonen A, van der Heijde D, Svensson B. Rheumatoid factor and anti-CCP do not predict progressive joint damage in patients with early rheumatoid arthritis treated with prednisolone: A randomised study.
BMJ Open 2014;4:e005246
570. Kavanaugh A, McInnes IB, Mease P, Krueger GG, Gladman D, van der Heijde D, Zhou Y, Lu J, Leu JH, Goldstein N, Beutler A. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial, the GO-REVEAL study).
Ann Rheum Dis 2014;73:1689-94

569. Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, Miceli-Richard C, Wei JC, Pedersen R, Bonin R, Rahman MU, Logeart I, Wajdula J, Koenig AS, Vlahos B, Alvarez D, Bukowski JF. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial.

Arthritis Rheumatol. 2014 Aug;66(8):2091-102

568. van der Heijde D, Deodhar A, Braun J, Mack M, Hsu B, Gathany TA, Inman RD, Han C, and the GO-RAISE investigators. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial.

J Rheumatol 2014;41:1095-1103

567. van Gaalen FA, Bakker PAC, de Hooge M, Schoones JW, van der Heijde D. Assessment of sacroiliitis by radiographs and MRI: Where are we now?

Curr Opin Rheum 2014;26:384-8

566. van Onna M, van Tubergen A, van der Heijde DM, Jurik AG, Landewé R. Bone Marrow Edema on Magnetic Resonance Imaging (MRI) of the Sacroiliac Joints Is Associated with Development of Fatty Lesions on MRI over a 1-year Interval in Patients with Early Inflammatory Low Back Pain: A 2-year Followup Study.

J Rheumatol 2014;41:1088-94

565. de Rooy DPC, van Nies JAB, Kapetanovic MC, Kristjansdottir H, Andersson MLE, Forslind K, van der Heijde DMFM, Gregersen PK, Lindqvist E, Huizinga TWJ, Gröndal G, Svensson B, van der Helm-van Mil AHM. Smoking as a risk factor for the radiological severity of rheumatoid arthritis: a study on six cohorts. Ann Rheum Dis 2014; 73:1384-7

564. Fagerli KM, van der Heijde D, Heiberg MS, Wierød A, Kalstad S, Rødevand E, Mikkelsen K, Kvien TK, Lie E. Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study.

Rheumatology 2014;53:1087-94

563. Stolwijk C, van Tubergen A, Ramiro S, Essers I, Blaauw M, van der Heijde D, Landewé R, van den Bosch F, Dougados M, Boonen A. Aspects of validity of the self-administered comorbidity questionnaire in patients with ankylosing spondylitis.

Rheumatology 2014;53:1054-64

562. Maksymowych WP, van der Heijde D, Allaart CF, Landewé R, Boire G, Tak PP, Gui Y, Ghahary A, Kilani R, Marotta A. 14-3-3 η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage.

Arthritis Res Ther 2014;16:R99

561. D'Agostino MA, Boers M, Kirwan J, van der Heijde D, Østergaard M, Schett G, Landewé RB, Maksymowych WP, Naredo E, Dougados M, Iagnocco A, Bingham CO, Brooks PM, Beaton DE, Gandjbakhch F, Gossec L, Guillemin F, Hewlett SE, Kloppenburg M, March L, Mease PJ, Moller I, Simon LS, Singh JA, Strand V, Wakefield RJ, Wells GA, Tugwell P, Conaghan PG. Updating the OMERACT Filter: Implications for Imaging and Soluble Biomarkers.

J Rheumatol 2014;41:1016-24

560. Tugwell P, Boers M, D'Agostino MA, Beaton D, Boonen A, Bingham CO, Choy E, Conaghan PG, Dougados M, Duarte C, Furst DE, Guillemin F, Gossec L, Heiberg T, van der Heijde DM, Hewlett S, Kirwan JR, Kvien TK, Landewé RB, Mease PJ, Ostergaard M, Simon L, Singh JA, Strand V, Wells G. Updating the OMERACT Filter: Implications of Filter 2.0 to Select Outcome Instruments Through Assessment of "Truth": Content, Face, and Construct Validity.

J Rheumatol 2014;41:1000-4

559. Wells G, Beaton DE, Tugwell P, Boers M, Kirwan JR, Bingham CO, Boonen A, Brooks P, Conaghan PG, D'Agostino MA, Dougados M, Furst DE, Gossec L, Guillemin F, Helliwell P, Hewlett S, Kvien TK, Landewé

- RB, March L, Mease PJ, Ostergaard M, Simon L, Singh JA, Strand V, van der Heijde DM Updating the OMERACT Filter: Discrimination and Feasibility.
J Rheumatol 2014;41:1005-10
558. Gvozdenovic E, Koevoets R, Wolterbeek R, van der Heijde D, Huizinga T, Allaart C, Landewé R. Assessment of global disease activity in RA patients monitored in the METEOR database: the patient's versus the rheumatologist's opinion.
Clin Rheumatol 2014;33:461-6
557. Braun J, Baraliakos X, Hermann K-GA, Deodhar A, van der Heijde D, Inman R, Beutler A, Zhou Y, Xu S, Hsu B. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial.
Ann Rheum Dis 2014;73:1107-13
556. Navarro-Compán V, van der Heijde D, Ahmad HA, Miller CG, Wolterbeek R, Landewé R. Measurement error in the assessment of radiographic progression in rheumatoid arthritis (RA) clinical trials: the smallest detectable change (SDC) revisited.
Ann Rheum Dis 2014;73:1067-70
555. Nam JL, Villeneuve E, Hensor EMA, Wakefield RJ, Conaghan PG, Green MJ, Gough A, Quinn M, Reece R, Cox SR, Buch MH, van der Heijde DM, Emery P. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial.
Ann Rheum Dis 2014;73:1027-36
554. Kloppenburg M, Bøyesen P, Smeets W, Haugen I, Liu R, Visser W, van der Heijde DM. Report from the OMERACT Hand Osteoarthritis Special Interest Group: Advances and Future Research Priorities.
J Rheumatol 2014;41:810-8 Erratum J Rheum 2014;41:1033
553. van Onna M, van Tubergen A, van der Heijde D, Jurik AG, Landewé R. Gadolinium contrast-enhanced MRI sequence does not have an incremental value in the assessment of sacroiliitis in patients with early inflammatory back pain by using MRI in combination with pelvic radiographs: a 2-year follow-up study.
Clin Exp Rheumatol 2014;32:225-30
552. van der Heijde D, Sieper J, Maksymowych W, Brown M, Lambert R, Rathmann S, Pangal A. Spinal inflammation in the absence of sacroiliac joint inflammation on MRI in patients with active non-radiographic axial spondyloarthritis.
Arthritis Rheum 2014;66:667-73
551. Hemke R, Doria AS, Tzaribachev N, Maas M, van der Heijde DM, van Rossum MA. Selecting Magnetic Resonance Imaging (MRI) Outcome Measures for Juvenile Idiopathic Arthritis (JIA) Clinical Trials: First Report of the MRI in JIA Special Interest Group.
J Rheumatol 2014;41:354-8
550. van der Heijde D, Zack D, Wajdula J, Sridharan S, Koenig A. Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis.
Scand J Rheumatol 2014;43:49-53
549. Ramiro S, van Tubergen A, van der Heijde D, Van den Bosch F, Dougados M, Landewé R. How to deal with missing items in BASDAI and BASFI.
Rheumatology 2014;53:374 -6
548. Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, van der Heijde D, Winthrop K, Landewé R. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
Ann Rheum Dis 2014;73:529-35
547. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgerit

F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, [van der Heijde D](#). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Ann Rheum Dis* 2014;73:492-509

546. Kroon FPB, van der Burg LRA, Ramiro S, Landewé RBM, Buchbinder R, [van der Heijde D](#). Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis) (Protocol). *Cochrane Database of Systematic Reviews* 2014;1:CD010952. DOI: 10.1002/14651858.CD010952

545. Keystone E, Breedveld F, [van der Heijde D](#), Landewé R, Florentinus S, Arulmani U, Liu S, Kupper H, Kavanaugh A. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension. *J Rheumatol* 2014;41:5-14

544. van Tuyl LHD, [van der Heijde D](#), Knol DL, Boers M. Chronological reading of radiographs in rheumatoid arthritis increases efficiency and does not lead to bias. *Ann Rheum Dis* 2014;73:391-5

543. McInnes IB, Sieper J, Braun J, Emery P, [van der Heijde D](#), Isaacs JD, Dahmen G, Wollenhaupt J, Schulze-Koops H, Kogan J, Ma S, Schumacher MM, Bertolino AP, Hueber W, Tak PP. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. *Ann Rheum Dis* 2014;73:349-56

542. Sivera F, Andres M, Carmona L, Kydd ASR, Moi J, Seth R, Sriranganathan M, van Durme C, van Echteld I, Vinik O, Wechalekar MD, Aletaha D, Bombardier C, Buchbinder R, Edwards CJ, Landewé R, Bijlsma JW, Branco JC, Burgos-Vargas R, Catrina AI, Elewaut D, Ferrari AJL, Kiely P, Leeb BF, Montecucco C, Muller-Ladner U, Østergaard M, Zochling J, Falzon L [van der Heijde DM](#). Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. *Ann Rheum Dis* 2014;73:328-35

541 Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, Reveille JD, Rudwaleit M, [van der Heijde D](#), Stach C, Hoepken B, Fichtner A, Coteur G, de Longueville M, Sieper J. Efficacy of Certolizumab Pegol on Signs and Symptoms of Axial Spondyloarthritis including Ankylosing Spondylitis: 24 Week Results of a Double-Blind Randomized Placebo-Controlled Phase 3 Study. *Ann Rheum Dis* 2014;73:39-47

540. Schiff M, Weinblatt ME, Valente R, [van der Heijde D](#), Citera G, Elegbe A, Maldonado M, Fleischmann R. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. *Ann Rheum Dis* 2014;73:86-94

539. Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, Woltering F, Stach C, Hoepken B, Arledge T, [van der Heijde D](#). Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). *Ann Rheum Dis* 2014;73:48-55

538. [van der Heijde D](#), Fleischmann R, Wollenhaupt J, Deodhar AA, Kielar D, Woltering F, Stach C, Hoepken B, Arledge T Mease PJ. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. *Ann Rheum Dis* 2014;73:233-7

537. Nam JL, Villeneuve E, Hensor EMA, Conaghan PG, Keen HI, Buch MH, Gough AK, Green MJ, Helliwell PS, Keenan AM, Morgan AW, Quinn M, Reece R, [van der Heijde DM](#), Wakefield RJ, Emery P. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study) *Ann Rheum Dis* 2014;73:75-85

536. Fagerli KM, Lie E, [van der Heijde D](#), Schrupf Heiberg M, Stavland Lexberg A, Rodevand E, Kalstad S, Mikkelsen K, Kvien TK. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. *Ann Rheum Dis* 2014;73:132-7

535. Schoels M, Braun J, Dougados M, Emery P, Fitzgerald O, Kavanaugh A, Kvien TK, Landewé R, Luger T, Mease P, Olivieri I, Reveille J, Ritchlin C, Rudwaleit M, Sieper J, Smolen JS, de Wit M, [van der Heijde D](#). Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. *Ann Rheum Dis* 2014;73:238-42

534. Smolen JS, Braun J, Dougados M, Emery P, FitzGerald O, Helliwell P, Kavanaugh A, Kvien TK, Landewé R, Luger T, Mease P, Olivieri I, Reveille J, Ritchlin C, Rudwaleit M, Schoels M, Sieper J, de Wit M, Baraliakos X, Betteridge N, Burgos-Vargas R, Collantes-Estevez E, Deodhar A, Elewaut D, Gossec L, Jongkees M, Maccarone M, Redlich K, Van den Bosch F, Cheng-Chung Wei J, Winthrop K, [van der Heijde D](#). Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. *Ann Rheum Dis* 2014;73:6-16

533. Smolen J, [van der Heijde D](#), Machold K, Aletaha D, Landewé R. Proposal for new nomenclature of disease-modifying antirheumatic drugs. *Ann Rheum Dis* 2014;73:3-5

2013

532. Machado P, Landewé R, [van der Heijde D](#). New developments in the diagnosis and treatment of axial spondyloarthritis. *Clinical Investigation* 2013;3:153-71

531. Ciurea A, Scherer A, Exer P, Bernhard J, Dudler J, Beyeler B, Kissling R, Stekhoven D, Rufibach K, Tamborrini G, Weiss B, Mueller R, Nissen M, Michel B, [van der Heijde D](#), Dougados M, Boonen A, Weber U; Rheumatologists of the Swiss Clinical Quality Management Program for Axial Spondyloarthritis. Tumor necrosis factor-alpha inhibition in radiographic and non-radiographic axial spondyloarthritis: results from a large observational cohort. *Arthritis Rheum* 2013;65:3096-3106

530. Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, [van der Heijde D](#), McInnes I, van Laar JM, Landewé R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2013;385:1705-13

529. [van der Heijde D](#), Braun J, Deodhar A, Inman RD, Xu S, Mack ME, Hsu B. Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE). *Rheumatology* 2013;52:321-5

528. Knevel R, Tsonaka R, Le Cessie S, van der Linden M, Huizinga T, [van der Heijde D](#), Houwing-Duistermaat J, van der Helm-van Mil A. Comparison of methodologies for analysing the progression of joint destruction in rheumatoid arthritis. *Scand J Rheumatol* 2013;42:182-9

527. Keystone EC, [van der Heijde D](#), Kavanaugh A, Kupper H, Liu S, Guérette B, Mozaffarian N. Clinical, functional, and radiographic benefits fo longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis.
J Rheumatol 2013;40:1487-97
526. van den Berg R, de Hooge M, van Gaalen F, Reijnierse M, Huizinga T, [van der Heijde D](#). Percentage of patients with spondyloarthritis in patients referred because of chronic back pain and performance of classification criteria: experience from the SpondyloArthritis Caught Early (SPACE) cohort.
Rheumatology 2013;52:1492-9 Correction in Rheumatology 2015;54:1336
525. Haugen I, Slatkowsky-Christensen B, Bøyesen P, [van der Heijde D](#), Kvien T. Cross-sectional and longitudinal associations between radiographic features and measures of pain and physical function in hand osteoarthritis.
Osteoarthritis Cartilage 2013;21:1191-8
524. Grandaunet B, Watterdal Syversen S, Hoff M, Haugeberg G, van der Heijde D, Kvien TK, Standal T. Dickkopf-1 Is Associated with Periarticular Bone Loss in Patients with Rheumatoid Arthritis.
OJRA 2013;3:216-20
523. Kiltz U, Baraliakos X, Braun J, [van der Heijde D](#). Withdrawal of medical therapies in axial spondyloarthritis: what would be the optimal trial design?
Clin Exp Rheum 2013;31:Suppl.78:47-50
522. Kavanaugh A, McInnes IB, Mease PJ, Krueger GG, Gladman DD, [van der Heijde D](#), Mudivarthi S, Xu W, Mack M, Xu Z, Beutler A. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study.
Ann Rheum Dis 2013;72:1777-85
521. Fagerli KM, Lie E, [van der Heijde D](#), Schrupf Heiberg M, Kalstad S, Rodevand E, Mikkelsen K, Stavland, Lexberg A, Kvien TK. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.
Ann Rheum Dis 2013;72:1840-4
520. van den Berg R, de Hooge M, Rudwaleit M, Sieper J, van Gaalen F, Reijnierse M, Landewé R, Huizinga T, [van der Heijde D](#). ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort.
Ann Rheum Dis 2013;72:1646-53
519. Siebuhr A, Bay-Jensen A, Leeming DJ, Platt A, Byrjalsen I, Christiansen C, [van der Heijde D](#), Karsdal M. Serological identification of fast progressors of structural damage with rheumatoid arthritis
Arthritis Research & Therapy 2013, 15:R86
518. Moltó A, Paternotte S, Comet D, Thibout E, Rudwaleit M, Claudepierre P, [van der Heijde D](#), Dougados M. Performances of the Assessment of SpondyloArthritis International Society Axial Spondyloarthritis Criteria for Diagnostic and Classification Purposes in Patients Visiting a Rheumatologist Because of Chronic Back Pain: Results From a Multicenter, Cross-Sectional Study.
Arthritis Care & Research 213;65:1472-81
517. Helliwell PS, Mease PJ, Fitzgerald O, Taylor WJ, [van der Heijde D](#). Peripheral Spondyloarthritis and Psoriatic Arthritis; Overlaps and Distinctions: A Report from the GRAPPA 2012 Annual Meeting.
J Rheumatol 2013;40:1446-9
516. Krabben A, Stomp W, [van der Heijde DMFM](#), van Nies JAB, Bloem JL, Huizinga TWJ, Reijnierse M, van der Helm-van Mil AHM. MRI of hand and foot joints of patients with anticitrullinated peptide antibody positive arthralgia without clinical arthritis.
Ann Rheum Dis 2013;72:1540-4

515. Navarro-Compán V, Landewé R, Ahmad HA, Miller CG, Xu D, Wolterbeek R, [van der Heijde D](#). Rate of adjudication of radiological progression in rheumatoid arthritis randomized controlled trials depending on preset limits of agreement: a pooled analysis from 15 randomized trials. *Rheumatology* 2013;52:1404-7
514. de Hooge M, van den Berg R, Navarro-Compán V, van Gaalen F, [van der Heijde D](#), Huizinga T, Reijnen M. Magnetic resonance imaging of the sacroiliac joints in the early detection of spondyloarthritis: No added value of gadolinium compared with short tau inversion recovery sequence. *Rheumatology* 2013;52:1220-4
513. Landewé R, Strand V, [van der Heijde D](#). From inhibition of radiographic progression to maintaining structural integrity: a methodological framework for radiographic progression in rheumatoid arthritis and psoriatic arthritis clinical trials. *Ann Rheum Dis* 2013;72:1113-7
512. Halvorsen S, Kjøpke Vøllestad N, Arrestad Provan S, Semb A, van der Heijde D, Hagen KB, Dagfinrud H. Cardiorespiratory Fitness and Cardiovascular Risk in Patients With Ankylosing Spondylitis: A Cross-Sectional Comparative Study *Arthritis Care Res* 2013;65:969-76
511. Mandl P, Balint PV, Brault Y, Backhaus M, D'Agostino MA, Grassi W, [van der Heijde D](#), de Miguel E, Wakefield RJ, Logeart I, Dougados M. Clinical and Ultrasound-Based Composite Disease Activity Indices in Rheumatoid Arthritis: Results From a Multicenter, Randomized Study *Arthritis Care Res* 2013;65:879-87
510. Smolen JS, [van der Heijde DM](#), Keystone EC, van Vollenhoven RF, Goldring MB, Guerette B, Cifaldi MA, Chen N, Liu S, Landewé RBM. Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate. *Ann Rheum Dis* 2013;72:1156-62
509. van Gaalen FA, Verduijn W, Roelen EL, Bohringer S, Huizinga TWJ, [van der Heijde DM](#), Toes REM. Epistasis between two HLA antigens defines a subset of individuals at a very high risk for ankylosing spondylitis. *Ann Rheum Dis* 2013;72:974-8
508. Koevoets R, Dirven L, Klarenbeek NB, van Krugten MV, Ronday HK, [van der Heijde DMFM](#), Huizinga TWJ, Kerstens PSJM, Lems WF, Allaart CF. Insights in the relationship of joint space narrowing versus erosive joint damage and physical functioning of patients with RA. *Ann Rheum Dis* 2013;72:870-4
507. Sieper J, [van der Heijde D](#), Dougados M, Mease PJ, Maksymowych WP, Brown MA, Arora V, Pangan AL. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). *Ann Rheum Dis* 2013;72:815-22
506. Colebatch AN, Edwards CJ, Østergaard M, [van der Heijde D](#), Balint PV, D'Agostino M-A, Forslind K, Grassi W, Haavardsholm EA, Haugeberg G, Jurik A-G, Landewé RBM, Naredo E, O'Connor PJ, Ostendorf B, Potocki K, Schmidt WA, Smolen JS, Sokolovic S, Watt I, Conaghan PG. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. *Ann Rheum Dis* 2013;72:804-14
505. Vossen MHE, den Broeder AA, Hendriks-Roelofs F, [van der Heijde DMFM](#), Reijnen M. Improvement in deployment of MRI of the sacroiliac joints in patients suspected for spondyloarthritis using a targeted intervention: A case study. *Rheumatology* 2013;52:933-8

504. Maehlen, M.T., Provan, S.A., de Rooy, D.P.C., van der Helm-van Mil, A.H.M., Krabben, A., Saxne, T., Lindqvist, E., Semb, A.G., Uhlig, T., van der Heijde, D., Mero, I.L., Olsen, I.C., Kvien, T.K., Lie, B.A. Associations between APOE Genotypes and Disease Susceptibility, Joint Damage and Lipid Levels in Patients with Rheumatoid Arthritis. PLoS ONE , 2013;8:art. no. e60970

503. Engvall I-L, Svensson B, Boonen A, van der Heijde D, Lerner UH, Hafström I. Low-dose prednisolone in early rheumatoid arthritis inhibits collagen type I degradation by matrix metalloproteinases as assessed by serum 1CTP-A possible mechanism for specific inhibition of radiological destruction. Rheumatology 2013;52:733-42

502. Dougados M, Devauchelle-Pensec V, Ferlet JF, Jousse-Joulin S, D'Agostino M-A, Backhaus M, Bentin J, Chales G, Chary-Valckenaere I, Conaghan P, Wakefield RJ, Etcheparre F, Gaudin P, Grassi W, van der Heijde D, Mariette X, Naredo E, Szkudlarek M. The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound Ann Rheum Dis 2013;72:665-71

501. van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, Cardiel MH, Cohen S, Nash P, Song Y-W, Tegzová D, Wyman BT, Gruben D, Benda B, Wallenstein G, Krishnaswami S, Zwillich SH, Bradley JD, Connell CA, and the ORAL Scan Investigators. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013;65:559-70

500. Sieper J, van der Heijde D. Review: Nonradiographic axial spondyloarthritis: New definition of an old disease? Arthritis Rheum 2013;65:543-51

499. Schoels MM, van der Heijde D, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murikama MM, Nishimoto N, Smolen JS. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis 2013;72 583-9

498. Smolen JS, Schoels MM, Nishimoto N, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Betteridge N, Bingham C, Bykerk V, Choy E, Combe B, Cutolo M, Graninger W, Lanasa A, Martin-Mola E, Montecucco C, Østergaard, Pavelka K, Rubbert-Roth A, Sattar N, Scholte-Voshaar M, Tanaka Y, Trauner M, Valentini G, Winthrop KL, de Wit M, van der Heijde D. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2013;72 482-92

497. Knevel R, Lukas C, van der Heijde D, Rincheval N, Combe B, van der Helm-van Mil AHM. Defining erosive disease typical of RA in the light of the ACR/EULAR 2010 criteria for rheumatoid arthritis; results of the data driven phase. Ann Rheum Dis 2013;72 590-5

496. van der Heijde D, van der Helm-van Mil AHM, Aletaha D, Bingham CO, Burmester GR, Dougados M, Emery P, Felson D, Knevel R, Kvien TK, Landewé RBM, Lukas C, McInnes I, Silman AJ, Smolen JS, Stanislawska-Biernat E, Zink A, Combe B. EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. Ann Rheum Dis 2013;72 479-81

495. Ramiro S, van Tubergen A, Stolwijk C, Landewé R, van den Bosch F, Dougados M, van der Heijde D. [Scoring radiographic progression in ankylosing spondylitis: Should we use the modified Stoke Ankylosing Spondylitis Spine Score \(mSASSS\) or the Radiographic Ankylosing Spondylitis Spinal Score \(RASSS\)?](#) Arthritis Research & Therapy 2013, 15:R14 (17 January 2013)

494. Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, Maldonado M, Fleischmann R.

Head-to-Head Comparison of Subcutaneous Abatacept versus Adalimumab for Rheumatoid Arthritis.
Arthritis Rheum 2013;65:28-38

2012

493. [van der Heijde D](#), Deodhar A, Inman RD, Braun J, Hsu B, Mack M. Comparison of three methods for calculating the Bath Ankylosing Spondylitis Metrology Index in the GO-RAISE study.
Arthritis Care Res 2012;64:1919-22

492. Tubach F, Ravaud P, Martin-Mola E, Awada H, Bellamy N, Bombardier C, Felson D, Hassouni N, Hochberg M, Logeart I, Matucci-Cerinic M, van de Laar M, [van der Heijde D](#), Dougados M. Minimal clinically important improvement and patient acceptable symptomatic state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: The reflect multinational study.
Arthritis Care Res 2012;64:1699-1707

491. Poddubnyy D, [van der Heijde D](#). Therapeutic controversies in spondyloarthritis: Nonsteroidal anti-inflammatory drugs.
Rheumatic Dis Clin North America 2012;38:601-11

490. Machado P, Landewé RBM, Braun J, Baraliakos X, Hermann K-GA, Hsu B, Baker D, [van der Heijde D](#). MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor.
Ann Rheum Dis 2012;71:2002-5

489. Lie E, Uhlig T, [van der Heijde D](#), Rødevand E, Kalstad S, Kaufmann C, Mikkelsen K, Kvien TK. Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA.
Rheumatology 2012;51:670-8

488. Radner H, Ramiro S, Buchbinder R, Landewé RB, [van der Heijde D](#), Aletaha D. Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity.
Cochrane Database Syst Rev 2012 Jan 18;1:CD008951

487. Baraliakos X, van den Berg R, Braun J, [van der Heijde D](#). Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis.
Rheumatology 2012;51:1378-87

486. Whittle SL, Colebatch AN, Buchbinder R, Edwards CJ, Adams K, Englbrecht M, Hazlewood G, Marks JL, Radner H, Ramiro S, Richards BL, Turner IH, Aletaha D, Bombardier C, Landewé RB, Müller-Ladner U, Bijlsma JWJ, Branco JC, Bykerk VP, da Rocha Castelar Pinheiro G, Catrina AI, Hannonen P, Kiely P, Leeb B, Lie E, Martinez-Osuna P, Montecucco C, Østergaard M, Westhovens R, Zochling J, [van der Heijde D](#). Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative
Rheumatology 2012;51:1416-25

485. van Tubergen A, [van der Heijde D](#), Dougados M, Mielants H, Landewé R. Are syndesmophytes most prevalent in the lumbar or in the cervical spine in patients with ankylosing spondylitis and do they develop in a specific direction?
Rheumatology 2012;51:1432-9

484. van den Berg R, Baraliakos X, Braun J, [van der Heijde D](#). First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.
Rheumatology 2012;51:1388-96

483. [van der Heijde D](#), Keystone EC, Curtis JR, Landewé RB, Schiff MH, Khanna D, Kvien TK, Ionescu L, Gervitz LM, Davies OR, Luijstens K, Furst DE. Timing and magnitude of initial change in Disease Activity Score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial. *J Rheumatol* 2012;39:1326-33
482. Keystone EC, Combe B, Smolen J, Strand V, Goel N, van Vollenhoven R, Mease P, Landewé R, Fleischmann R, Luijstens K, [van der Heijde D](#). Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. *Rheumatology* 2012;51:1628-38
481. Kroon F, Landewé R, Dougados M, [van der Heijde D](#). Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. *Ann Rheum Dis* 2012;71:1623-9
480. [van der Heijde DM](#). Pain management by pharmacotherapy in inflammatory arthritis. Systematic literature reviews of the 3e initiative 2010. *J Rheumatol* 2012;39 (Suppl 90):1-2
479. Englbrecht M, Tarner IH, [van der Heijde DM](#), Manger B, Bombardier C, Müller-Ladner U. Measuring pain and efficacy of pain treatment in inflammatory arthritis: A systematic literature review. *J Rheumatol* 2012;39 (Suppl 90):3-10
478. Radner H, Ramiro S, [van der Heijde DM](#), Landewé R, Buchbinder R, Aletaha D. How do gastrointestinal or liver comorbidities influence the choice of pain treatment in inflammatory arthritis? A Cochrane systematic review. *J Rheumatol* 2012;39 (Suppl 90):74-80
477. Richards BL, Whittle SL, [van der Heijde DM](#), Buchbinder R. The efficacy and safety of muscle relaxants in inflammatory arthritis: A Cochrane systematic review. *J Rheumatol* 2012;39 (Suppl 90):34-9
476. Tarner IH, Englbrecht M, Schneider M, [van der Heijde DM](#), Müller-Ladner U. The role of corticosteroids for pain relief in persistent pain of inflammatory arthritis: A systematic literature review. *J Rheumatol* 2012;39 (Suppl 90):17-20
475. Richards BL, Whittle SL, [van der Heijde DM](#), Buchbinder R. The efficacy and safety of antidepressants in inflammatory arthritis: A Cochrane systematic review. *J Rheumatol* 2012;39 (Suppl 90):21-27
474. Richards BL, Whittle SL, [van der Heijde DM](#), Buchbinder R. Efficacy and safety of neuromodulators in inflammatory arthritis: A Cochrane systematic review. *J Rheumatol* 2012;39 (Suppl 90):28-33
473. Ramiro S, Radner H, [van der Heijde DM](#), Buchbinder R, Aletaha D, Landewé RB. Combination therapy for pain management in inflammatory arthritis. A Cochrane systematic review. *J Rheumatol* 2012;39 (Suppl 90):47-55
472. Adams K, Bombardier C, [van der Heijde D](#). Safety of pain therapy during pregnancy and lactation in patients with inflammatory arthritis: A systematic literature review. *J Rheumatol* 2012;39 (Suppl 90):59-61
471. Colebatch AN, Marks JL, [van der Heijde DM](#), Edwards CJ. Safety of nonsteroidal anti-inflammatory drugs and/or paracetamol in people receiving methotrexate for inflammatory arthritis. A Cochrane systematic review. *J Rheumatol* 2012;39 (Suppl 90):62-73
470. Adams K, Bombardier C, [van der Heijde D](#). Safety and efficacy of on-demand versus continuous use of

nonsteroidal anti-inflammatory drugs in patients with inflammatory arthritis: A systematic literature review.

J Rheumatol 2012;39 (Suppl 90):56-8

469. Marks JL, van der Heijde DM, Colebatch AN, Buchbinder R, Edwards CJ. Pain pharmacotherapy in patients with inflammatory arthritis and concurrent cardiovascular or renal disease: A Cochrane systematic review.

J Rheumatol 2012;39 (Suppl 90):81-4

468. Hazlewood G, van der Heijde DM, Bombardier C. Paracetamol for the management of pain in inflammatory arthritis: A systematic literature review.

J Rheumatol 2012;39 (Suppl 90):11-6

467. Whittle SL, Richards BL, van der Heijde DM, Buchbinder R. The efficacy and safety of opioids in inflammatory arthritis: A Cochrane systematic review.

J Rheumatol 2012;39 (Suppl 90):40-6

466. van der Heijde D, Braun J, Dougados M, Sieper J, Pedersen R, Szumski A, Koenig AS. Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial

Rheumatology 2012;51:1894-1905

465. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St.Clair EW, Bridges Jr SL, Zhang J, McVie T, Howard G, van der Heijde D, Cofield SS. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The treatment of early aggressive rheumatoid arthritis trial.

Arthritis Rheum 2012;64:2824-35

464. Kavanaugh A, van der Heijde D, McInnes IB, Mease P, Krueger GG, Gladman DD, Gómez-Reino J, Papp K, Baratelle A, Xu W, Mudivarthi S, Mack M, Rahman MU, Xu Z, Zrubek J, Beutler A. Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.

Arthritis Rheum 2012;64:2504-17

463. van den Berg R, van Gaalen F, van der Helm-van Mil A, Huizinga T, van der Heijde D. Performance of classification criteria for peripheral spondyloarthritis and psoriatic arthritis in the Leiden early arthritis cohort.

Ann Rheum Dis 2012;71:1366-9

462. Hermann K-G, Baraliakos X, van der Heijde DMFM, Jurik A-G, Landewé R, Marzo-Ortega H, Østergaard M, Rudwaleit M, Sieper J, Braun J. Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: A consensual approach by the ASAS/OMERACT MRI study group.

Ann Rheum Dis 2012;71:1278-88

461. Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Kaufmann C, Rødevand E, Mikkelsen K, Kalstad S, Kvien TK. Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria.

Rheumatology 2012;51:1479-83

460. Dougados M, Brault Y, Logeart I, van der Heijde D, Gossec L, Kvien T. Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: The example of the Rheumatoid Arthritis Impact of Disease (RAID).

Arthritis Research Ther 2012;14:R129

459. Chung H-Y, Machado P, van der Heijde D, D'Agostino M-A, Dougados M. Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort.

Ann Rheum Dis 2012;71:809-16

458. Haugen IK, Bøyesen P, Slatkowsky-Christensen B, Sesseng S, [van der Heijde D](#), Kvien TK. Associations between MRI-defined synovitis, bone marrow lesions and structural features and measures of pain and physical function in hand osteoarthritis. *Ann Rheum Dis* 2012;71:899-904
457. Braun J, Baraliakos X, Hermann K-G, [van der Heijde D](#), Inman RD, Deodhar AA, Barattelle A, Xu S, Xu W, Hsu B. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. *Ann Rheum Dis* 2012;71:878-84
456. Radner H, Ramiro S, Buchbinder R, Landewé RBM, [van der Heijde D](#), Aletaha D. Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritides) and gastrointestinal or liver comorbidity. *Cochrane Database Syst Rev* 2012 Jan 18;1:CD008951
455. Braun J, Deodhar A, Inman RD, [van der Heijde D](#), Mack M, Xu S, Hsu B. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study, *Ann Rheum Dis* 2012;71:661-7
454. Wagner C, Visvanathan S, Braun J, [van der Heijde D](#), Deodhar A, Hsu B, Mack M, Elashoff M, Inman RD. Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab. *Ann Rheum Dis* 2012;71:674-80
453. Sieper J, [van der Heijde D](#), Dougados M, Brown LS, Lavie F, Pangan AL. Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. *Ann Rheum Dis* 2012;71:700-6
452. [van der Heijde D](#). Remission by imaging in rheumatoid arthritis: should this be the ultimate goal? *Ann Rheum Dis* 2012;71 i89-i92
451. Mandl P, Balint PV, Brault Y, Backhaus M, D'Agostino M-A, Grassi W, [van der Heijde D](#), de Miguel D, Wakefield RJ, Logeart I, Dougados M. Metrologic properties of ultrasound versus clinical evaluation of synovitis in rheumatoid arthritis: Results of a multicenter, randomized study. *Arthritis Rheum* 2012;64:1272-82
450. van Tubergen A, Ramiro S, [van der Heijde D](#), Dougados M, Mielants H, Landewé R. Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. *Ann Rheum Dis* 2012;71 518-23
449. Berdal G, Halvorsen S, [van der Heijde D](#), Mowe M, Dagfinrud H. Restrictive pulmonary function is more prevalent in patients with ankylosing spondylitis than in matched population controls and is associated with impaired spinal mobility: A comparative study. *Arthritis Res Ther* 2012;14(1):R19
448. Lillegraven S, [van der Heijde D](#), Uhlig T, Kvien TK, Haavardsholm E. What is the clinical relevance of erosions and joint space narrowing in RA? *Nat Rev Rheumatol* 2012;8:117-20
447. [van der Heijde D](#), Machado P, Braun J, Hermann K-GA, Baraliakos X, Hsu B, Baker D, Landewé R. MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. *Ann Rheum Dis* 2012;71:369-73
446. Haugen IK, Bøyesen P, Slatkowsky-Christensen B, Sesseng S, Bijsterbosch J, [van der Heijde D](#), Kvien TK. Comparison of features by MRI and radiographs of the interphalangeal finger joints in patients with hand osteoarthritis. *Ann Rheum Dis* 2012;71:345-50

445. Ash Z, Gaujoux-Viala C, Gossec L, Hensor E, FitzGerald O, Winthrop K, [van der Heijde D](#), Emery P, Smolen JS, Marzo-Ortega H. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis.
Ann Rheum Dis 2012;71:319-26

444. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, [van der Heijde D](#), FitzGerald O, Aletaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Canete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P, Kavanaugh A, Kvien TK, Landewé R, Luger T, Maccarone M, McGonagle D, McHugh N, McInnes IB, Ritchlin C, Sieper J, Tak PP, Valesini G, Vencovsky J, Winthrop KL, Zink A, Emery P. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.
Ann Rheum Dis 2012;71:4-12

2011

443. Ramiro S, Radner H, [van der Heijde D](#), van Tubergen A, Buchbinder R, Aletaha D, Landewé RB. Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).
Cochrane Database Syst Rev 2011 Oct 5;(10):CD008886

442. Gooch, K; Feeny, D; Wong, RL; Kupper, H; Pangan, AL; Revicki, DA; van der Heijde, D. Is the Health Utilities Index 3 valid for patients with ankylosing spondylitis?
Value Health. 2011 Jan;14(1):160-5

441. Landewé R, [van der Heijde D](#). New considerations in the design of clinical trials for ankylosing spondylitis.
Clinical Investigation 2011;1:1505-12

440. Dougados M, d'Agostino MA, Benessiano J, Berenbaum F, Breban M, Claudepierre P, Combe B, Dargent-Molina P, Daurès JP, Fautrel B, Feydy A, Goupille P, Leblanc V, Logeart I, Pham T, Richette P, Roux C, Rudwaleit M, Saraux A, Treluyer JM, [van der Heijde D](#), Wendling D. The DESIR cohort: A 10-year follow-up of early inflammatory back pain in France: Study design and baseline characteristics of the 708 recruited patients.
Revue du Rhumatisme (Edition Francaise) 2011;78:446-452
Joint Bone Spine. 2011;78:598-603

439. Baraliakos X, Landewé R, [van der Heijde D](#), Listing J, Baker D, Hsu B, Braun J. The relationship of biomarkers and radiographic progression in patients treated with infliximab.
Eur Musc Rev 2011;6:94-95

438. van den Berg R, Stanislawska-Biernat E, [van der Heijde D](#). Comparison of recommendations for the use of anti-tumour necrosis factor therapy for ankylosing spondylitis in 23 countries.
Rheumatology 2011;50:2270-7

437. Emery P, [van der Heijde D](#), Østergaard M, Conaghan PG, Genovese MC, Keystone EC, Fleischmann R, Hsia EC, Xu W, Xu S, Rahman MU. Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis.
Ann Rheum Dis 2011;70:2126-30

436. Lie E, [van der Heijde D](#), Uhlig T, Mikkelsen K, Kalstad S, Kaufmann C, Rodevand E, Kvien TK. Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register.
Ann Rheum Dis 2011;70:2103-10

435. Maehlen MT, Nordang GB, Syversen SW, [van der Heijde DM](#), Kvien TK, Uhlig T, Lie BA. FCRL3 -169C/C genotype is associated with anti-citrullinated protein antibody-positive rheumatoid arthritis and with radiographic progression.

J Rheumatol 2011;38:2329-35

434. Mjaavatten MD, van der Heijde DM, Uhlig T, Haugen AJ, Nygaard H, Bjørneboe O, Kvien TK. Should Anti-citrullinated Protein Antibody and Rheumatoid Factor Status Be Reassessed During the First Year of Followup in Recent-Onset Arthritis? A Longitudinal Study.

J Rheumatol 2011;38:2336-41

433. Haraoui B, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Codreanu C, Pereira Da Silva J, de Wit M, Dougados M, Durez P, Emery P, Eurico Fonseca J, Gibofsky A, Gomez-Reino J, Graninger W, Hamuryudan V, Jose Jannaut M, Kalden J, Kvien TK, Laurindo I, Martin-Mola E, Montecucco C, Santos Moreno P, Pavelka K, Poor G, Cardiel MH, Stanislawska-Biernat E, Takeuchi T, van der Heijde D for the Treat to Target Taskforce. Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire.

Ann Rheum Dis 2011;70:1999-2002

432. van Onna M, Jurik AG, van der Heijde D, van Tubergen A, Heuft-Dorenbosch L, Landewé R. HLA-B27 and gender independently determine the likelihood of a positive MRI of the sacroiliac joints in patients with early inflammatory back pain: a 2-year MRI follow-up study.

Ann Rheum Dis 2011;70:1981-5

431. Chung HY, Machado P, van der Heijde D, D'Agostino M-A, Dougados M. HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging: results from the DESIR cohort of patients with recent onset axial spondyloarthritis.

Ann Rheum Dis 2011;70:1930-6

430. Brakenhoff LKPM, van der Heijde DM, Hommes DW. IBD and arthropathies: a practical approach to its diagnosis and management.

Gut 2011;60:1426-35

429. Klarenbeek NB, Koevoets R, van der Heijde DMFM, Gerards AH, tenWolde S, Kerstens PJSM, Huizinga TWJ, Dijkmans BAC, Allaart CF. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis.

Ann Rheum Dis 2011;70:1815-21

428. Machado P, Landewé R, Braun J, Hermann K-G, Baraliakos X, Baker D, Hsu B, van der Heijde D. A stratified model for health outcomes in ankylosing spondylitis.

Ann Rheum Dis 2011;70:1758-64

427. Strand V, Kingsbury SR, Woodworth T, Landewé R, Ostergaard M, Peterfy C, van der Heijde D, D'Agostino MA, Maksymowych W, Tak PP, Wells G, Conaghan PG. OMERACT 10 Sharp symposium: Important findings in examination of imaging methods for measurement of joint damage in rheumatoid arthritis.

J Rheumatol 2011;38:2009-13

426. Landewé RB, Strand V, Conaghan PG, van der Heijde D. Damage and progression on radiographs in individual joints: data from pivotal randomized controlled trials.

J Rheumatol 2011;38:2018-22

425. Baraliakos X, van der Heijde D, Braun J, Landewé RB. OMERACT Magnetic Resonance Imaging initiative on structural and inflammatory lesions in ankylosing spondylitis – Report of a Special Interest Group at OMERACT 10 on sacroiliac joint and spine lesions.

J Rheumatol 2011;38:2051-4

424. Haugen IK, Moe RH, Slatkowsky-Christensen B, Kvien TK, van der Heijde D, Garratt A. The AUSCAN subscales, AIMS-2 hand/finger subscale, and FIOHA were not unidimensional scales.

J Clin Epid 2011;64:1039-46

423. Rahman MU, Buchanan J, Doyle MK, Hsia EC, Gathany T, Parasuraman S, Aletaha D, Matteson EL, Conaghan PG, Keystone E, van der Heijde D, Smolen JS. Changes in patient characteristics in anti-tumour

necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years.

Ann Rheum Dis 2011;70 1631-1640

422. Giles JT, van der Heijde DM, Bathon JM. Association of circulating adiponectin levels with progression of radiographic joint destruction in rheumatoid arthritis.

Ann Rheum Dis 2011;70 1562-1568

421. Machado PMMC, Landewé RBM, van der Heijde D. Endorsement of definitions of disease activity states and improvement scores for the Ankylosing Spondylitis Disease Activity Score: Results from OMERACT 10

J Rheumatol 2011;38;1502-6

420. Lukas C, Combe B, Ravaud P, Sibilia J, Landewé R, D van der Heijde. Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis data from the Etude et Suivi des Polyarthrites Indifférenciées Récentes (Study and Followup of Early Undifferentiated Polyarthritis).

Arthritis Rheum 2011;63:1804-11

419. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JWJ, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.

Reumatologia 2011;19:5-21

418. Koevoets R, Klarenbeek NB, Guler-Yuksel M, van Oosterhout M, van Krugten MV, Kerstens PSJM, Huizinga TWJ, Dijkmans BAC, van der Heijde DMFM, Allaart CF. Simplified versions of the original disease activity score: validation in the BeSt trial.

Ann Rheum Dis 2011;70 1471-4

417. Bijsterbosch J, Haugen IK, Malines C, Maheu E, Rosendaal FR, Watt I, Berenbaum F, Kvien TK, van der Heijde DM, Huizinga TWJ, Kloppenburg M. Reliability, sensitivity to change and feasibility of three radiographic scoring methods for hand osteoarthritis,

Ann Rheum Dis 2011;70 1465-7

416. Scherer HU, van der Woude D, Willemze A, Trouw LA, Knevel R, Syversen SW, van der Linden MPM, Lie B, Huizinga TWJ, van der Heijde DMFM, van der Helm-van Mil AHM, Kvien TK, Toes REM.

Distinct ACPA fine specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis.

Ann Rheum Dis 2011;70 1461-4

415. van der Heijde D, Landewé R. Dramatic repair of joint damage in psoriatic arthritis.

J Rheumatol 2011;38:969-70

414. Machado P, van der Heijde D. How to measure disease activity in axial spondyloarthritis?

Current Opinion in Rheumatology 2011;23:339-45

413. Kiltz U, van der Heijde D, Cieza A, Boonen A, Stucki G, Ustun B, Braun J. Developing and validating an index for measuring health in patients with ankylosing spondylitis.

Rheumatology 2011;50:894-8

412. Haugen IK, Lillegraven S, Slatkowsky-Christensen B, Haavardsholm EA, Sesseng S, Kvien TK, van der Heijde D, Boyesen P. Hand osteoarthritis and MRI: development and first validation step of the proposed Oslo Hand Osteoarthritis MRI score.

Ann Rheum Dis 2011;70:1033-8

411. Vastesaeger N, van der Heijde D, Inman RD, Wang Y, Deodhar A, Hsu B, Rahman MU, Dijkmans B,

Geusens P, Vander Cruyssen B, Collantes E, Sieper J, Braun J. Predicting the outcome of ankylosing spondylitis therapy.
Ann Rheum Dis 2011;70:973-81

410. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, Ferraccioli G, Gottenberg J-E, Isaacs J, Kvien TK, Mariette X, Martin-Mola E, Pavelka K, Tak PP, [van der Heijde D](#), van Vollenhoven RF, Emery P. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
Ann Rheum Dis 2011;70 909-920

409. [van der Heijde D](#), Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewé R, Rudwaleit M, Braun J for the Assessment of SpondyloArthritis international Society. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.
Ann Rheum Dis 2011;70 905-8

408. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman RD, Jongkees M, Khan MA, Kiltz U, Kvien TK, Leirisalo-Repo M, Maksymowych WP, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen BJ, [van der Heijde D](#). 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.
Ann Rheum Dis 2011;70 896-904

407. de Wit MPT, Smolen JS, Gossec L, [van der Heijde DMFM](#). Treating rheumatoid arthritis to target: the patient version of the international recommendations.
Ann Rheum Dis 2011;70 891-5

406. Emery P, Fleischmann R, [van der Heijde D](#), Keystone EC, Genovese MC, Conaghan PG, Hsia EC, Xu W, Baratelle A, Beutler A, Rahman MU. The effects of golimumab on radiographic progression in rheumatoid arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy.
Arthritis Rheum 2011;63:1200-10

405. Gooch K, Feeny D, Wong RL, Kupper H, Pangan AL, Revicki DA, [van der Heijde D](#). Is the Health Utilities Index 3 valid for patients with ankylosing spondylitis?
Value Health 2011;14:160-5

404. Landewé R, [van der Heijde D](#). Joint space narrowing, cartilage and physical function: are we deceived by measurements and distributions?
Ann Rheum Dis 2011;70:717-8

403. Hazlewood G, Aletaha D, Carmona L, Landewé RBM, [van der Heijde DM](#), Bijlsma JWJ, et al. Algorithm for identification of undifferentiated peripheral inflammatory arthritis: a multinational collaboration through the 3e Initiative.
J Rheumatol 2011;38:Suppl 87:54-8

402. Machado PMMS, Koevoets R, Bombardier C, [van der Heijde DM](#). The value of magnetic resonance imaging and ultrasound in undifferentiated arthritis: a systematic review.
J Rheumatol 2011;38:Suppl 87:31-7

401. Koevoets R, Machado P, Bombardier C, [van der Heijde DM](#). The value of conventional radiographs in undifferentiated arthritis: a systematic review.
J Rheumatol 2011;38:Suppl 87:26-30

400. Bombardier C, [van der Heijde D](#). Introduction how to investigate and follow up undifferentiated peripheral inflammatory arthritis? 3e Initiative 2008-2009: Systematic Reviews and Clinical Algorithm
J Rheumatol 2011;38:Suppl 87: 1-2

399. Hashimoto J, Garner P, [van der Heijde D](#), Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Yoshikawa H, Nishimoto N. [Humanized anti-interleukin-6-receptor antibody \(tocilizumab\) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk](#)

[for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study.](#)

Mod Rheumatol. 2011;21:10-5

398. [van der Heijde D](#). Erosions versus joint space narrowing in rheumatoid arthritis: what do we know? Ann Rheum Dis 2011;70 i116-i118

397. Grandaunet B, Syversen SW, Hoff M, Sundan A, Haugeberg G, [van der Heijde D](#), Kvien TK, Standal T. Association between high plasma levels of hepatocyte growth factor and progression of radiographic damage in the joints of patients with rheumatoid arthritis. Arthritis Rheum 2011;63:662-9

396. Bøyesen P, Haavardsholm EA, Østergaard M, [van der Heijde D](#), Sesseng S, Kvien TK. MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression. Ann Rheum Dis 2011;70 428-433

395. Felson DT, Smolen JS, Wells G, Zhang B, vanTuyl LHD, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewé R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, [van der Heijde D](#), Verstappen S, White B, Wolfe F, Zink A, Boers M. American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials Arthritis Rheum. 2011;63:573-86

394. Felson DT, Smolen JS, Wells G, Zhang B, vanTuyl LHD, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewé R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, [van der Heijde D](#), Verstappen S, White B, Wolfe F, Zink A, Boers M. American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials Ann Rheum Dis 2011;70 404-413

393. Dougados M, Paternotte S, Braun J, Burgos-Vargas R, Maksymowych WP, Sieper J, [van der Heijde D](#). ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis 2011;70:249-51

392. Bøyesen P, Haavardsholm EA, [van der Heijde D](#), Østergaard M, Berner Hammer H, Sesseng S, Kvien TK. Prediction of MRI erosive progression: a comparison of modern imaging modalities in early rheumatoid arthritis patients. Ann Rheum Dis 2011;70:176-9

391. Lie E, [van der Heijde D](#), Uhlig T, Mikkelsen K, Rodevand E, Koldingsnes W, Kaufmann C, Kvien TK. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis 2011;70:157-63

390. Machado P, Landewé R, Lie E, Kvien TK, Braun J, Baker D, [van der Heijde D](#), for the Assessment of SpondyloArthritis international Society. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70:47-53

389. Rudwaleit M, [van der Heijde D](#), Landewé, Akkoc N, Brandt J, Chou CT, Dougados M, Huang F, Gu J, Kirazli Y, Van den Bosch F, Olivieri I, Roussou E, Scarpato S, Sorensen IJ, Valle-Onate R, Weber U, Wei J, Sieper J. The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011;70:25-31

388. Machado P, Castrejon I, Katchamart W, Koevoets R, Kuriya B, Schoels M, Silva-Fernandez L, Thevissen K, Vercoutere W, Villeneuve E, Aletaha D, Carmona L, Landewé R, [van der Heijde D](#), Bijlsma JWJ, Bykerk V, Canhao H, Catrina AI, Durez P, Edwards CJ, Mjaavatten MD, Leeb BF, Losada B, Martin-Mola EM, Martinez-Osuna P, Montecucco C, Müller-Ladner U, Østergaard M, Sheane B, Xavier RM, Zochling J, Bombardier C. Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. *Ann Rheum Dis* 2011;70:15-24

2010

387. [van der Heijde D](#), Breedveld FC, Kavanaugh A, Keystone EC, Landewé R, Patra K, Pangan AL. Disease Activity, Physical Function, and Radiographic Progression After Longterm Therapy with Adalimumab Plus Methotrexate: 5-Year Results of PREMIER. *J Rheumatol* 2010;37:2237-46

386. Klarenbeek NB, Guler-Yuksel M, [van der Heijde DMFM](#), Hulsmans HMJ, Kerstens PJSM, Molenaar THE, de Sonnaville PBJ, Huizinga TWJ, Dijkmans BAC, Allaart CF. Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab. *Ann Rheum Dis* published 2010;69 2107-13

385. van den Berg R, [van der Heijde D](#). How should we diagnose spondyloarthritis according to the ASAS classification criteria. *Pol Arch Med Wewn* 2010;120:452-7

384. [van der Heijde D](#), Rudwaleit M, Landewé RBM, Sieper J. Justification for including MRI as a tool in the diagnosis of axial SpA. *Nat Rev Rheumatol* 2010;6:670-2 (doi:10.1038/nrrheum.2010.160)

383. Fransen J, Visser K, van Dongen H, Huizinga T, van Riel PLCM, [van der Heijde DM](#). Validity of the disease activity score in undifferentiated arthritis. *Arthritis Care Res* 2010;62:1392-8

382. Deodhar A, Braun J, Inman RD, Mack M, Parasuraman S, Buchanan J, Hsu B, Gathany T, [van der Heijde D](#). Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: Results from a randomized, placebo-controlled trial *Arthritic Care Res* 2010;62:1266-71

381. Brakenhoff LKPM, [van der Heijde DM](#), Hommes DW, Huizinga TWJ, Fidder HH. The joint-gut axis in inflammatory bowel diseases. *Journal of Crohn's and Colitis*; 2010;4:257-68

380. Dougados M, Jousse-Joulin S, Mistretta F, D'Agostino M-A, Backhaus M, Bentin J, Chales G, Chary-Valckenaere I, Conaghan P, Etchepare F, Gaudin P, Grassi W, [van der Heijde D](#), Sellam J, Naredo E, Szkudlarek M, Wakefield R, Saraux A. Evaluation of several ultrasonography scoring systems of synovitis and comparison to clinical examination: Results from a prospective multi-center study of rheumatoid arthritis. *Ann Rheum Dis* 2010;69:828-35

379. Landewé RBM, Houbiers JGA, Van den Bosch F, in't Hout J, Verschueren PCPM, Meijerink JH, van den Hoogen FHJ, Masek BA, Bruyn GAW, Wouters JMGW, Voskuyl AE, van Laar JM, Bijlsma JJW, [van der Heijde DMFM](#), Breedveld FC, van de Putte LBA, Miltenburg AMM, de Keyser F. Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial. *Ann Rheum Dis* 2010;69 1655-1659

378. van der Helm-van Mil AHM, Knevel R, [van der Heijde D](#), Huizinga TWJ. How to avoid phenotypic misclassification in using joint destruction as an outcome measure for rheumatoid arthritis?

Rheumatology 2010;49:1429-35

377. Zhang J, Redden DT, McGwin G Jr, Callahan LF, Smith EA, Alarcón GS, Moreland LW, van der Heijde DM, Brown EE, Arnett DK, Mikuls TR, Bridges SL Jr, for the Consortium for the Longitudinal Evaluations of African Americans with Early Rheumatoid Arthritis Investigators. Generalized bone loss as a predictor of three-year radiographic damage in African American patients with recent-onset rheumatoid arthritis. *Arthritis Rheum* 2010;62:2219-26

376. Machado P, Landewé R, Braun J, Hermann KG, Baker D, van der Heijde D. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. *Ann Rheum Dis* 2010;69:1465-70

375. Dougados M, Combe B, Braun J, Landewé R, Sibilia J, Cantagrel A, Feydy A, van der Heijde D, Leblanc V, Logeart I. A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. *Ann Rheum Dis* 2010;69:1430-5

374. Maksymowych WP, Gooch K, Dougados M, Wong RL, Chen N, Kupper H, van der Heijde D. Thresholds of patient-reported outcomes that define the patient acceptable symptom state in ankylosing spondylitis vary over time and by treatment and patient characteristics. *Arthritis Care Res* 2010;62:826-34

373. Pham T, van der Heijde DM, Pouchot J, Guillemin F. Development and validation of the French ASQoL questionnaire. *Clin Exp Rheumatol* 2010, 28 (3):379-85

372. Mjaavatten MD, van der Heijde D, Uhlig T, Haugen AJ, Nygaard H, Sidenvall G, Helgetveit K, Kvien TK. The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: A longitudinal study of 376 patients with very early undifferentiated arthritis. *Arthritis Research & Therapy* 2010;12:R76

371. Burgos PI, Causey ZL, Tamhane A, Kelley JM, Brown EE, Hughes LB, Danila MI, van Everdingen A, Conn DL, Jonas BL, Callahan LF, Smith EA, Brasington R, Moreland LW, van der Heijde DM, Alarcon GS, Bridges Jr SL. Association of IL4R single nucleotide polymorphisms with rheumatoid nodules in African Americans with rheumatoid arthritis. *Arthritis Research & Therapy* 2010;12:R75

370. Boonen A, Brinkhuizen T, Landewé R, van der Heijde D, Severens JL. Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. *Ann Rheum Dis* 2010;69:1123-8

369. van der Woude D, Syversen SW, van der Voort EIH, Verpoort KN, Goll GL, van der Linden MPM, van der Helm-van Mil AHM, van der Heijde DMFM, Huizinga TWJ, Kvien TK, REM Toes. The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis. *Ann Rheum Dis* 2010;69:1110-6

368. van der Heijde D, Maksymowych WP. Spondyloarthritis: state of the art and future perspectives. *Ann Rheum Dis* 2010;69:949-54

367. Knevel R, Huizinga TWJ, Aletaha D, Burmester G, Combe B, Landewé RB, Smolen JS, Sokka T, van der Heijde DMFM. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. *Ann Rheum Dis* 2010;69:987-94

366. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JWJ, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte

M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, [van der Heijde D](#). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.
Ann Rheum Dis 2010;69:955-63

365. Syversen SW, Haavardsholm EA, Boyesen P, Goll GL, Okkenhaug C, Gaarder PI, [van der Heijde D](#), Kvien TK. Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs.
Ann Rheum Dis 2010;69:845-50

364. Lukas C, [van der Heijde D](#), Fatenejad S, Landewé R. Repair of erosions occurs almost exclusively in damaged joints without swelling.
Ann Rheum Dis 2010;69:851-5

363. Bridges Jr SL, Causey ZL, Burgos PI, Huynh BQN, Hughes LB, Danila M, van Everdingen A, Ledbetter S, Conn DL, Tamhane A, Westfall AO, Jonas BL, Callahan LF, Smith EA, Brasington R, Moreland LW, Alarcón GS, [van der Heijde DM](#). [Radiographic severity of Rheumatoid Arthritis in African Americans: Results from a multicenter observational study](#).
Arthritis Care & Research 2010;62:624-31

362. Reilly MC, Gooch KL, Wong RL, Kupper H, [van der Heijde D](#). Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis.
Rheumatology 2010;48:812-9.

361. van der Linden MPM, Boja R, Klarenbeek NB, Huizinga TWJ, [van der Heijde DM](#), van der Helm-van Mil AHM. Repair of joint erosions in rheumatoid arthritis: prevalence and patient characteristics in a large inception cohort.
Ann Rheum Dis 2010;69:727-9

360. Lie E, [van der Heijde DMFM](#), Uhlig T, Heiberg MS, Koldingsnes W, Rodevand E, Kaufmann C, Mikkelsen K, Kvien TK. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
Ann Rheum Dis 2010;69:671-6

359. Schoels M, Knevel R, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas DT, Burmester G, Combe B, Cutolo M, Dougados M, Emery P, [van der Heijde D](#), Huizinga TWJ, Kalden J, Keystone EC, Kvien TK, Martin-Mola E, Montecucco C, de Wit M, Smolen JS. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search.
Ann Rheum Dis 2010;69:638-43

358. Smolen JS, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, [van der Heijde D](#) for the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force.
Ann Rheum Dis 2010;69:631-7

357. Machold KP, Landewé R, Smolen JS, Stamm TA, [van der Heijde DM](#), Verpoort KN, Brickmann K, Vazquez-Mellado J, Karateev DE, Breedveld FC, Emery P, Huizinga TWJ. The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis.
Ann Rheum Dis 2010;69:495-502

356. Emery P, Breedveld F, [van der Heijde D](#), Ferraccioli G, Dougados M, Robertson D, Pedersen R, Koenig AS, Freundlich B, for the Combination of Methotrexate and Etanercept in Early Rheumatoid Arthritis Trial Group. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis.
Arthritis Rheum 2010;62:674-82

355. Maksymowych WP, Gooch KL, Wong RL, Kupper H, [van der Heijde DMFM](#). Impact of age, sex, physical function, health-related quality of life and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis.
J Rheumatol 2010;37:385-92

354. Kiltz U, [van der Heijde D](#). Health-related quality of life in patients with rheumatoid arthritis and in patients with ankylosing spondylitis.
Clin Exp Rheumatol 2010;27(4 Suppl 55):S108-11

353. Syversen SW, Goll GL, [van der Heijde D](#), Landewé R, Lie BA, Ødegard S, Uhlig T, Gaarder PI, Kvien TK. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study.
Ann Rheum Dis 2010;69 345-351

352. Berner Hammer H, Ødegard S, Syversen SW, Landewé R, [van der Heijde D](#), Uhlig T, Møwinckel, Kvien TK. Calprotectin (a major S100 leukocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis.
Ann Rheum Dis published 2010;69:150-4

351. Boonen A, Braun J, van der Horst-Bruinsma I, Huang F, Maksymowych WP, Kostanjsek N, Cieza A, Stucki G, [van der Heijde D](#). The ASAS/WHO ICF Core Sets for Ankylosing Spondylitis: how to classify the impact of AS on functioning and health.
Ann Rheum Dis published 2010;69:102-7

350. Landewé RBM, Gunther KP, Lukas C, Braun J, Combe B, Conaghan PG, Dreinhofer K, Fritschy D, Getty J, van der Heide HJL, Kvien TK, Machold K, Mihai C, Mosconi M, Nelissen R, Pascual E, Pavelka K, Pileckyte M, Puhl W, Punzi L, Ruther W, San-Julian M, Tudisco C, Westhovens R, Witso E, [van der Heijde DMFM](#). EULAR/EFORT Recommendations for the diagnosis and initial management of patients with acute or recent onset swelling of the knee.
Ann Rheum Dis 2010;69:12-9

2009

349. Thabet M, Huizinga TWJ, [van der Heijde DM](#), van der Helm-van Mil AHM. The prognostic value of baseline erosions in undifferentiated arthritis.
Arthr Res Ther 2009;11:R155

348. Visser K, [van der Heijde DMFM](#). Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: A systematic review of the literature.
Clin Exp Rheumatol 2009;27:1017-25

347. Maksymowych WP, Fitzgerald O, Wells GA, Gladman DD, Landewé R, Østergaard M, Taylor WJ, Christensen R, Tak P-P, Boers M, Syversen SW, Bathon JM, Ritchlin CJ, Mease PJ, Bykerk VP, Garnero P, Geusens P, El-Gabalawy H, Aletaha D, Inman RD, Byers Kraus V, Kvien TK, [van der Heijde D](#). Proposal for Levels of Evidence Schema for Validation of a Soluble Biomarker Reflecting Damage Endpoints in RA, PsA, and AS, and Recommendations for Study Design
J Rheumatol 2009;36:1792-9

346. Maksymowych WP, Landewé R, Tak P-P, Ritchlin CJ, Østergaard M, Mease PJ, El-Gabalawy H, Garnero P, Gladman DD, Fitzgerald O, Aletaha D, Bykerk VP, Bathon JM, Syversen SW, Boers M, Geusens P, Inman RD, Kraus V, Kvien TK, Taylor WJ, Wells GA, [van der Heijde D](#). Reappraisal of OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage Endpoints in RA, PsA, and Spondyloarthritis: The OMERACT 9 v2 Criteria
J Rheumatol 2009;36:1785-91

345. Syversen SW, Landewé R, [van der Heijde D](#), Bathon JM, Boers M, Bykerk VP, Fitzgerald O, Gladman DD, Garnero P, Geusens P, Gladman DD, El-Gabalawy H, Inman RD, Kraus V, Kvien TK, Mease PJ, Østergaard M, Ritchlin CJ, Tak P-P, Taylor WJ, Maksymowych WP. Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in RA: A Systematic Literature

Search on 5 Candidate Biomarkers.
J Rheumatol 2009;36:1769-84

344. Landewé R, van der Heijde D. A systematic comparison of rheumatoid arthritis and ankylosing spondylitis: Structural outcomes.
Clin Exp Rheumatol 2009;27 (4 suppl 55):S102-S107

343. Kiltz U, van der Heijde D. Health-related quality of life in patients with rheumatoid arthritis and in patients with ankylosing spondylitis.
Clin Exp Rheumatol 2009;27 (4 suppl 55):S108-S111

342. Visser K, van der Heijde D, Dougados M. Methotrexate in rheumatoid arthritis: Experience and recommendations from the 3E initiative.
International Journal of Clinical Rheumatology, 4 (3):239243

341. Boonen A, van Berkel M, Cieza A, Stucki G, van der Heijde D. Which aspects of functioning are relevant for patients with ankylosing spondylitis: results of focus group interviews.
J Rheumatol 2009;36(11):2501-11

340. Vosse D, Landewé R, van der Heijde D, van der Linden S, van Staa T-P, Geusens P. Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case control study.
Ann Rheum Dis 2009;68:1839-42

339. van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landewé R. The ASDAS is a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis
Ann Rheum Dis 2009;68:1811-8

338. Haavardsholm EA, Østergaard M, Berner Hammer H, Boyesen P, Boonen A, van der Heijde D, Kvien TK. Monitoring anti-TNF{alpha} treatment in RA: Responsiveness of magnetic resonance imaging and ultrasonography of the dominant wrist compared to conventional measures of disease activity and structural damage.
Ann Rheum Dis 2009;68:1572-9

337. Lukas C, Landewé RBM, Fatenejad S, van der Heijde DMFM. Subtle changes in individual joints result in both positive and negative change scores in a patient: Results from a clinical trial in patients with rheumatoid arthritis.
Ann Rheum Dis 2009;68:1691-5

336. Boonen A, van Berkel M, Kirchberger I, Cieza A, Stucki G, van der Heijde D. Aspects relevant for functioning in patients with ankylosing spondylitis according to the health professionals: a Delphi study with the ICF as reference.
Rheumatology 2009;48 (8) : 997-1002

335. Smolen JS, van der Heijde DMFM, Aletaha D, Xu S, Han J, Baker D, St.Clair EW. Progression of radiographic joint damage in rheumatoid arthritis: Independence of erosions and joint space narrowing
Ann Rheum Dis 2009;68:1535-40

334. Rudwaleit M, Jurik A-G, Hermann K-G, Landewé R, van der Heijde D, Baraliakos X, Marzo-Ortega H, Ostergaard M, Braun J, Sieper J. Defining active sacroiliitis on Magnetic Resonance Imaging (MRI) for classification of axial spondyloarthritis - a consensual approach by the ASAS/ OMERACT MRI Group
Ann Rheum Dis 2009;68:1520-27

333. Sharp JT, Angwin J, Boers M, Duryea J, Finckh A, Hall JR, Kauffman JA, Landewé R, Langs G, Lukas C, Bernelot Moens HJ, Peloschek P, Strand V, van der Heijde D. Multiple computer-based methods of measuring joint space width can discriminate between treatment arms in the COBRA trial - Update of an ongoing OMERACT project.
J Rheumatol 2009;36 (8):1825-8

332. Braun J, [van der Heijde D](#), Doyle MK, Han C, Deodhar A, Inman R, de Vlam K, Burmester GR, Van den Bosch F, Xu S, Visvanathan S, Rahman MU. Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab. *Arthritis Rheum* 2009;61: 1032-6
331. van der Woude D, Young A, Jayakumar KJ, Mertens BJ, Toes REM, [van der Heijde D](#), Huizinga TWJ, van der Helm-van Mil AHM. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: Results from two large early arthritis cohorts. *Arthritis Rheum* 2009;61: 2262-71
330. van der Linden MPM, Feitsma AL, le Cessie S, Kern M, Olsson LM, Raychaudhuri S, Begovich AB, Chang M, Catanese JJ, Kurreeman FAS, van Nies J, [van der Heijde DM](#), Gregersen PK, Huizinga TWJ, Toes REM, van der Helm-Van Mil AHM. Association of a single-nucleotide polymorphism in CD40 with the rate of joint destruction in rheumatoid arthritis. *Arthritis Rheum* 2009;61: 2242-7
329. Kiltz U, [van der Heijde D](#), Mielants H, Feldtkeller E, Braun J. ASAS/EULAR recommendations for the management of ankylosing spondylitis - the patient version *Ann Rheum Dis* 2009;68:1381-6
328. Goldbach-Mansky R, Wilson M, Fleischmann R, Olsen N, Silverfield J, Kempf P, Kivitz A, Sherrer Y, Pucino F, Csako G, Costello R, Hang Pham T, Snyder C, [van der Heijde D](#), Tao X, Wesley R, Lipsky PR. Comparison of Tripterygium wilfordii Hook F Versus Sulfasalazine in the Treatment of Rheumatoid Arthritis. A Randomized Trial. *Ann Int Med* 2009;151:229-40
327. [van der Heijde DM](#), Revicki DA, Gooch KL, Wong RL, Kupper H, Harnam N, Thompson C, Sieper J, ATLAS Study Group. Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. *Arthritis Research & Therapy* 2009, 11:R124
326. [van der Heijde D](#), Salonen D, Weissman BN, Landewé R, Maksymowych WP, Kupper H, Ballal S, Gibson E, Wong R, Canadian (M03-606) study group, ATLAS study group. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. *Arthritis Research & Therapy* 2009, 11:R127
325. Dijkmans B, Emery P, Hakala M, Leirisalo-Repo M, Mola E.M, Paolozzi L, Salvarani C, Sanmarti R, Sibilia J, Sieper J, Van Den Bosch F, [van der Heijde D](#), van der Linden S, Wajdula J. Etanercept in the longterm treatment of patients with ankylosing spondylitis. *J Rheumatol* 2009;36 (6):1256-64.
324. [van der Heijde D](#), Burmester GR, Melo-Gomes JR, Codreanu C, Martin Mola E, Pedersen R, Robertson D, Chang D, Koenig AS, Freundlich B. Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy *Ann Rheum Dis* 2009;68:1113-8
323. Salliot C, [van der Heijde D](#). Long term safety of Methotrexate monotherapy in rheumatoid arthritis patients: A systematic literature research. *Ann Rheum Dis* 2009;68:1100-4
322. Visser K, [van der Heijde D](#). Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. *Ann Rheum Dis* 2009;68:1220-7
321. Visser K, Katchamart W, Loza W, Martinez-Lopez JA, Salliot C, Trudeau J, Bombardier C, Carmona L, [van der Heijde D](#), Bijlsma JWJ, Boumpas DT, Canhao H, Edwards CJ, Hamuryudan V, Kvien TK, Leeb BF,

Martin-Mola EM, Mielants H, Muller-Ladner U, Murphy G, Østergaard, Pereira IA, Ramos-Remus C, Valentini G, Zochling J, Dougados M. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative.

Ann Rheum Dis 2009;68:1086-93

320. Hashimoto J, Garnero P, van der Heijde D, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Yoshikawa H, Nishimoto N. A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs. Mod Rheumatol 2009;19:273-82

319. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sorensen IJ, Ozgocmen S, Roussou E, Valle-Onate R, Weber U, Wei J, Sieper J. The Development of Assessment of SpondyloArthritis international Society (ASAS) Classification Criteria for Axial Spondyloarthritis (Part II): Validation and Final Selection

Ann Rheum Dis 2009;68 777-783

318. Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, Burgos-Vargas R, Collantes-Estevez E, Davis J, Dijkmans B, Dougados M, Emery P, van der Horst-Bruinsma IE, Inman R, Khan MA, Leirisalo-Repo M, van der Linden S, Maksymowych WP, Mielants H, Olivieri I, Sturrock R, de Vlam K, Sieper J: The Development of Assessment of SpondyloArthritis international Society (ASAS) Classification Criteria for Axial Spondyloarthritis (Part I): Classification of paper patients by expert opinion including uncertainty appraisal

Ann Rheum Dis 2009;68:770-776

317. Sieper J, van der Heijde DM, Landewé RBM, Brandt J, Burgos-Vargas R, Collantes Estevez E, Dijkmans BAC, Dougados M, Khan MA, Leirisalo-Repo M, van der Linden S, Maksymowych WP, Mielants H, Olivieri I, M Rudwaleit. New criteria for inflammatory back pain in patients with chronic back pain - a real patient exercise of the Assessment in SpondyloArthritis international Society (ASAS)

Ann Rheum Dis 2009;68 784-788

316. Smolen JS, Landewé RBM, Mease PJ, Brzezicki J, Mason D, Luijstens K, van Vollenhoven RF, Kavanaugh A, Schiff MH, Burmester GR, Strand V, Vencovsky J, van der Heijde DMFM. Efficacy and Safety of Certolizumab Pegol Plus Methotrexate in Active Rheumatoid Arthritis: The RAPID 2 Study. A randomized controlled. Trial.

Ann Rheum Dis 2009;68 797-804

315. Halvorsen EH, Haavardsholm EA, Pollmann S, Boonen A, van der Heijde D, Kvien TK, Molberg Ø. Serum IgG antibodies to Peptidylarginine Deiminase 4 predict radiographic progression in rheumatoid arthritis patients treated with TNF- α blocking agents.

Ann Rheum Dis 2009;68:249-52

314. Cieza A, Hilfiker R, Boonen A, van der Heijde D, Braun J, Stucki G. Towards an ICF-based clinical measure of functioning in people with ankylosing spondylitis: a methodological exploration.

Disabil Rehabil. 2009;31(7):528-37

313. van der Heijde D, Schiff MH, Sieper J, Kivitz A, Wong R, Kupper H, Dijkmans BAC, Mease PJ, Davis Jr JC. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.

Ann Rheum Dis 2009;68 922-929

312. Landewé R, Dougados M, Mielants H, van der Tempel H, van der Heijde D. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine.

Ann Rheum Dis 2009;68 863-867

311. Smolen J, Han C, van der Heijde D, Emery P, Bathon J, Keystone E, Maini R, Kalden J, Aletaha D, Baker

D, Han J, Bala M, St.Clair E. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNF-blockade.
Ann Rheum Dis 2009;68 823-827

310. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, Dougados M, Hermann K-G, Landewé R, Maksymowych W, van der Heijde D. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis.
Ann Rheum Dis 2009;68 ii1-ii44

309. Lukas, C., Guillemin, F., Landewé, R., van der Heijde D, Logeart, I., Fautrel, B., Daures, J.P., Combe, B. Factors determining a DMARD initiation in early inflammatory arthritis patients. The ESPOIR cohort study.
Clin Exp Rheum 2009;27. 84-91.

308. Visvanathan S, van der Heijde D, Deodhar A, Wagner C, Baker D, Han J. and Braun J. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis.
Ann Rheum Dis 2009;68:175-182

307. Hafstrom I, Albertsson K, Boonen A, van der Heijde D, Landewé R.B.M, Svensson B, Remission achieved after 2 years treatment with low dose prednisolone in addition to DMARD's in early RA is associated with reduced joint destruction still present after 4 years: an open two year continuation study.
Ann Rheum Dis 2009;68 508-513

306. Hoff M, Haugeberg G, Ødegard S, Syversen SW, Landewé R, van der Heijde D, Kvien K. Cortical hand bone loss after one year in early rheumatoid arthritis predicts radiographic hand joint damage at 5 and 10 year follow-up.
Ann Rheum Dis 2009;68:324-9

305. Syversen SW, Goll GL, van der Heijde D, Landewé R, Gaarder PI, Odegard S, Haavardsholm EA, Kvien TK. Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression.
J Rheumatol 2009;36:2-7

304. Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, van der Linden S, van der Heijde D. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis
Ann Rheum Dis 2009;68 18-24

2008

303. Inman RD, Davis JC Jr., van der Heijde D, Diekman L, Sieper J, Kim SI, Mack M, Han J, Visvanathan S, Xu Z, Hsu B, Beutler A, Braun J. Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial
Arthritis Rheum 2008;58:3402-12

302. Keystone E, van der Heijde D, Mason D Jr, Landewé R, van Vollenhoven R, Combe B, Emery P, Strand V, Mease P, Desai C, Pavelka K. Certolizumab Pegol Plus Methotrexate Is Significantly More Effective Than Placebo Plus Methotrexate in Active Rheumatoid Arthritis. Findings of a Fifty-Two-Week, Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study.
Arthritis Rheum 2008;58:3319-29

301. van der Heijde D, Landewé R, Baraliakos X, Houben H, van Tubergen A, Williamson P, Xu W, Baker D, Goldstein N, Braun J, the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis.
Arthritis Rheum 2008;58: 3063-70

300. Karonitsch T, Aletaha D, Boers M, Bombardieri S, Combe B, Dougados M, Emery P, Felson D, Gomez-

Reino J, Keystone E, Kvien TK, Martin-Mola E, Matucci-Cerinic M, Richards P, van Riel P, Siegel J, Smolen JS, Sokka T, [van der Heijde D](#), van Vollenhoven R, Ward M, Wells G, Zink A, Landewé R. Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis

Ann Rheum Dis 2008;67:1365-73

299. Aletaha D, Landewé R, Karonitsch T, Bathon J, Boers M, Bombardier C, Bombardieri S, Choi H, Combe B, Dougados M, Emery P, Gomez-Reino J, Keystone E, Koch G, Kvien TK, Martin-Mola E, Matucci-Cerinic M, Michaud K, O'Dell J, Paulus H, Pincus T, Richards P, Simon L, Siegel J, Smolen JS, Sokka T, Strand V, Tugwell P, [van der Heijde D](#), van Riel P, Vlad S, van Vollenhoven R, Ward M, Weinblatt M, Wells G, White B, Wolfe F, Zhang B, Zink A, Felson D. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.

Ann Rheum Dis 2008;67:1360-4

298. Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P, Xu W, Visvanathan S, Baker D, Goldstein N, [van der Heijde D](#), The Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period.

Arthritis Rheum 2008;59(9):1270-8

297. Vosse D, Landewé R, Garnero P, [van der Heijde D](#), van der Linden S, Geusens P. Association of markers of bone- and cartilage degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis.

Rheumatology 2008;47(8):1219-22

296. [van der Heijde D](#), Pangan AL, Schiff MH, Braun J, Borofsky M, Torre J, Davis JC, Wong RL, Kupper H, Collantes E, for the ATLAS Study Group. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis

Ann Rheum Dis 2008;67 1218-1221

295. Lukas C, Sharp JT, Angwin J, Boers M, Duryea J, Hall JR, Kauffman JA, Landewé R, Langs G, Bernelot Moens HJ, Peloschek P, [van der Heijde D](#). Automated measurement of joint space width in small joints of patients with rheumatoid arthritis.

J Rheumatol. 2008;35(7):1288-1293

294. Zochling J, Sieper J, [van der Heijde D](#), Braun J. Development of a core set of domains for data collection of patients with ankylosing spondylitis receiving anti-tumor necrosis factor- α therapy.

J Rheum 2008;35(6):1079-82

293. Antoni CE, Kavanaugh A, [van der Heijde D](#), Beutler A, Keenan G, Zhou B, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman DD, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen JS. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: Findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).

J Rheum 2008;35(5):869-76

292. Cohen S, Dore R, Lane N, Ory P, Peterfy C, Sharp J, [van der Heijde D](#), Zhou L, Tsuji W, Newmark R. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.

Arthritis Rheum 2008;58(5):1299-309

291. [van der Heijde D](#), Landewé R, Einstein S, Ory P, Vosse D, Ni L, Lin S.-L, Tsuji W, Davis Jr. J. Radiographics progression of ankylosing spondylitis after up to two years of treatment with etanercept

Arthritis Rheum 2008;58(5):1324-31

290. Gossec L, Dougados M, Phillips C, Hammoudeh M, de Vlam K, Pavelka K, Pham T, Braun J, Sieper J, Olivieri I, [van der Heijde D](#), Collantes E, Stone M, Kvien T, and on behalf of ASA (ASsessment in AS international working Group). Dissemination and evaluation of the ASAS/EULAR recommendations for

the management of ankylosing spondylitis: results of a study among 1507 rheumatologists.
Ann Rheum Dis 2008;67:782-8

289. Kavanaugh A, Klareskog L, van der Heijde D, Li J, Freundlich B. and Hooper M.
Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate.
Ann Rheum Dis 2008;67:1444-7

288. van der Heijde D, Landewé R, Feldtkeller E, Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions.
Ann Rheum Dis 2008;67(4):489-93

287. Visvanathan S, Wagner C, Marini J.C, Baker D, Gathany T, Han J, van der Heijde D, Braun J.
Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.
Ann Rheum Dis 2008;67(4):511-7

286. Bons JAP, van der Heijde D, Bouwman FG, Mariman EC, van Diejen-Visser MP, Landewé R, van der Linden S, Wodzig W.K.W.H. Searching for potential biomarkers that can be used as biomarkers for diagnosing ankylosing spondylitis.
Biomarkers in Medicine 2008;2:23-30

285. Dougados M, Luo MP, Maksymowych WP, Chmiel JJ, Chen N, Wong RL, Davis Jr JC, van der Heijde D; for the ATLAS Study Group. The Patient Acceptable Symptom State (PASS) concept as a potential outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial.
Arthritis Care Res 2008;59:553-60

284. Halvorsen EH, Pollmann S, Gilboe IM, van der Heijde D, Landewé R, Ødegard S, Kvien TK, Molberg, O. Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity.
Ann Rheum Dis 2008;67(3):414-7

283. Dias EM, Lukas C, Landewé R, Fatenejad S, van der Heijde D. Reliability and sensitivity to change of the Simple Erosion Narrowing Score compared with the Sharp-van der Heijde method for scoring radiographs in rheumatoid arthritis.
Ann Rheum Dis 2008;67:375-9

282. Davis Jr JC, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, Fleischmann RM, Inman RD, Ni L, Lin S-L, Tsuji WH. Efficacy and safety of up to 192 weeks of etanercept therapy in patientst with ankylosing spondylitis.
Ann Rheum Dis 2008;67:346-52

281. Mikuls TR, Hughes LB, Westfall AO, Holers VM, Parrish L, van der Heijde D, van Everdingen M, Alarcon GS, Conn DL, Jonas B, Callahan LF, Smith EA, Gilkeson G, Howerd G, Moreland LW, Bridges Jr SL. Cigarette smoking, disease severity, and autoantibody expression in African American with recent-onset rheumatoid arthritis.
Ann Rheum Dis 2008;67 1529-1534

280. van der Heijde D, Landewé R, van Vollenhoven R, Fatenejad S, Klareskog L. Level of radiographic damage and radiographic progression are determinants of phycical function: a longitudinal analysis of the TEMPO trial.
Ann Rheum Dis 2008;67:1267-70

279. Syversen SW, Gaarder PI, Goll GL, Odegard S, Haavardsholm EA, Mowinckel P, van der Heijde D, Landewé R, Kvien TK. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study.
Ann Rheum Dis 2008;67:212-7

278. [van der Heijde D](#), Burmester G, Melo-Gomes J, Codreanu C, Martin Mola E, Pedersen R, Freundlich B, Chang DJ. For the Etanercept Study 400 investigators. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
Ann Rheum Dis 2008;67:182-8

2007

277. [van der Heijde D](#), Klareskog L, Landewé R, Bruyn GA, Cantagrel A, Durez P, Herrero-Beaumont G, Molad Y, Codreanu C, Valentini G, Zahora R, Pedersen R, MacPeck D, Wajdula S, Fatenejad S.; TEMPO Study Investigators. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis.
Arthritis Rheum 2007;56(12):3884-6

276. Han C, Smolen J, Kavanaugh A, [van der Heijde D](#), Braun J, Westhovens R, Zhao N, Rahman MU, Baker D, Bala M. The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases.
Arthritis Res Ther 2007;9(5):R103

275. Landewé R, [van der Heijde D](#). Primer: Challenges in randomized and observational studies.
Nature Clinical Practice Rheumatology 2007;3(11):661-6

274. Vosse D, Heijckmann C, Landewé R, [van der Heijde D](#), van der Linden S, Geusens P. Comparing morphometric X-ray absorptiometry and radiography in defining vertebral wedge fractures in patients with ankylosing spondylitis.
Rheumatology 2007;46(11):1667-71

273. Davis JC Jr, Revicki D, [van der Heijde DM](#), Rentz AM, Wong RL, Kupper H, Luo MP. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study.
Arthritis Rheum 2007;57(6):1050-7

272. [van der Heijde D](#), Kavanaugh A, Gladman DD, Antoni C, Krueger GG, Guzzo C, Zhou B, Dooley LT, de Vlam K, Geusens P, Birbara C, Halter D, Beutler A; IMPACT 2 Study. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.
Arthritis Rheum 2007;56(8):2698-2707

271. Gladman DD, Inman RD, Cook RJ, Maksymowych WP, Braun J, Davis JC, Landewé RB, Mease P, Brandt J, Vargas RB, Chandran V, Helliwell P, Kavanaugh A, O'shea FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone MA, Taylor W, Veale DJ, [van der Heijde D](#). International Spondyloarthritis Interobserver Reliability Exercise – The INSPIRE Study: II. Assessment of Peripheral Joints, Enthesitis, and Dactylitis.
J Rheumatol 2007;34(8):1740-5

270. Gladman DD, Inman RD, Cook RJ, [van der Heijde D](#), Landewé RB, Braun J, Davis JC, Mease P, Brandt J, Vargas RB, Chandran V, Helliwell P, Kavanaugh A, O'shea FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone MA, Taylor W, Veale DJ, Maksymowych WP. International Spondyloarthritis Interobserver Reliability Exercise – The INSPIRE Study: I. Assessment of Spinal Measures.
J Rheumatol 2007;34(8):1733-9

269. [van der Heijde D](#), Landewé R, Boonen A, Einstein SG, Herborn G, Rau R, Wassenberg S, Weissman BV, Winalski CS, Sharp JT. Expert agreement confirms that negative changes in hand and foot radiographs are a surrogate for repair in patients with rheumatoid arthritis.
Arthritis Res Ther 2007;9(4):R62

268. Maksymowych WP, Landewé R, Conner-Spady B, Dougados M, Mielants H, van der Tempel H, Poole AR, Wang N, [van der Heijde D](#). Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis.
Arthritis Rheum 2007;56(6):1846-53

267. Schett G, Landewé R, van der Heijde D. Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction?
Ann Rheum Dis 2007;66(6):709-11
266. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D, Kishimoto T. Study of Active Controlled Monotherapy Used for Rheumatoid Arthritis, an IL-6 inhibitor (SAMURAI): - Evidence of clinical and radiographic benefit from an X-Ray Reader-Blinded Randomized Controlled Trial of Tocilizumab.
Ann Rheum Dis 2007;66(9):1162-7.
265. Tubach F, Ravaud P, Beaton D, Boers M, Bombardier C, Felson DT, van der Heijde D, Wells G, Dougados M. Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders.
J Rheumatol 2007;34(5):1188-93
264. Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, Gottlieb AB, Krueger GG, Nash P, Ritchlin CT, Taylor W, Adebajo A, Braun J, Cauli A, Carneiro S, Choy E, Dijkmans B, Espinoza L, van der Heijde D, Husni E, Lubrano E, McGonagle D, Qureshi A, Soriano ER, Zochling J. Consensus on a core set of domains for psoriatic arthritis.
J Rheumatol 2007;34(5):1167-70
263. Gladman DD, Mease PJ, Healy P, Helliwell PS, Fitzgerald O, Cauli A, Lubrano E, Krueger GG, van der Heijde D, Veale DJ, Kavanaugh A, Nash P, Ritchlin C, Taylor W, Strand V. Outcome measures in psoriatic arthritis. J Rheumatol 2007;34(5):1159-66
262. Lie BA, Viken MK, Odegard S, van der Heijde D, Landewé R, Uhlig T, Kvien TK. Associations between the PTPN22 1858C>T polymorphism and radiographic joint destruction in patients with rheumatoid arthritis: Results from a 10-year longitudinal study.
Ann Rheum Dis 2007; 66(12):1604-09
261. Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, Rudwaleit M, Sieper J. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
Arthritis Rheum 2007;57(4):639-47
260. van der Heijde D, Landewé R, Sharp JT; OMERACT Subcommittee on Repair. Repair in rheumatoid arthritis, current status. Report of a workshop at OMERACT 8.
J Rheumatol 2007;34(4):884-8
259. Sharp JT, Angwin J, Boers M, Duryea J, von Ingersleben G, Hall JR, Kauffman JA, Landewé R, Langs G, Lukas C, Maillefert JF, Bernelot Moens HJ, Peloschek P, Strand V, van der Heijde D. Computer based methods for measurement of joint space width: update of an ongoing OMERACT project.
J Rheumatol 2007;34(4):874-83
258. van der Heijde D, Landewé R, Hermann KG, Rudwaleit M, Ostergaard M, Oostveen A, O'Connor P, Maksymowych WP, Lambert RG, Lukas C, Jurik AG, Boers M, Baraliakos X, Braun J; ASAS/OMERACT MRI in AS Working Group. Is there a preferred method for scoring activity of the spine by magnetic resonance imaging in ankylosing spondylitis?
J Rheumatol 2007;34(4):871-3
257. Lukas C, Braun J, van der Heijde D, Hermann KG, Rudwaleit M, Ostergaard M, Oostveen A, O'Connor P, Maksymowych WP, Lambert RG, Jurik AG, Baraliakos X, Landewé R; ASAS/OMERACT MRI in AS Working Group. Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment.
J Rheumatol 2007;34(4):862-70
256. van der Heijde D. Long-term effects of early treatment in patients with rheumatoid arthritis.
Nat Clin Pract Rheumatol 2007;3(5):258-9

255. Maksymowych WP, Landewé R, Boers M, Garnero P, Geusens P, El-Gabalawy H, Heinegard D, Krause V, Lohmander S, Matyas J, Saxne T, van der Heijde D. Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials. *J Rheumatol* 2007;34(4):634-40

254. Keeling SO, Landewé R, van der Heijde D, Bathon J, Boers M, Garnero P, Geusens P, El-Gabalawy H, Inman RD, Kraus VB, Kvien TK, Mease PJ, Ostergaard M, Ritchlin C, Syversen SW, Maksymowych WP. Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein. *J Rheumatol* 2007;34(3):623-33

253. Maksymowych WP, Richardson R, Mallon C, van der Heijde D, Boonen A. Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis. *Arthritis Rheum* 2007;57(1):133-9

252. Heuft-Dorenbosch L, Landewé R, Weijers R, Houben H, van der Linden S, Jacobs P. van der Heijde D. Performance of various criteria sets in patients with inflammatory back pain of short duration; the Maastricht early spondyloarthritis clinic. *Ann Rheum Dis* 2007;66(1):92-8

251. Diarra D, Solina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heijde D, Landewé R, Lacey D, Richards WG, Schett G. Dickkopf-1 is a master regulator of joint remodeling. *Nature Med* 2007;13(2):156-63

250. Boonen A, van der Heijde D, Landewé R, van Tubergen A, Mielants H, Dougados M, van der Linden S. How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis? *Ann Rheum Dis* 2007;66(6):771-7

249. Verstappen SM, Jacobs JW, van der Heijde DM, van der Linden S, Verhoef CM, Bijlsma JW, Boonen A. Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis. *Ann Rheum Dis* 2007;66(6):727-31

2006

248. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdman E, Laine L; MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomized comparison. *Lancet*. 2006 ;368(9549):1771-81

247. van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, Tornero-Molina J, Wajdula J, Pedersen R, Fatenejad S; TEMPO Study Investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. *Arthritis Rheum* 2006;54(4):1063-74

246. van Echteld I, Cieza A, Boonen A, Stucki G, Zochling J, Braun J, van der Heijde D. Identification of the most common problems by patients with ankylosing spondylitis using the international classification of functioning, disability and health. *J Rheumatol* 2006;33(12):2475-83

245. Spoorenberg A, van Tubergen A, Landewé R, Dougados M, van der Linden S, Mielants H. van der Tempel H, van der Heijde D. Krankheitsaktivität beim Morbus Bechterew aus Sicht des Arztes und aus Patientensicht *Morbus-Bechterew-Journal* 2006;105:4-6

244. Smolen JS, Han C, [van der Heijde D](#), Emery P, Bathon JM, Keystone E, Kalden JR, Schiff M, Bala M, Baker D, Han J, Maini RN, St Clair EW. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. *Arthritis Rheum* 2006;54(3):716-22

243. Braun J, [van der Heijde D](#). Preface. *Best Pract Res Clin Rheumatol* 2006;20(3):399-400

242. Landewé R, [van der Heijde D](#), Klareskog L, van Vollenhoven R, Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. *Arthritis Rheum* 2006;54(10):3119-25

241. [van der Heijde D](#), Canas Da Silva J, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X, Olivieri I, Raeman F, Settas L, Sieper J, Szechinski J, Walker D, Boussuge M-P, Wajdula J, Paolozzi L, Fatenejad S. Once-weekly 50 mg dosing of Etanercept (Enbrel) is as effective as 25 mg twice-weekly dosing in patients with ankylosing spondylitis. *Ann Rheum Dis* 2006;65:1572-7

240. Vosse, [van der Heijde](#), Landewé, Geusens, Mielants, Dougados, van der Linden. Determinants of hyperkyphosis in patients with ankylosing spondylitis. *Ann Rheum Dis* 2006;65:770-774

239. [van der Heijde D](#), Han C, DeVlam K, Burmester G, van den Bosch F, Williamson P, Bala M, Han J, Braun J. Infliximab Improves Productivity and Reduces Workday Loss In Patients With Ankylosing Spondylitis: Results from a Randomized, Placebo-Controlled Trial (ASSERT). *Arthritis Care Res* 2006;55:569-574

238. [van der Heijde D](#), Kivitz A, Schiff M, Sieper J, Dijkmans B, Braun J, Dougados M, Reveille J, Wong R, Kupper H, Davis J for the ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2006;54:2136-2

237. Zochling J, Braun J, [van der Heijde D](#). Assessments in ankylosing spondylitis. *Best Pract Res Clin Rheumatol* 2006;20(3):521-37

236. Mease P, [van der Heijde D](#). Joint damage in psoriatic arthritis: how is it assessed and can it be prevented ? *Int J Adv Rheumatol* 2006;4(2):38-48

235. Braun J, Landewé R, Hermann K-G, Han J, Yan S, Williamson P, [van der Heijde D](#) for the ASSERT Study Group. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. *Arthritis Rheum* 2006;54(5):1646-1652

234. Cannon C, Curtis S, Bolognese J, Laine L. for the MEDAL Steering Committee. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Study Program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. *AHJ* 2006;152(2):237-245

233. Geusens P, Landewé R, Garnero P, Chen D, Dunstan D, Lems W, Stinissen P, [van der Heijde D](#), van der Linden S, Boers. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. *Arthritis Rheum* 2006;54:1772-1777

232. Landewé R, [van der Heijde D](#). The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28.

Arthritis Research & Therapy, 2006 8:107

231. van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, Tornero-Molina J, Wajdula J, Pedersen R and Fatenejad S for the TEMPO Study Investigators. Comparison of Etanercept and Methotrexate, Alone and Combined, in the the Treatment of Rheumatoid Arthritis: Two-Year Clinical and Radiography Results from the TEMPO Study, ad Double-Blind, Randomized Trial. Arthritis Rheum 2006;54(4):1063-1074

230. **Landewé R, van der Heijde D, van der Linden S, Boers M.** Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission . Ann Rheum Dis 2006;65:637-641

229. Bathon J, Fleischmann, van der Heijde D, Tesser J, Peloso P, Chon Y, White B. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheum 2006;33:234-243

228. Smolen JS, van der Heijde DM, St. Clair EW, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Schiff M, Baker D, Han C, Han J, Bala M for the active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of earlyh onset (ASPIRE) study group. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 2006;54(3):702-10

227. Heuft-Dorenbosch L, Landewé R, Weijers R, Wanders A, Houben H, van der Linden S, van der Heijde D. Combining information obtained from MRI and conventional radiographs in order to detect sacroiliitis in patients with recent-onset inflammatory back pain. Ann Rheum Dis 2006;65:804-808

226. Kavanaugh A, Antoni C, Gladman D, Wassenberg S, Zhou B, Beutler A, Keenan G, Burmester G, Furst D, Weisman M, Kalden J, Smolen J, van der Heijde D. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): Results of radiographic analyses after 1 year. Ann Rheum Dis 2006;65(8):1038-43

225. Ødegård S, Landewé R, van der Heijde D, Kvien T, Mowinckel P, Uhlig T. Association of early radiographic damage with impaired physical function in rheumatoid arthritis: a ten-year, longitudinal observational study in 238 patients. Arthritis Rheum 2006;54(1):68-75

224. Pham T, Landewé R, van der Linden S, M Dougados M, Sieper J, Braun J, Davis J, Rudwaleit M, Collantes E, R Burgos-Vargas R, Edmonds J, I Olivieri I, van der Horst-Bruinsma I, Mielants H, Stone M, Emery P, van der Heijde D. An International Study on Starting TNF-blocking agents in Ankylosing Spondylitis (ISSAS). Ann Rheum Dis 2006;65(12):1620-5

223. Davis J, Dougados M, Braun J, Sieper J, van der Heijde D, van der Linden S. The Definition of Disease Duration in Ankylosing Spondylitis: Reassessing the Concept. Ann Rheum Dis 2006;65(11):1518-20

222. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis J, Dijkmans B, Dougados M, Geher P, Inman R, Khan A, Kvien T, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock R, van der Linden S, Wendling D, Bohm H, van Royen B, Braun J. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-452

221. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D for the ASAS working group. First Update of the International ASAS Consensus Statement for the Use of Anti-TNF Agents in Patients with Ankylosing Spondylitis Ann Rheum Dis 2006;65(3):316-320

220. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.

Ann Rheum Dis 2006;65:423-432

219. van der Heijde D, Klareskog L, Singh A, Tornero J, Melo-Gomes JM, Codreanu C, Pedersen R, Freundlich B, Fatenejad S. Patient-reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial

Ann Rheum Dis 2006;65(3):328-334

218. Boonen A, van der Heijde D, Severens J, Boendermaker A, Landewé R, Braun J, Brandt J, Sieper J, van der Linden S. Markov model into the cost-utility over five years of etanercept and infliximab compared to usual care in patients with active ankylosing spondylitis

Ann Rheum Dis 2006;65(2):201-8

217. Zochling J, van der Heijde D, Dougados M, Braun J. The process of producing recommendations for rheumatic diseases: what is evidence?

Ann Rheum Dis. 2006;65:979

216. Landewé R, Geusens P, van der Heijde D, Boers M, van der Linden S, Garnero P. Arthritis instantaneously causes collagen type I and type II degradation in patients with early rheumatoid arthritis: a longitudinal analysis

Ann Rheum Dis 2006;65:40-4

215. Heuft-Dorenbosch L, Weijers R, Landewé R, van der Linden S, van der Heijde D. Magnetic Resonance Imaging changes of sacroiliac joints in patients with recent-onset inflammatory back pain: inter-reader reliability and prevalence of abnormalities.

Arthritis Res Therapy 2006;8:R11

2005

214. Boonen A, van der Heijde D. Review of the cost of illness of ankylosing spondylitis and methodological notes.

Expert Rev Pharmacoeconomics Outcome Res 2005;5(2):163-81

213. Hermann K-GA, Landewé RBM, Braun J, van der Heijde DMFM. Magnetic resonance imaging of inflammatory lesions in the spine in ankylosing spondylitis clinical trials: Is paramagnetic contrast medium necessary?

J Rheumatol 2005;32:2056-60

212. Landewé R, Hermann K-G, van der Heijde D, Baraliakos X, Jurik A-G, Lambert R, Østergaard M, Rudwaleit M, Salonen D, Braun J and the ASAS/OMERACT MRI in AS working group. Scoring sacro-iliac joints by magnetic resonance imaging, a multiple-reader reliability experiment

J Rheumatol 2005;32:2050-5

211. van der Heijde D, Landewé R, and the ASAS working group. Selection of a method for scoring radiographs for AS clinical trials by ASAS and OMERACT.

J. Reumatol 2005 Oct; 32(10): 2048-49

210. van der Heijde D, Landewé R, Hermann K-G, Jurik A-G, Maksymowych W, Rudwaleit M, O'Connor P, Braun J and the ASAS/OMERACT MRI in AS working group. Application of the OMERACT filter to scoring methods for MRI of the SI joints and the spine. Recommendations for a research agenda at OMERACT 7.

J Rheumatol 2005;32:2042-7

209. Gladman D.D, Mease P, Kreuger G, van der Heijde D, Antoni C, Helliwell P, Kavanaugh A, Nash P, Ritchlin C, Strand V, Taylor W. Outcome measures in psoriatic arthritis (PsA).

J Rheumatol. 2005;32:2262-9

208. Landewé R, van der Heijde D. Radiographic progression in rheumatoid arthritis. Clin Exp Rheum 2005;23(suppl 39):S63-S68
207. Boonen A, Severens JL, van Tubergen A, Landewé R, Bonsel G, van der Heijde D, van der Linden SJ. Willingness of patients with ankylosing spondylitis to pay for inpatient treatment is influenced by the treatment environment and expectations of improvement. Ann Rheum Dis 2005;64:1650-52
206. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafström I for the BARFOT Study Group. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate. Arthritis Rheum 2005;52:3360-70
205. Landewé R, van der Heijde D. Presentation and analysis of radiographic data in clinical trials and observational studies. Ann Rheum Dis 2005;64 suppl IV:i48-51
204. Sharp JT, van der Heijde D, Angwin J, Duryea J, Bernelot Moens HJ, Jacobs JW, Maillfert JF, Strand CV. Measurement of Joint Space Width and Erosion Size J Rheumatol 2005;32(12):2456-61
203. Boonen A, van der Heijde D. Conventional x-ray in early arthritis. Rheum Dis Clin North Am 2005;31(4):681-98
202. Schuwirth L, Gorter S, van der Heijde D, Rethans JJ, Brauer J, Houben H, van der Linden, S, van der Vleuten C, Scherpbier A. The role of a computerised case-based testing procedure in practice performance assessment. Adv Health Sci Educ Theory Pract 2005;10(2);145-55
201. Davis JC, van der Heijde D, Dougados M, Woolley JM. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy Arthritis Rheum 2005;53:494-501
200. van der Heijde D, Landewé R, van der Linden S. How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured? Arthritis Rheum 2005;52:1979-1985
199. Wells G, Boers M, Shea B, Brooks P, Simon L, Strand V, Aletaha D, Anderson J, Bombardier C, Dougados M, Emery P, Felson D, Franssen J, Furst D, Hazes M, Johnson K, Kirwan J, Landewé R, Lassere M, Michaud K, Suarez-Amalzor M, Silman A, Smolen J, van der Heijde D, van Riel P, Wolfe F, Tugwell P. Minimal Disease Activity State for Rheumatoid Arthritis: A Preliminary Definition. J Rheum 2005;32(10):2016-24
198. Davis J, van der Heijde D, Dougados M, Braun J, Cush J, Clegg D, Inman R, de Vries T, Tsuji W. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rheumatol 2005;32(9):1751-4
197. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE and Lipsky PE for the ATTRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study Arthritis Rheum 2005;52:1020-1030
196. van der Heijde D, Landewé R. Imaging in spondylitis. Curr Opin Rheumatol 2005;17(4):413-7
195. Baraliakos X, Hermann K-G, Landewé R, Listing J, Golder W, Brandt J, Rudwaleit M, Bollow M, Sieper J, van der Heijde D, Braun J. Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging (MRI): a comparison between contrast enhanced T1 and short-tau

inversion recovery (STIR) sequences.
Ann Rheum Dis 2005;64:1141-1144

194. Baraliakos X, Landewé R, Hermann K-G, Listing J, Golder W, Brandt J, Rudwaleit M, Bollow M, Sieper J, van der Heijde D, Braun J. Inflammation in ankylosing spondylitis – a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging (MRI)
Ann Rheum Dis 2005;64:730-4

193. van der Heijde D, Klareskog L, Boers M, Landewé R, Codreanu C, Bolosiu H, Pedersen R, and Fatenejad S for the TEMPO investigators. Comparison of different definitions to classify remission and sustained remission: one year TEMPO results
Ann Rheum Dis 2005;64:1582-1587

192. Gossec L, van der Heijde D, Melian A, Krupa DA, James MK, Cavanaugh PF, Reicin AS and Dougados M. The Efficacy of Cyclo-oxygenase-2 Inhibition by Etoricoxib and Naproxen on the Axial Manifestations of Ankylosing Spondylitis in the Presence of Peripheral Arthritis
Ann Rheum Dis 2005;64:1563-67

191. Sigl T, Cieza A, van der Heijde D, Stucki G. ICF-based comparison of disease-specific instruments measuring physical functional ability for ankylosing spondylitis.
Ann Rheum Dis 2005;64:1576-1581

190. Davis JC, van der Heijde DM, Braun J, Dougados M, Cush J, Clegg D, Inman R, Kivitz A, Solinger A, Tsuji W. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.
Ann Rheum Dis 2005;64:1557-1562

189. Spoorenberg A, van Tubergen A, Landewé R, Dougados M, van der Linden Sj, Mielants H, van der Tempel H, van der Heijde D. Measuring Disease activity in Ankylosing Spondylitis (AS): Patients and physicians have different perspectives.
Rheumatology (Oxford) 2005;44:789-95

188. Bruynesteyn K, Boers M, Kostense P, van der Linden S, van der Heijde D. Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change
Ann Rheum Dis 2005;64:179-182

187. Boonen A, van den Heuvel R, van Tubergen A, Goossens M, Severens JL, van der Heijde D, van der Linden Sj. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain or ankylosing spondylitis.
Ann Rheum Dis 2005;64:396-402

186. Wanders A, van der Heijde D, Landewé R, Behier JM, Calin A, Olivieri I, Zeidler H, Dougados M. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial.

185. van der Heijde D, Baraf HS, Ramos-Remus C, Calin A, Weaver A, Schiff M, James M, Markind JE, Reicin AS, Melian A, Dougados M. Evaluation of the Efficacy of Etoricoxib in Ankylosing Spondylitis: Results of a 52-Week Randomized Controlled Study
Arthritis Rheum 2005;52:1205-1215

184. Wanders A, Landewé R, Dougados M, Mielants H, van der Linden Sj, van der Heijde D. Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation?
Ann Rheum Dis 2005;64 988-994

183. van der Heijde D, Landewé R, Klareskog L, Rodríguez-Valverde V, Settas L, Pedersen R, Fatenejad S. Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study.
Arthritis Rheum 2005;52:49-60

182. van der Heijde D, Dougados M, Davis J, Weisman M, Maksymowych W, Braun J, Hallegua D, Bruckel J. ASAS/SAA recommendations for conducting clinical trials in ankylosing spondylitis
Arthritis Rheum 2005;52:386-94

181. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J, and the ASSERT Study Group. Efficacy and Safety of Infliximab In Patients With Ankylosing Spondylitis: Results of a Randomized, Placebo-Controlled Trial (ASSERT)
Arthritis Rheum 2005;52:582-91

180. van der Heijde D, Sharp J, Wassenberg S, Gladman D. Psoriatic arthritis imaging: a review of scoring methods.
Ann Rheum Dis 2005;64 suppl 2:ii61-4

179. van der Heijde D, Braun J, Landewé R, Davis J, Sieper J, van der Linden S, Dougados M. ASsessment in Ankylosing Spondylitis (ASAS) international working group: a model for psoriatic arthritis and psoriasis?
Ann Rheum Dis 2005;64 Suppl 2:ii108-9

178. Nash P, Mease PJ, Braun J, and van der Heijde D. Seronegative spondyloarthropathies: to lump or split?
Ann Rheum Dis 2005; 64: ii9 - ii13

177. van der Heijde D, Boonen A. Importance of radiographic assessment in RA in clinical practice.
Int J Adv Rheumatol 2005;3:13-18

176. Breedveld F, Han C, Bala M, van der Heijde D, Baker D, Kavanaugh AF, Maini RN, Lipsky PE. Association Between Baseline Radiographic Damage and Improvement in Physical Function After Treatment of Patients with Rheumatoid Arthritis.
Ann Rheum Dis 2005;64:52-5

175. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, Bombardier C, Felson D, Hochberg M, van der Heijde D, Dougados M. Evaluation of clinically relevant changes in patient- reported outcomes in knee and hip osteoarthritis: the Minimal Clinically Important Improvement
Ann. Rheum Dis 2005;64:29-33

174. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, Bombardier C, Felson D, Hochberg M, van der Heijde D, Dougados M. Evaluation of clinically relevant states in patient- reported outcomes in knee and hip osteoarthritis: The Patient Acceptable Symptom State
Ann Rheum Dis Jun 2005;64(1)34-37

173. Schurgers LJ, Teunissen KJ, Knapen MH, Geusens P, van der Heijde D, Kwaijtaal M, van Diest R, Ketteler M, Vermeer C. Characteristics and performance of an immunosorbent assay for human matrix Gla-protein.
Clin Chim Acta 2005;351:131-8

2004

172-2. Spoorenberg A, de Vlam K, van der Linden S, Dougados M, Mielants H, van de Tempel H, van der Heijde D. Radiological scoring methods in ankylosing spondylitis. Reliability and change over 1 and 2 years.
J Rheumatol. 2004;31(1):125-32

172. Bruynesteyn K, van der Heijde D, Boers M, van der Linden S, Lassere M, van der Vleuten C. The Sharp/van der Heijde method out-performed the Larsen/Scott method on the individual patient level in assessing radiographs in early rheumatoid arthritis.
J Clin Epidemiol 2004;57(5):502-12

171. Heuft-Dorenbosch L, Vosse D, Landewé R, Spoorenberg A, Dougados M, Mielants H, van der Tempel H, van der Linden S, van der Heijde D. Measurement of spinal mobility in ankylosing spondylitis: comparison of Occiput-to-Wall and Tragus-to-Wall distance

J Rheum 2004;31(9):1779-84

170. Boonen A, van der Heijde D, Landewé R, Chorus A, van Lankveld W, Miedema H, van der Tempel H, van der Linden Sj. Is avoidant coping independent of disease activity and stable over time in patients with ankylosing spondylitis?

Ann Rheum Dis 2004;63(10):1264-8

169. Wanders A, Landewé R, Spoorenberg A, de Vlam K, Mielants H, Dougados M, van der Linden S, van der Heijde D. Scoring of radiographic progression in randomised clinical trials in ankylosing spondylitis: a preference for paired reading order.

Ann Rheum Dis 2004;63(12):1601-4.

168. van der Heijde D. Intensive management reduced disease activity in rheumatoid arthritis.

ACP J Club 2004;141(3):70.

167. Udrea G, Ciobanu C, Mihai C, Stoica V, Suteanu S, van der Heijde D, van der Linden S. Evaluation of a Romanian version of the Bath Ankylosing Spondylitis Functional Index (BASFI) in patients with spondylarthropathies.

Rom J Intern Med 2004;42(1):199-209.

166. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, Dewoody K, Weiss R, Baker D. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial.

Arthritis Rheum 2004;50(11):3432-3443

165. van der Heijde D. Quantification of radiological damage in inflammatory arthritis: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

Best Pract Res Clin Rheumatol 2004;18(6):847-860

164. Welsing P, Landewé R, van Riel P, Boers M, van Gestel A, van der Linden Sj, Swinkels H, van der Heijde D. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis.

Arthritis Rheum 2004;50(7):2082-93

163. Wanders A, Landewé R, Spoorenberg A, Dougados M, van der Linden S, Mielants H, van der Tempel H, van der Heijde D. What is the most appropriate radiologic scoring method for Ankylosing Spondylitis? A comparison of the available methods based on the outcome measures in rheumatology clinical trials filter.

Arthritis Rheum 2004;50(8):2622-32

162. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, St Clair EW, Keenan GF, van der Heijde D, Marsters PA, Lipsky PE; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.

Arthritis Rheum 2004;50(4):1051-65.

161. Braun J, Baraliakos X, Golder W, Hermann K-G, Listing J, Brandt J, Rudwaleit M, Zühlendorf S, Bollow M, Sieper J, van der Heijde D. Analysing chronic spinal changes in ankylosing spondylitis - a systematic comparison of conventional x- rays with magnetic resonance imaging (MRI) using established and new scoring systems.

Ann Rheum Dis 2004;63 :1046-1055

160. Bruynesteyn K, Wanders A, Landewé R, van der Heijde D. How the type of risk reduction influences required sample sizes in randomised clinical trials

Ann Rheum Dis 2004;63(11):1368-1371

159. Bruynesteyn K, van der Linden Sj, Landewé R, Gubler F, Weijers R, van der Heijde D. Progression of RA on plain films judged differently by expert radiologists and rheumatologists.

J Rheumatol 2004;31(6):1088-94

158. Heuft-Dorenbosch L, van Tubergen A, Spoorenberg A, Landewé R, Dougados M, Mielants H, van der Tempel H, van der Heijde D. The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index. *Arthritis Rheum* 2004;15;51(2):154-9.

157. Sharp J, Wolfe F, Boers M, van der Heijde D, Larsen A, Lassere M, Paulus H, Rau R, Strand V. Variability of precision in scoring radiographic abnormalities in rheumatoid arthritis by experienced readers. *J Rheumatol* 2004;31(6):1062-72

156. van der Heijde D, Kalden JR, Scott D, Smolen J, Strand V. Long-term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years: concise report. *Ann Rheum Dis* 2004;63(6):737-9

155. Landewé R, Geusens P, Boers M, van der Heijde D, Lems W, te Koppele J, van der Linden S, Garnero P. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. *Arthritis Rheum* 2004;50(5):1390-9.

154. Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, Simon L, Strand V, Woodworth T, Dougados M. OMERACT-OARSI Initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. *Osteoarthritis Cartilage* 2004;12(5):389-99

153. Rudwaleit M, van der Heijde D, A Kahn, Braun J, Sieper J. How to diagnose axial spondyloarthritis early? *Ann Rheum Dis* 2004;63:535-543

152. Landewé RB, Rump B, van der Heijde D, van der Linden S. Which patients with ankylosing spondylitis should be treated with Tumor Necrosis Factor-inhibiting therapy? A survey among Dutch rheumatologists. *Ann Rheum Dis* 2004;63:530-534

151. van der Heijde D. Assessment of radiographs in longitudinal observational studies. *J Rheum* 2004;31 Suppl 69:46-47

149. Wanders AJ, Gorman JD, Davis JC, Landewé RB, van der Heijde DM. Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis. *Arthritis Rheum* 2004;51(1):1-8.

148. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. *Lancet* 2004;28,363(9410):675-81.

147. van der Heijde D. New directions in classification and outcome assessment in ankylosing spondylitis. *Curr Rheumatol Rep* 2004;6(2):98-101.

146. Landewé R, van der Heijde D. Radiographic progression depicted by probability plots: presenting data with optimal use of individual values. *Arthritis Rheum* 2004;50(3):699-706

145. Bruynesteyn K, Landewé R, van der Linden S, van der Heijde D. Radiography as primary outcome in rheumatoid arthritis: acceptable sample sizes for trials with 3 months' follow-up. *Ann Rheum Dis* 2004;63(11):1413-1418

144. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short-term improvement after anti-TNF{alpha} therapy in ankylosing spondylitis. *Ann Rheum Dis* 2004;63(11):1438-1444

143. van der Heijde D. Overview of radiologic efficacy of new treatments. *Rheum Dis Clin North Am* 2004;30(2):285-93

2003

142. Miceli-Richard C, van der Heijde D, Dougados M. Spondyloarthropathy for practicing rheumatologists: diagnosis, indication for disease-controlling antirheumatic therapy, and evaluation of the response. *Rheum Dis Clin North Am*. 2003;29(3): 449-62

141. Pham T, van der Heijde D, Lassere M, Altman R, Bellamy N, Hochberg M, Simon L, Strand V, Woodworth T, Dougados M. Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria. *J Rheumatol*. 2003;30(7): 1648-54.

140. Landewé RB, van der Heijde D. Early rheumatoid arthritis: Towards tailor-made therapy. *Curr Rheumatol Rep* 2003;5(4);287-93

139. de Klerk E, van der Heijde D, van der Tempel H, Landewé R, van der Linden Sj. The compliance questionnaire rheumatology compared with electronic medication event monitoring: a validation study. *J Rheumatol* 2003;30(11): 2469-75

138. Davis J, van der Heijde D, Braun J, Dougados M, Cush J, Clegg D, Kivitz A, Fleischmann A, Inman R, Tsuji W for the Enbrel Ankylosing Spondylitis Study Group. Recombinant Human Tumor Necrosis Factor Receptor (Etanercept) for Treating Ankylosing Spondylitis A Randomized, Controlled Trial. *Arthritis Rheum* 2003; 48(11): 3230-6.

137. van der Heijde D, Landewé R. Imaging: Do erosions heal? *Ann Rheum Dis* 2003;62(suppl.II):ii10-12

136. Landewé RB, van der Heijde D. Is radiographic progression a realistic outcome measure in clinical trials with early inflammatory arthritis? *Clin Exp Rheum* 2003;21(suppl. 31):S37-S41

135. van der Heijde D. Impact of imaging in established rheumatoid arthritis. *Best Pract Res Clin Rheumatol* 2003;17(5):783-790

134. Pham T, van der Heijde D, Calin A, Khan MA, van der Linden S, Bellamy N, et al. Initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group. *Ann Rheum Dis* 2003;62(9):812-6.

133. Braun J, Pham T, Sieper J, Davis J, van der Linden Sj, Dougados M, van der Heijde D. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. *Ann Rheum Dis*. 2003;62(9):817-824

132. Schulpen GJC, Vierhout WPM, van der Heijde DM, Landewé RB, Winkens RAG, Wesselingh AMK, et al. Joint Consultation of General Practitioner and Rheumatologist: Does it matter? *Ann Rheum Dis* 2003;62:159-161

131. Schulpen GJC, Vierhout WPM, van der Heijde DM, Landewé RB, Winkens RAG, Wesselingh AMK, et al. Patients at the outpatient clinic of rheumatology: Do they really need to be there? *Eur J Int Med* 2003;14(3):158-161

130. Boonen A, [van der Heijde D](#), Landewé R, Guillemin F, Rutten-van Mölken M, Dougados M, Mielants H, de Vlam K, van der Tempel H, boessen S, Spoorenberg A, Schouten H, van der Linden Sj. Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. *Ann Rheum Dis* 2003;62:732-740
129. Boonen A, [van der Heijde D](#), Landewé R, Guillemin F, Spoorenberg A, Schouten H, Rutten-van Mölken M, Dougados M, Mielants H, de Vlam K, van der Tempel H, van der Linden Sj. Costs of ankylosing spondylitis in three European countries: the patient's perspective. *Ann Rheum Dis* 2003;62:741-747
128. Braun J, [van der Heijde D](#). Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides. *Expert Opin Investig Drugs* 2003;12(7):1097-1109
127. Landewé R, [van der Heijde D](#). Principles of assessment from a clinical perspective. *Best Pract Res Clin Rheumatol* 2003;17(3):365-79
126. [van der Heijde D](#), Sharp J, Rau R, Strand V on behalf of subcommittee on healing of erosions of the OMERACT imaging committee. OMERACT Workshop: Repair of structural damage in rheumatoid arthritis. *J Rheumatol* 2003;30(5):1108-9
125. Sharp J, [van der Heijde D](#), Boers M, Boonen A, Bruynesteyn K, Emery P, Genant H, Herborn G, Jurik A, Lassere M, McQueen F, Østergaard M, Peterfy C, Rau R, Strand V, Wassenberg S, Weissman B for the Subcommittee on Healing of Erosions of the OMERACT Imaging Committee. Repair of erosions in rheumatoid arthritis does occur. Results from two studies by the OMERACT subcommittee on healing of erosions. *J Rheumatol* 2003;30:5:1102-7
124. Feldtkeller E, Khan MA, [van der Heijde D](#), van der Linden Sj, Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative versus positive patients with ankylosing spondylitis. *Rheumatol Int* 2003;23:61-66
123. Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, Bollow M, Sieper J, [van der Heijde D](#). MRI examinations of the spine in patients with ankylosing spondylitis (AS) before and after infliximab therapy after evaluation of a new scoring system. *Arthritis Rheum* 2003;48(4):1126-1136
122. van Tubergen A, [van der Heijde D](#), Anderson J, Landewé R, Dougados M, Braun J, Bellamy N, Udrea G, van der Linden S for the ASAS Working Group. Comparison of ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel *Ann Rheum Dis* 2003;62:215-221
121. van Tubergen A, Heuft-Dorenbosch L, Schulpen G, Landewé R, Wijers R, [van der Heijde D](#), van Engelshoven J, van der Linden Sj. Radiographic assessment of sacroiliitis by radiologists and rheumatologists: Does training improve quality? *Ann Rheum Dis* 2003;62:519-525
120. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewé R, van der Tempel H, Mielants H, Dougados M, [van der Heijde D](#). Assessment of enthesitis in ankylosing spondylitis. *Ann Rheum Dis* 2003;62:127-32
119. van Tubergen A, Landewé R, Heuft L, Spoorenberg A, [van der Heijde D](#), van der Tempel H, van der Linden Sj. Assessment of disability with the WHODAS II in patients with ankylosing spondylitis. *Ann Rheum Dis* 2003;62:140-5
118. Landewé R, Boers M, [van der Heijde D](#). How to interpret radiologic progression in randomised clinical trials? *Rheumatology*;2003;42:2-5

117. de Klerk E, van der Heijde D, Landewé R, van der Tempel H, Urquhart J, van der Linden Sj. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica and gout. *J Rheumatol* 2003;30:44-54

116. Doward LC, Spoorenberg A, Reynolds S, Whalley D, Helliwell PS, Kay L, McKenna SP, Tennant A, van der Heijde D, Chamberlain MA. The development of the ASQoL: A quality of life instrument specific to Ankylosing Spondylitis. *Ann Rheum Dis* 2003;62:20-6

115. Landewé R, Boers M, van der Heijde D. Reply to Drs McEntegart and Madhok on article Modified disease activity score versus radiologic progression as an indicator of rheumatoid arthritis disease status. *Arthritis & Rheum* 2003;48(1):272

2002

114 Braun J, van der Heijde D, Pincus T. Innovative therapies for the spondyloarthritides. *Clinical and Experimental Rheumatology* 2002;20:Suppl 28;1-187

113. Auléléy G-R, Benbouazza K, Spoorenberg A, Collantes E, Hajjaj-Hassouni N, van der Heijde D, Dougados M. Evaluation of the smallest detectable difference in outcome or process variables in ankylosing spondylitis. *Arthritis Rheum* 2002;47:582-7

112. Santen van M, Bolwijn P, Landewé R, Verstappen F, Bakker C, Hidding A, van der Heijde D, Houben H, van der Linden S. High or low intensity aerobic fitness training in fibromyalgia. Does it matter? *J Rheumatol* 2002;29:582-7

111. Braun J, van der Heijde D, Dougados M, Emery P, Khan M, Sieper J, van der Linden Sj. Staging of Patients with Ankylosing Spondylitis — A Preliminary Proposal *Ann Rheum Dis* 2002;61(suppl iii):iii19-iii23

110. van Tubergen A, Boonen A, Landewé R, van Molken-Rutten M, van der Heijde D, Hidding A, van der Linden Sj. Cost-effectiveness of combined spa-exercise therapy in ankylosing spondylitis: A randomised controlled trial. *Arthritis Rheum* 2002;47:459-67

109. Garnero P, Landewé R, Boers M, Verhoeven A, van der Linden S, Christgau S, van der Heijde D, Boonen A, Geusens P. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis. *Arthritis Rheum* 2002;46:2847-56

108. Gorter S, Rethans J-J, van der Heijde D, Scherpbier A, Houben H, van der Vleuten C, van der Linden Sj. Reproducibility of clinical performance assessment in practice using incognito standardized patients. *Medical Education* 2002;36:827-32

107. van der Heijde D, Braun J, McGonagle D, Siegel J. Treatment Trials in Ankylosing Spondylitis: Current and Future Considerations. *Ann Rheum Dis* 2002;61 (suppl III):iii24-iii32

106. Bruynesteyn K, van der Heijde D, Boers M, Saudan A, Peloso P, Paulus H, Houben H, Griffiths B, Edmonds J, Bresnihan B, Boonen A, van der Linden Sj. Detecting radiological changes in rheumatoid arthritis that are considered important by clinical experts: Influence of reading with or without known sequence. *J Rheumatol* 2002;29(11):2306-12

105. Strand V, Landewé R, van der Heijde D. Using estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis. *Ann Rheum Dis* 2002;61(suppl II):ii64-ii66

104. Bruynesteyn K, [van der Heijde D](#), Boers M, Verhoeven A, Boonen A, van der Linden S. Contribution of progression of erosive damage in previously eroded joints in early rheumatoid arthritis trials: COBRA trial as an example.
Arthritis Rheum 2002;47:532-6
103. Braun J, [van der Heijde D](#). Imaging and scoring in ankylosing spondylitis.
Best Pract Res Clin Rheumatol 2002;16:573-604
102. Dougados M, [van der Heijde D](#). Ankylosing spondylitis: how should the disease be assessed?
Best Pract Res Clin Rheumatol 2002;16:605-18
101. Braun J, Golder W, Bollow M, Sieper J, [van der Heijde D](#). Imaging and scoring in ankylosing spondylitis.
Clin Exp Rheumatol 2002;20 (Suppl 28):S178-S184
100. Braun J, [van der Heijde D](#), Pincus T. Novel anti-rheumatic therapies challenge old views on ankylosing spondylitis and other spondyloarthritides.
Clin Exp Rheumatol 2002;20 (Suppl 28): S1-S2
99. Spoorenberg A, [van der Heijde D](#), Dougados M, de Vlam K, Mielants H, van de Tempel H, van der Linden S. Reliability of self assessed joint counts in ankylosing spondylitis.
Ann Rheum Dis 2002;61:799-803
98. Boers M, [van der Heijde D](#). Prevention or retardation of joint damage in rheumatoid arthritis. Issues of definition, evaluation and interpretation of plain radiographs.
Drugs 2002;62:1717-24
97. [van der Heijde D](#). Structural damage in rheumatoid arthritis as visualized through radiographs.
Arthritis Research 2002; 4 (suppl 2): S29-S33
96. Gorter S, Scherpbier A, Brauer J, Rethans J-J, [van der Heijde D](#), Houben H, van der Vleuten C, van der Linden S. Doctor-patient interaction: standardized patients' reflections from inside the rheumatological office.
J Rheumatol 2002;29:1496-500
95. Boonen A, [van der Heijde D](#), Landewé R, Spoorenberg A, Schouten H, Rutten-van Mólken M, Guillemin F, Dougados M, Mielants H, de Vlam K, van der Tempel H, van der Linden S. Work-status and productivity costs due to Ankylosing Spondylitis: comparison among three European countries.
Ann Rheum Dis 2002;61:429-37
94. Bruynesteyn K, [van der Heijde D](#), Boers M, Saudan A, Peloso P, Paulus H, Houben H, Griffiths B, Edmonds J, Bresnihan B, Boonen A, van der Linden S. Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference.
Arthritis Rheum 2002;46:913-20
93. Landewé R, Boers M, Verhoeven A, Westhovens R, van de Laar M, Markusse H, van Denderen C, Westedt M, Peeters A, Dijkmans B, Jacobs P, Boonen A, [van der Heijde D](#), van der Linden S. COBRA-combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention.
Arthritis Rheum 2002;2:347-56
92. Landewé R, [van der Heijde D](#). Follow-up studies in rheumatoid arthritis.
Ann Rheum Dis 2002;61:479-81 (editorial)
91. van Tubergen A, Debats I, Ryser L, Londono J, Burgos-Vargas R, Cardiel M, Landewé R, Stucki G, [van der Heijde D](#). The use of a numerical rating scale as an answer modality in ankylosing Spondylitis specific questionnaires.
Arthritis Rheum 2002;47:242-8

90. van der Heijde D, Simon L, Smolen J, Strand V, Sharp J, Boers M, Breedveld F, Weissmann M, Weinblatt M, Rau R, Lipsky P. How to report radiographic data in randomized clinical trials in rheumatoid arthritis? Guidelines from a roundtable discussion.
Arthritis Rheum 2002;47:215-8

89. Gorter S, van der Heijde D, van der Linden Sj, Houben H, Rethans J-J, Scherpbier A, van der Vleuten C. Psoriatic arthritis: Performance of rheumatologists in daily practice. A study with incognito standardized patients.
Ann Rheum Dis 2002;61:219-24

88. Sieper J, Rudwaleit M, Braun J, van der Heijde D. Diagnosing reactive arthritis. Role of clinical setting in the value of serological and microbiological assays.
Arthritis Rheum 2002;47:319-27

87. van Tubergen A, Coenen J, Landewé R, Spoorenberg A, Chorus A, Boonen A, van der Linden Sj, van der Heijde D. Assessment of fatigue in patients with ankylosing spondylitis: a psychometric analysis.
Arthritis Rheum 2002;47:8-16

86. van Santen M, Bolwijn P, Verstappen F, Bakker C, Hidding A, Houben H, van der Heijde D, Landewé R, van der Linden S. A randomized clinical trial comparing fitness and biofeedback training versus basic treatment in patients with fibromyalgia.
J Rheumatol. 2002;29:575-81.

2001

85. Swinkels HL, Laan RF, van 't Hof MA, de Vries N, van der Heijde DM, van Riel PL. Modified Sharp method: factors influencing reproducibility and variability.
Sem Arthritis Rheum 2001;31:176-90

84. Gorter SL, Rethans J-J, Scherpbier AJJA, van der Linden Sj, van Santen-Hoeufft MHM, van der Heijde DMFM, Houben HHML, van der Vleuten CPM. How to introduce incognito standardized patients into outpatient clinics of specialists in rheumatology.
Medical Teacher 2001;23:138-44

83. van der Heijde D. Aspects of the radiological evaluation of rheumatoid arthritis.
Ann Med Interne 2001; 152: 518-21

82. Salvarani C, Vlachonikolis I, van der Heijde D, Fornaciari G, Macchioni P, Beltrami M, Olivieri I, Di Gennaro F, Politi P, Stockbrügger R, Russel M on behalf of the European Collaborative IBD Study Group. Musculoskeletal manifestations in a population-based cohort of Inflammatory Bowel Disease patients
Scand J Gastroenterol 2001;12:1307-13

81. Boonen A, Chorus A, Miedema H, van der Heijde D, Landewé R, Schouten H, van der Tempel H, van der Linden Sj. Withdrawal from labour force due to work disability in patients with ankylosing spondylitis.
Ann Rheum Dis 2001;60:1033-9

80. van Tubergen A, Landewé R, van der Heijde D, Hidding A, Wolter N, Asscher M, Falkenbach A, Genth E, Goei Thè H, van der Linden S. Combined spa-exercise therapy is effective in ankylosing spondylitis: a randomized controlled trial.
Arthritis Rheum 2001;45:430-8

79. van der Heijde D. Radiographic progression in rheumatoid arthritis: does it reflect outcome? Does it reflect therapy?
Ann Rheum Dis 2001;60:iii47-iii50

78. Geusens P, Vosse D, van der Heijde D, Vanhoof J, van Tubergen A, Raus J, van der Linden Sj. High prevalence of thoracic vertebral deformities and discal wedging in ankylosing spondylitis patients with hyperkyphosis.
J Rheumatol 2001;28:1856-61

77. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. ASAS preliminary definition of short-term improvement in ankylosing spondylitis. *Arthritis Rheum* 2001;44:1876-86
76. van der Heijde D. Radiographic assessment of joint disease in rheumatoid arthritis. Joint damage occurs early in the disease course. *J Musculoskeletal Med* 2001;5 (suppl):S15-S20
75. Boonen A, van der Heijde D, van der Linden Sj, Muhammad Asim Khan. Portrait of a rheumatologist as a great artist. *J Rheumatol* 2001;28:843-4
74. Boonen A, de Vet R, van der Heijde D, van der Linden Sj. Work-status and its determinants among patients with ankylosing spondylitis. A systematic review of the literature. *J Rheumatol* 2001;28:1056-62
73. Boonen A, Chorus A, Miedema H, van der Heijde D, van der Tempel H, van der Linden Sj. Employment, work-disability and work-days lost in patients with Ankylosing Spondylitis: a cross-sectional study among Dutch patients. *Ann Rheum Dis* 2001;60:353-8
72. van der Heijde D, Lassere M, Edmonds J, Kirwan J, Strand V, Boers M for the OMERACT imaging task force. Minimal Clinically Important Difference in plain films in RA: group discussions, conclusions and recommendations. *J Rheumatol* 2001;28:914-5
71. Lassere M, van der Heijde D, Johnson KR, Boers M, Edmonds J. Reliability of measures of disease activity and disease damage in RA: Implications for the smallest detectable difference, the minimum clinical important difference, and analysis of treatment effects in randomized controlled trials. *J Rheumatol* 2001;28:892-903
70. Lassere M, van der Heijde D, Johnson KR. Foundations of the Minimum Clinically Important Difference (MCID) *J Rheumatol* 2001;28:890-1
69. Lassere M, van der Heijde D, Johnson K, Bruynesteyn K, Molenaar E, Boonen A, Verhoeven A, Emery P, Boers M. Robustness and generalisability of smallest detectable difference in radiological progression. *J Rheumatol* 2001;28:911-3
68. Bruynesteyn K, van der Heijde D, Boers M, Lassere M, Boonen A, Edmonds J, Houben H, Paulus H, Peloso P, Saudan A, van der Linden Sj. Minimal clinically important difference in radiological progression of joint damage over 1 year in RA: Preliminary results of a validation study with clinical experts. *J Rheumatol* 2001;28:904-910
67. Strand S, Lassere M, van der Heijde D, Johnson K, Boers M. Recent RA clinical trials using radiographic endpoints – updated research agenda. *J Rheumatol* 2001;28:887-9
66. van der Heijde D. OMERACT 5 Imaging Working Group Report on Plain films. Introduction. *J Rheumatol* 2001;28:880
65. Gorter S, van der Linden Sj, Brauer J, van der Heijde D, Houben H, Rethans J-J, Scherpbier A, van der Vleuten C, Boonen A, Dinant H, Goei The H, Griep E, van der Horst-Bruinsma I, Linssen A, van Santen-Hoeufft M, van der Tempel H, Westgeest T. Rheumatologists' performance in daily practice. *Arthritis Rheum* 2001;45:16-27
64. Dougados M, Béhier J-M, Jolchine I, Calin A, van der Heijde D, Olivieri I, Zeidler H, Herman H. Efficacy of Celecoxib, a Cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: A six-week

controlled study with comparison against placebo and against a conventional nonsteroidal anti-inflammatory drug.

Arthritis Rheum 2001;44:180-5

2000

63. Saag K, van der Heijde D, Fisher C, Samara A, DeTora L, Bolognese J, Sperling R, Daniels B; for the Osteoarthritis Studies Group. Rofecoxib, a new Cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other Nonsteroidal Anti-inflammatory Drugs. A 6-week and a 1-year trial in patients with osteoarthritis.

Archives Fam Med 2000;9:1124-34

62. Wolfe F, van der Heijde D, Larsen A. Assessing radiographic status of rheumatoid arthritis: Introduction of a shortened erosion scale (SES).

J Rheumatol 2000;27:2090-9

61. Dougados M, Le Claire P, van der Heijde D, Bloch D, Bellamy N, Altman R. Special article: Response criteria for clinical trials on osteoarthritis of the knee and hip. A report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials Response Criteria Initiative.

OsteoArthritis and Cartilage 2000;8:395-403

60. Braun J, Kingsley G, van der Heijde D, Sieper J. On the difficulties of establishing a consensus on the definition and diagnostic workup for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive Arthritis, Berlin, July 3-6th 1999

J Rheumatol 2000;75:2185-92

59. Lipsky P, van der Heijde D, St. Clair EW, Furst DE, Breedveld F, Kalden JR, Smolen J, Weisman M, Emery P, Feldmann M, Harriman GR, Maini R for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis.

New Eng J Med 2000;343:1594-1602

58. Hulsmans HMJ, Jacobs JWG, van der Heijde D, van Albada-Kuipers GA, Schenk Y, Bijlsma JWJ. Course of radiological damage during the first 6 years of rheumatoid arthritis.

Arthritis Rheum 2000;43:1927-40

57. van der Heijde D. Impact of rheumatoid arthritis on physical function during the first five years. No longer a question mark? (editorial)

Rheumatology 2000;39:579-80

56. Gorter S, Rethans J-J, Scherpbier A, van der Heijde D, Houben H, van der Vleuten C, van der Linden Sj. Developing Case-specific checklists for standardized patient-based assessments in internal medicine: a review of the literature.

Academic Medicine 2000;75:1130-7

55. van der Linden Sj, van der Heijde D. Clinical aspects, outcome assessment and management of ankylosing spondylitis and post-enteric reactive arthritis.

Current Opinion Rheumatol 2000;12:263-8

54. Proudman SM, Conaghan PG, Richardson C, Green MJ, McGonagle D, Wakefield RJ, Griffiths B, Reece R, Miles S, Veale D, Martin M, Huston G, Gough A, Adebajo A, Helliwell P, van der Heijde D, Emery P.

Treatment of poor-prognosis early rheumatoid arthritis: A randomized study of treatment with methotrexate, cyclosporin A and intraarticular corticosteroids compared with sulfasalazine alone.

Arthritis and Rheum 2000;43:1809-19

53. van der Heijde DMFM. Radiographic imaging: The "gold standard" for assessment of disease progression in rheumatoid arthritis.

Rheumatology 2000;39(suppl 1):9-16

52. Molenaar E, van der Heijde D, Boers M. Update in outcome assessment in rheumatic disorders. *Current Opinion* 2000;12:91-8

51. van der Heijde DM, van Riel PL, Nuver-Zwart IH, van de Putte LB. Alternative methods for analysis of radiographic damage in a randomized, double-blind, parallel group clinical trial comparing hydroxychloroquine and sulfasalazine. *J Rheumatol* 2000;27:535-9

50. Morton S, Paulus H, van der Heijde D, Shekelle P, Strand V, Lassere M, Kirwan J, Sharp J, Sanders M. On variability of effects for a metaanalysis of rheumatoid arthritis radiographic progression - discussion. *J Rheumatol* 2000;27:542-3

49. van der Heijde D, van Riel P, Nuver-Zwart I, van de Putte L. Analyzing radiographic damage in a randomized, double-blind, parallel group clinical trial comparing hydroxychloroquine and sulfasalazine. *J Rheumatol* 2000;27:535-7

48. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. *J Rheumatol* 2000;27:261-3

1999

47. de Klerk E, van der Heijde D, van der Tempel H, van der Linden S. Development of a questionnaire to investigate patient compliance with antirheumatic drug therapy. *J Rheumatol* 1999;26:2635-41

46. van der Heijde D, Dankert T, Nieman F, Rau R, Boers M. Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis *Rheumatology* 1999;38:941-7

45. van der Heijde D, Boonen A, Boers M, Kostense P, van der Linden S. Reading radiographs in chronological order, in pairs or as single films has important implications for the discriminative power of rheumatoid arthritis clinical trials *Rheumatology* 1999;38:1213-20

44. Wolfe F, Lassere M, van der Heijde D, et al. Preliminary core set of domains for longitudinal observational studies in rheumatology. *J Rheumatol* 1999;484-9

43. Dougados M, van der Heijde D. Evaluation of functional capacity in ankylosing spondylitis (editorial). *J Rheumatol* 1999;1:4-6

42. Lassere M, Boers M, van der Heijde D, et al. Smallest detectable difference in radiological progression. *J Rheumatol* 1999;26:731-9

41. Molenaar E, Boers M, van der Heijde D, et al. Imaging in RA: results of group discussions. *J Rheumatol* 1999;26:749-51

40. Molenaar E, Edmonds J, Saudan A, Lassere M, Boers M, van der Heijde D. A practical exercise in reading RA radiographs by the Larsen and Sharp methods. *J Rheumatol* 1999;26:746-8

39. Spoorenberg A, de Vlam K, van der Heijde D, de Klerk E, Dougados M, Mielants H, van der Tempel H, Boers M, van der Linden S. Radiological scoring methods in AS: reliability and sensitivity to change over one year. *J Rheumatol* 1999;26:997-1002

38. Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H, van der Tempel H, van der Linden S. Relative value of ESR and CRP in assessment of disease activity in AS. *J Rheumatol* 1999;26:980-4

37. Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H, van der Tempel H, van der Linden S. A comparative study of the usefulness of the BASFI and the Dougados Functional Index in the assessment of AS.
J Rheumatol 1999;26:961-5

36. van der Heijde D, van der Linden S, Bellamy N, Calin A, Dougados M, Khan MA. Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the AS module of OMERACT 4.
J Rheumatol 1999;26:945-7

35. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method.
J Rheumatol 1999;743-5

34. van der Heijde D, van der Linden S, Dougados M, Bellamy N, Russell A, Edmonds J. AS: plenary discussion and results of voting on selection of domains and some specific instruments.
J Rheumatol 1999;1003-5

33. van der Heijde D, Spoorenberg A. Plain radiographs as an outcome measure in AS.
J Rheumatol 1999;26:985-7

32. van der Heijde D, Boers M, Lassere M. Methodological issues in radiographic scoring methods in RA.
J Rheumatol 1999;26:726-30

31. van der Heijde D, Calin A, Dougados M, Khan A, van der Linden S, Bellamy N. Selection of instruments in the core set for DC-ART, SM-ARD, physical therapy, and clinical record keeping in AS. Progress report of ASAS working group.
J Rheumatol 1999;26:951-4

1998

30. van der Heijde D, van der Linden S. Outcome measures in ankylosing spondylitis and other spondyloarthritides.
Baill Clin Rheumatol 1998;12:683-93

1997

29. van der Heijde D, Bellamy N, Calin A, Dougados M, Khan MA, van der Linden S on behalf of the ASAS working group. Preliminary core sets for endpoints in ankylosing spondylitis.
J Rheumatol 1997;24:2225-9

28. Boers M, Verhoeven A, Markusse H, van de Laar M, Westhovens R, van Denderen C, van Zeben J, Dijkmans B, Peeters A, Jacobs P, van den Brink H, Schouten H, van der Heijde D, Boonen A, van der Linden S. Combination of step-down corticosteroids, methotrexate and sulfasalazine, compared to sulfasalazine alone in early, active rheumatoid arthritis produces excellent 1-year disease control and low toxicity; the COBRA trial.
Lancet 1997;350:309-18

27. Young A & van der Heijde DM. Can we predict aggressive disease?
Baill Clin Rheumatol 1997;27-48

26. de Jong Z, van der Heijde DM, Whalley D, McKenna SP. The reliability and construct validity of the RAQoL: A rheumatoid arthritis-specific quality of life instrument.
Br J Rheumatol 1997;36:878-3

25. Whalley D, McKenna SP, de Jong Z, van der Heijde DM. Quality of life in rheumatoid arthritis.
Br J Rheumatol 1997;36:884-8

24. de Klerk E, van der Linden Sj, van der Heijde D, Urquhart J. Facilitated analysis of data on drug regimen compliance.
Statist Med 1997;16:1653-64

23. Egsmose C, Hansen T, Andersen L, Beier MJ, Ejstrup L, Peters ND, van der Heijde DM. Limited effect of sulphasalazine treatment in reactive arthritis. A randomised double blind placebo controlled trial.
Ann Rheum Dis 1997;56:32-6

22. Russel MGVM, Pastoor CJ, Brandon S, Rijken J, Engels LGJB, van der Heijde DMFM, Stockbrügger RW. Validation of the Dutch translation of the inflammatory bowel disease questionnaire (IBDQ). A health-related quality of life questionnaire in inflammatory bowel disease.
Digestion 1997;58:282-8

21. van der Heijde DMFM: The continuing challenge of prognostic factors: prediction or association? (editorial)
J Rheumatol 1997;24:6-8

1996

20. van der Heijde DMFM. Plain X-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability.
In: Bailliere Clin Rheum. Modern imaging techniques. Part I: Traditional Methods. Bird HA and Dougados M (eds.).
Bailliere Tindall, London, 1996;10:435-53

19. Paulus HE, van der Heijde DMFM, Bulpitt KJ, Gold RH. Monitoring radiographic changes in early rheumatoid arthritis. (editorial)
J Rheumatol 1996;23:801-5

18. van der Linden S, van der Heijde DMFM. Clinical and epidemiologic aspects of ankylosing spondylitis and spondyloarthropathies.
Curr Opin Rheumatol 1996;8:269-74

1995

17. van der Heijde DMFM. Joint erosions and patients with early rheumatoid arthritis.
Br J Rheumatol 1995;34(suppl):74-8

16. van Riel PLCM, van der Heijde DMFM, Nuver-Zwart IH, van de Putte LBA. Radiographic progression in rheumatoid arthritis: results of 3 comparative trials.
J Rheumatol 1995;22:1797-9

15. van der Linden Sj, van der Heijde D. Ankylosing spondylitis and other B27 related spondylarthropathies.
In: Bailliere Clin Rheum. Classification and assessment of rheumatic diseases: Part I. Silman AJ and Symmons DPM (eds.).
Bailliere Tindall, London, 1995;9:355-73

14. van der Heijde DMFM, van Leeuwen MA, van Riel PLCM, van de Putte LBA. Radiographic progression on X-rays of hands and feet during the first three years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification)
J Rheumatol 1995;22:1792-6

1994

13. van Leeuwen MA, van der Heijde DMFM, van Rijswijk MH et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiological damage, physical disability, joint counts and acute phase reactants.
J Rheumatol 1994;21:425-9

1993

12. van Leeuwen MA, van Rijswijk MH, van der Heijde DMFM et al. The acute-phase response relation to radiographic progression in early rheumatoid arthritis: A prospective study during the first three years of disease.

Br J Rheumatol 1993;32 (Suppl 3):9-13

11. van der Heijde DMFM, van Riel PLCM, van 't Hof MA, van de Putte LBA. Development of a Disease Activity Score based on judgment in clinical practice by rheumatologists.

J Rheumatol 1993;20:579-81

10. van der Heijde DMFM, van Riel PLCM, van 't Hof MA, van de Putte LBA. Validity of single variables and indices to measure disease activity in rheumatoid arthritis.

J Rheumatol 1993;20:538-41

1992

9. van der Heijde DMFM, van Riel PLCM, van Leeuwen MA, van 't Hof MA, van Rijswijk MH, van de Putte LBA. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective followup study of 147 patients.

Br J Rheumatol 1992;31:519-25

8. van der Heijde DMFM, van Leeuwen MA, van Riel PLCM, Koster AM, van 't Hof MA, van Rijswijk MH, van de Putte LBA. Biannual radiographic assessments of hands and feet in a threeyear prospective followup of patients with early rheumatoid arthritis.

Arthritis Rheum 1992;35:26-34

7. van der Heijde DMFM, van 't Hof MA, van Riel PLCM, van Leeuwen MA, van Rijswijk MH, van de Putte LBA. A comparison of validity of single variables and composed indices for measuring disease activity in rheumatoid arthritis.

Ann Rheum Dis 1992;51:177-81

1991

6. van der Heijde DMFM, van Riel PLCM, van Leeuwen MA, van 't Hof MA, van Rijswijk MH, van de Putte LBA. Older versus younger onset rheumatoid arthritis: results at onset and after 2 years of a prospective followup study of early rheumatoid arthritis.

J Rheumatol 1991;18:1285-9

1990

5. van der Heijde DMFM, van Riel PLCM, van de Putte LBA. Sensitivity of a Dutch Health Assessment Questionnaire in a trial comparing hydroxychloroquine vs. sulphasalazine.

Scand J Rheum 1990;19:407-12

4. van der Heijde DMFM, van 't Hof MA, van Riel PLCM, Theunisse HAM, Lubberts EW, van Leeuwen MA, van Rijswijk MH, van de Putte LBA. Judging disease activity in clinical practice in rheumatoid arthritis. First step in the development of a 'disease activity score'.

Ann Rheum Dis 1990;49:916-20

1989

3. van der Heijde DMFM, van Riel PLCM, NuverZwart HH, Gribnau FWJ, van de Putte LBA. Effects of hydroxychloroquine and sulfasalazine on progression of joint damage in rheumatoid arthritis.

Lancet 1989;i:10368

1988

2. Wijnands MJH, Corstens FHM, [van der Heijde DMFM](#), van de Putte LBA, Lenders JWM. Lymphatic obstruction as a cause of oedema in rheumatoid arthritis. *Neth J Med* 1988;33:1403

1. [van der Heijde DMFM](#), van Riel PLCM, van Rijswijk MH, van de Putte LBA. Influence of prognostic features on the final outcome in rheumatoid arthritis: a review of the literature. *Semin Arthritis Rheum* 1988;17:28492

2. Thesis

Disease activity and outcome in rheumatoid arthritis. A methodological study. 8 maart 1991, Katholieke Universiteit Nijmegen.

3. Letters to the editor

38. Jonsson MK, Paulshus Sundlisæter N, Haugedal Nordal H, Berner Hammer H, Aga A-B, [van der Heijde D](#), Kvien TK, Svanes Fevang B-T, Lillegraven S, Haavardsholm EA. Response to: 'Calprotectin is not independent from baseline erosion in predicting radiological progression in early rheumatoid arthritis' by Chevreau et al

37. Ez-Zaitouni Z, van Lunteren M, Bakker PAC, van den Berg R, Reijniere M, Fagerli KM, Landewé RBM, Ramonda R, Jacobsson LTH, van Gaalen FA, [van der Heijde D](#). The influence of discrepant imaging judgements on the classification of axial spondyloarthritis is limited: a replication in the SpondyloArthritis Caught Early (SPACE) cohort. *Ann Rheum Dis* 2018; 77:e1

36. Smolen JS, Landewé RBM, [van der Heijde D](#). Response to: 'The time has come to revisit alternative interpretations of data underlying the EULAR management recommendations for rheumatoid arthritis' by Pirišć et al. *Ann Rheum Dis* 2017; 76:e50

35. Smolen JS, Landewé RBM, [van der Heijde D](#). Response to: '2016 update of the EULAR recommendations for the management of rheumatoid arthritis: no utopia for patients in low/middle-income countries?' by Misra et al. *Ann Rheum Dis* 2017; 76:e48

34. Ramiro S, Smolen JS, Landewé RBM, [van der Heijde D](#), Gossec L. Response to: 'The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studies' by Tillet et al. *Ann Rheum Dis* Published 16 August 2017, doi:10.1136/annrheumdis-2017-212012

33. Ez-Zaitouni Z, Landewé R, [van der Heijde D](#), van Gaalen FA. Alternative diagnoses in patients with chronic back pain not diagnosed with axial spondyloarthritis: data from the SPACE cohort. *Ann Rheum Dis* Published 22 August 2017, doi:10.1136/annrheumdis-2017-212175

32. Ramiro S, Smolen JS, Landewé R, [van der Heijde D](#), Gossec L. How are enthesitis, dactylitis and nail involvement measured and reported in recent clinical trials of psoriatic arthritis? A systematic literature review. *Ann Rheum Dis* Published 5 June 2017, doi:10.1136/annrheumdis-2017-211447

31. Ez-Zaitouni Z, van Lunteren M, Bakker PAC, van den Berg R, Reijniere M, Minde Fagerli K, Landewé RBM, Ramonda R, Jacobsson LTH, van Gaalen FA, [van der Heijde D](#). The influence of discrepant imaging judgements on the classification of axial spondyloarthritis is limited: a replication in the SpondyloArthritis Caught Early (SPACE) cohort. *Ann Rheum Dis* Published 17 April 2017, doi:10.1136/annrheumdis-2017-211553

30. Navarro-Compán V, Ramiro S, Landewé R, Dougados M, Miceli-Richard C, Richette P, [van der Heijde D](#). In patients with axial spondyloarthritis, inflammation on MRI of the spine is longitudinally related to disease

- activity only in men: 2 years of the axial spondyloarthritis DESIR cohort.
Ann Rheum Dis. 2017 Mar 3. pii: annrheumdis-2016-210697. doi: 10.1136/annrheumdis-2016-210697.
29. Landewé RB, van der Heijde DM. Why CAPS criteria are not diagnostic criteria?
Ann Rheum Dis 2017; 76:e7 Published Online First: 31 Oct 2016, doi:10.1136/annrheumdis-2016-210656
28. Claudepierre P, de Hooge MSM, Feydy A, Reijnierse M, Saraux A, Dougados M, van der Heijde D. Reliability of mSASSS scoring in everyday practice in DESIR-cohort study centres: cross-sectional study of agreement with trained readers.
Ann Rheum Dis 2016;75:2213-4
27. Sepriano A, Rudwaleit M, Sieper J, van den Berg R, Landewé R, van der Heijde D. Five-year follow-up of radiographic sacroiliitis: progression as well as improvement?
Ann Rheum Dis 2016;75:1262-3
26. Poddubnyy D, van Tubergen A, Landewé R, Sieper J, van der Heijde D. Defining an optimal referral strategy for patients with a suspicion of axial spondyloarthritis: what is really important? Response to 'Evaluating the ASAS recommendations for early referral of axial spondyloarthritis in patients with chronic low back pain; is one parameter present sufficient for primary care practice?' by van Hooft et al.
Ann Rheum Dis Published 2015;74:e69
25. Deodhar A, Sieper J, Reveille JD, van der Heijde D, Gensler LS, Landewé R. Reply to letter to the editor.
Arthritis Rheumatol. 2014 Nov 21. doi: 10.1002/art.38962.
24. Landewé RBM, van der Heijde D. Comment on: 'Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial' by Qian-wen et al.
Ann Rheum Dis Published 10 July 2014, doi:10.1136/annrheumdis-2014-206124
23. Ramiro S, van Tubergen A, Stolwijk C, van der Heijde D, Landewé R. Neutral lateral fingertip-to-floor distance can be derived from height.
Ann Rheum Dis 2014;73:1748-9
22. Machado P, Landewé R, Braun J, Baraliakos X, Hermann K-GA, Hsu B, Baker D, van der Heijde D. Ankylosing spondylitis patients with and without psoriasis do not differ in disease phenotype.
Ann Rheum Dis 2013;72 1104-7
21. Navarro-Compan, van der Heijde D, Combe B, Cosson C, van Gaalen FA. Value of high-sensitivity C-reactive protein for classification of early axial spondyloarthritis: results from the DESIR cohort.
Ann Rheum Dis 2013;72;785-6
20. Emery P, Conaghan PG, Fleischmann R, van der Heijde D, Keystone EC, Genovese MC, Hsia EC, Xu W, Beutler A. Reply to Graudl and Jurgens comment on the article 'Effect of golimumab combined with methotrexate on radiographic progression in rheumatoid arthritis.'
Arthritis Rheum 2012;64:1298-9
19. Dougados M, Braun, Burgos Vargas R, Gossec L, Maksymowych W, Sieper J, van der Heijde D. ASAS recommendations for variables to be collected in clinical trials/epidemiological studies of spondyloarthritis.
Ann Rheum Dis published 2012;71:1103-4
18. Heiberg T, Lie E, van der Heijde D, Kvien TK. Sleep problems are of higher priority for improvement for patients with ankylosing spondylitis than for patients with other inflammatory arthropathies.
Ann Rheum Dis 2011;70 872-73
17. Klarenbeek NB, Guler-Yuksel M, van der Heijde DMFM, Kerstens P, Mallee C, Westedt ML, Huizinga TWJ, Dijkmans BAC, Allaart CF. A comparison between the simplified erosion and narrowing score and the Sharp-van der Heijde score: post hoc analysis from the BeSt study.

Ann Rheum Dis 2011;70 714-6

16. Koevoets R, Allaart CF, van der Heijde DM, Huizinga TW. Disease activity monitoring in rheumatoid arthritis in daily practice: experiences with METEOR, a free online tool.
J Rheumatol 2010;37:2632-3

15. Vosse D, Heijckmann C, Landewé R, van der Heijde D, van der Linden S, Geusens P. Comment on: Comparing morphometric x-ray absorptiometry and radiography in defining vertebral wedge fractures in patients with ankylosing spondyliti: Reply.
Rheumatology 2008;47:1108-9

14. van der Heijde D, Klareskog L. Reply to letter by Yazici and Yazici commenting on the two-year report on the trial of etanercept and methotrexate with radiographic and patient outcomes.
Arthritis Rheum 2007;56(3):1031-2

13. van der Heijde D. Intensive management reduced disease activity in rheumatoid arthritis.
ACP J Club 2004;141:70

12. Klareskog L, van der Heijde D, Fatenejad S. Etanercept and methotrexate in rheumatoid arthritis.
Lancet. 2004 May 22;363(9422):1733

11. Braun J, Sieper J, van der Heijde D. Definition of discontinuation of anti-tumour necrosis factor therapy in rheumatoid arthritis: a preliminary proposal.
Ann Rheum Dis 2003;62(10):1023-1024

10. Boonen A, Chorus A, Landewé R, van der Heijde D, Miedema H, van der Tempel H, van der Linden S. Manual jobs increase the risk of patients with ankylosing spondylitis withdrawing from the labour force, also when adjusted for job related withdrawal in the general population.
Ann Rheum Dis 2002;61:658

9. van der Linden S, van der Heijde DMFM. Ankylosing spondylitis: evidence for a non-HLA-B27 protective effect.
Ann Rheum Dis 1998;57:263-4

8. van der Heijde DMFM, Jacobs JWG. The original "DAS" and the "DAS28" are not interchangeable: comment on the articles by Prevoo et al.
Arthritis Rheum 1998;41:942-3

7. van der Heijde DMFM. The continuing challenge of predictive factors in rheumatoid arthritis-reply
J Rheumatol 1997;24:1654

6. van der Heijde DMFM, van 't Hof MA, van Riel PLCM, van de Putte LBA. Disease activity score.
Ann Rheum Dis 1992;51:140

5. van der Heijde DMFM, van Riel PLCM, van 't Hof MA, van de Putte LBA. Comment on the article by Felson et al.
Arthritis Rheum 1991;34:1245

4. van der Heijde DMFM, van Riel PLCM, van 't Hof MA, van de Putte LBA. Response criteria for slow acting antirheumatic drugs.
Ann Rheum Dis 1990;29:956

3. van der Heijde DMFM, van Riel PLCM, van de Putte LBA. Longterm radiographic progression in treated rheumatoid arthritis.
Br J Rheum 1990;29:404

2. van der Heijde DMFM, van Riel PLCM, NuverZwart HH, van de Putte LBA: Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3year followup.
Lancet 1990;335:539

1. van Riel PLCM, van der Heijde DMFM, van de Putte LBA. Disease assessment in rheumatoid arthritis. *Ann Rheum Dis* 1989;48:962

4. Books / Booksections

41. van der Heijde D. Use of imaging as an outcome measure in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis in clinical trials. In: *Rheumatology*, Sixth edition, pp358-68

40. Bautista-Molano W, van der Heijde D. Imaging features in psoriatic arthritis. In: *Advances in the Management of Psoriatic Arthritis*. Veale DJ (Ed.). Future Medicine, London, UK 2013;pp48-61

39. Poddubnyy D, van der Heijde D. Therapeutic Controversies in Spondyloarthritis: Nonsteroidal Anti-inflammatory Drugs. In: *Rheumatic Dis Clin North America*, Braun J, Sieper J (eds). Saunders Elsevier, Philadelphia 2012;38:pp601-11

38. van der Heijde D, Østergaard M. Assessment of disease activity and damage in inflammatory arthritis. In: *EULAR Compendium on Rheumatic Diseases*, First Edition. Bijlsma JWJ, Burmester GR, da Silva JA, Faarvang KL, Hachulla E, Mariette X (eds). BMJ Publishing Group, London 2009;pp182-201

37. Landewé R, van der Heijde D. Broad issues in the approach to rheumatic diseases. Clinical trial design and analysis. In: *Kelley's Textbook of Rheumatology*, Eighth Edition. Firestein G, Budd RC, Harris ED, McInnes IB, Ruddy S, Sargent JS (eds). Saunders Elsevier, Philadelphia 2009;pp453-62

36. van der Linden Sj, van der Heijde D, Maksymowych WP. Spondyloarthropathies. Ankylosing Spondylitis. In: *Kelley's Textbook of Rheumatology*, Eighth Edition. Firestein G, Budd RC, Harris ED, McInnes IB, Ruddy S, Sargent JS (eds). Saunders Elsevier, Philadelphia 2009;pp1169-90

35. van der Heijde D. Outcome assessment of rheumatoid arthritis. Radiography. In: *Rheumatoid Arthritis*. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (editors) Mosby Elsevier, Philadelphia 2008;260-6

34. van der Heijde D. Ankylosing Spondylitis: clinical features. Editors: Klippel JM, Stone JH, Crofford LJ, White PH. *Primer on the Rheumatic Diseases*; Springer Science+Business media New York 2008: 193-200

33. Baratelle A, van der Heijde D. Radiographic imaging end points in rheumatoid arthritis trials. In: *Clinical trials in rheumatoid arthritis and osteoarthritis*. D. Reid, C. Miller (editors) Springer-Verlag London 2008:201-22

32. van der Heijde D. Study design and end points in ankylosing spondylitis clinical trials. In: *Clinical trials in rheumatoid arthritis and osteoarthritis*. D. Reid, C. Miller (editors) Springer-Verlag London 2008:69-80

31. Je kunt niet zien hoe ik me voel. NVR / Volle Maan Communicatiebureau. Amsterdam 2006. Interview.

30. van der Heijde D, Landewé R. Assessment of disease activity, function and quality of life. Editors: Weisman MH, Reveille JD, van der Heijde D. *Ankylosing Spondylitis and the Spondyloarthropathies*; Mosby Elsevier 2006 Philadelphia: 206-213..

29. van der Heijde D. Criteria and Outcome Assessment of Ankylosing Spondylitis. In: *Ankylosing spondylitis, diagnosis and management*. B.J. van Royen, B.A.C. Dijkmans (editors). Informa Health Care. 2006:83-93

28. van der Linden Sj, van der Heijde D, Braun Jurgen Spondyloarthropathies. Ankylosing Spondylitis. In: *Kelley's Textbook of Rheumatology*, Seventh Edition. Harris ED, Budd RC, Firestein G, Genovese MC, Sargent JS, Ruddy S, Sledge CB (eds). Saunders Elsevier, Philadelphia 2005;pp1125-41

27. van der Heijde D. Radiological measurements of periarticular bone loss, erosions, and joint space: x-ray measurement of erosions and joint space narrowing. In: Bone Disease in Rheumatology. M. Maricic, O. Gluck (editors), Lippincott, Williams & Wilkins, Philadelphia, 2005:53-58
26. van der Heijde D, van den Bosch F, van der Linden Sj, Mielants H. Spondylarthropathieën. In: Reumatologie en klinische immunologie. Bijlsma JWJ, Geusens PPMM, Kallenberg CGM, Tak PP (editors), Bohn Stafleu Van Loghum, Houten, 2004;82-101
25. van der Heijde D. Measurement of Radiological Outcomes. In: Rheumatoid Arthritis. St. Clair E. W, Pisetsky D, Haynes B.F. (editors), Lippincott Williams & Wilkins, Philadelphia, 2004, 90-97
24. van der Heijde D, Dougados M. Future trends. In: Fast Facts - Ankylosing Spondylitis. Dougados M, van der Heijde D (editors), Health Press Limited, Oxford, 2004; 80-1
23. van der Heijde D. Disease-controlling antirheumatic therapy. In: Fast Facts - Ankylosing Spondylitis. Dougados M, van der Heijde D (editors), Health Press Limited, Oxford, 2004;72-9
22. van Tubergen A, van der Heijde D. Physical therapy. In: Fast Facts - Ankylosing Spondylitis. Dougados M, van der Heijde D (editors), Health Press Limited, Oxford, 2004; 57-64
21. van der Heijde D. Assessment. In: Fast Facts - Ankylosing Spondylitis. Dougados M, van der Heijde D (editors), Health Press Limited, Oxford, 2004; 46-56
20. Boonen A, van der Heijde D. Epidemiology and socioeconomic impact. In: Fast Facts - Ankylosing Spondylitis. Dougados M, van der Heijde D (editors), Health Press Limited, Oxford, 2004; 24-31
19. van der Heijde DM, Landewé RB, Woolf AD How to assess musculoskeletal conditions. Best Pract Res Clin Rheumatol 2003;17(3)
18. van der Linden S, Heijde D van der. Classification of spondyloarthropathies. In: Rheumatology, 3rd Edition, Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds), Volume two, 2003;1149-52
17. van der Heijde D. Klinimetrie. In: Paramedische zorg bij reumatische aandoeningen. Munneke M and Verhoef J (eds). Elsevier Gezondheidszorg, 2003:pp 97-109
16. van der Heijde D, Bollow M, Braun J, Bildgebund bei Spondylitis ankylosans. In: Spondylitis ankylosans. Braun J, Sieper J (eds). Uni-Med Verlag Bremen, 2002:pp 117-25
15. van der Heijde D, van der Linden Sj, Khan MA, Sieper J, Braun J,. Stadieneinteilung der Spondylitis ankylosans. In: Spondylitis ankylosans. Braun J, Sieper J (eds). Uni-Med Verlag Bremen, 2002:pp110-7
14. van der Heijde D, Braun J. Standardmessmethoden. In: Spondylitis ankylosans. Braun J, Sieper J (eds). Uni-Med Verlag Bremen, 2002:pp 27-35
13. van der Linden Sj, van der Heijde D. Spondyloarthropathies. Ankylosing Spondylitis. In: Kelley's Textbook of Rheumatology, Sixth Edition. Ruddy S, Harris ED, Sledge CB(eds), Budd RC, Sargent JS (associate eds). WB Saunders Company, 2000;pp1039-53
12. van der Heijde D. Klinimetrie van reumatische aandoeningen. In: Fysiotherapie bij reumatische aandoeningen. Pelt R (ed) Elsevier, Bunge, 2000 (in press)
11. Gorter S, Rethans J-J, van der Heijde D, Scherpbier A, Houben H, van der Vleuten C, van der Linden S. Preparing a standardized patient project to assess daily clinical practice of rheumatologists. Full paper. Proceedings Ottawa conference on medical education and assessment: "Evolving Assessment: protecting the human dimension". 1998, Philadelphia, USA.
10. van der Linden Sj, van der Heijde D. Ankylosing spondylitis. Clinical features. In: Clinics of North America. Yu D (ed). WB Saunders Company, Philadelphia, 1998;24:663-76

9. van der Linden Sj, van der Heijde D (eds). Socio-economic evaluation in rheumatology. Rheumatology in Europe 1998;27:4-17

8. van der Linden Sj, van der Heijde D. Socio-economic evaluation in rheumatology: an introduction. Rheumatology in Europe 1998;27:4 (editorial)

7. van der Linden Sj, van der Heijde DMFM. Reumatologie. In: Het medisch jaar 1998. Van Es JC, Keeman JN, de Leeuw PW & Verstraete (eds). Bohn Stafleu van Loghum, Houten, 1998:78-90

6. van der Heijde D, van de Putte L. Neuropathic arthropathy in diabetes. In: Rheumatology, second edition. Klippel JH & Dieppe PA (eds). Mosby-Wolfe, London, 1997, 8.33.2-8.33.3

5. van der Heijde DMFM. Radiographs as an outcome measure in rheumatoid arthritis. Rheumatology in Europe 1995;24(suppl 2):127-8

4. Scott DL, van Riel P, van der Heijde D, Studnicka Benke A. Assessing disease activity in rheumatoid arthritis. The EULAR handbook of standard methods.

3. van der Heijde D, van de Putte L. Neuropathic arthropathy in diabetes. In: Rheumatology. Klippel JH & Dieppe PA (eds). Mosby-Wolfe, London, 1994, 7.23.2-7.23.3

2. van de Putte LBA, van Riel PLCM, Boerbooms AMTh, van der Heijde DMFM, Jeurissen MEC. DMARDs: do they retard progression of radiological joint damage in rheumatoid arthritis? Eular Publishers, 1993

1. van de Putte LBA, van der Heijde DMFM, van Riel PLCM. Sulfasalazin Behandlung und radiologische Gelenkschädigung bei Polyarthritits. In: Wagenhäuser FJ, ed. Salazopyrin EN Standortbestimmung und Ausblick. Eular Publishers, 1992

5. Scientific Dutch full-length papers

18. van Gaalen F, van den Berg R, de Hooge M, van der Heijde DMFM. Vroege herkenning van axiale spondyloarthritis met behulp van MRI: het SPACE-project. Ned Tijdschr Reumatol 2012;3:37-40

17. Landewé RBM, van der Heijde DMFM. Het herkennen van patienten met spondyloarthritis. Nieuwe classificatiecriteria. Ned Tijdschr Geneesk 2011;155:1365-70

16. van den Berg R, van der Heijde DMFM. Vroegdiagnostiek en behandeling inflammatoire rugpijn. Modern Medicine 2010;34:329-32

15. Visser K, van der Heijde DMFM, Dijkmans BAC, van den Hoogen FHJ, Jacobs, JWG, Jansen TLThA, Stolk JN, van der Veen MJ, Bijlsma JWJ. Multinationale evidence-based aanbevelingen voor het gebruik van methotrexaat voor reumatische aandoeningen. Resultaten van het 3E-initiatief. Ned Tijds Reumatol 2008;4:15-22

14. Drent M, Grutters J.C, Jansen T.L. Th. A, van der Heijde D. Sarcoïdose: ontwikkelingen in de medicamenteuze behandeling. Nederlands Tijdschrift voor Allergie 2007;3:88-96

13. van Tubergen A, van der Heijde D. Scoringsmethoden voor radiologische afwijkingen bij ankyloserende spondylitis. Ned Tijds Reumatol 2005;2:15-19

12. van der Heijde DMFM. Aan welke eisen moet een meetinstrument voldoen om bruikbaar te zijn in de klinische praktijk?
Revalidata 2003;114:19-21
11. Schulpen GJ, Vierhout WP, van der Heijde DM, Landewé RB, van der Linden S, Winkens RA. The value of joint general practitioner and rheumatologist consultations in primary care patients]
Ned Tijdschr Geneesk. 2003 Mar 8;147(10):447-50
10. van der Heijde DMFM. Cardiovasculaire eindpunten in vergelijkende trials met rofecoxib: critical appraisal van de studie van Konstam et al.
Ned Tijds Reumatol 2002;3 bijlage:14-5
9. Flikweert S, van der Heijde DMFM, Wiersma Tj, Bohnen AM, van den Bosch WJHM, Hissink Muller W, Kruize AA, Lagro HAHM, van der Veen MJ, Zanen S. Landelijke Transmurale Afspraak Reumatoïde artritis.
Ned Tijds Reumatol 2002;3:7-13
8. Flikweert S, van der Heijde DMFM, Wiersma Tj, Bohnen AM, van den Bosch WJHM, Hissink Muller W, Kruize AA, Lagro HAHM, van der Veen MJ, Zanen S. Landelijke Transmurale Afspraak Reumatoïde artritis.
Huisarts en Wetenschap 2002;45:544-7
7. Landewé R, van der Heijde D. Een doorbraak voor Bechterew-patiënten. Infliximab opent indrukwekkende behandelperspectieven.
Medisch Contact 2002;57:1187-90
6. van der Heijde DMFM, Boers M. De waarde van röntgenfoto's bij reumatoïde artritis.
Ned Tijdschr Gen 1997;141:1725-9
5. van der Heijde DMFM: Reumatoïde artritis.
Ned Tijdschr Tandheelkd 1992;7:52-4
4. van der Heijde DMFM. Prognose van reumatoïde artritis.
Tijdschrift v Huisarts Geneeskunde 1992;9:901-3
3. van der Heijde DMFM. Antistolling en de tandheelkundige praktijk.
Ned Tijdschr Tandheelkd 1991;98:350-2
2. van der Heijde DMFM, Elving L. Diabetes mellitus. Inzichten in de behandeling anno 1990.
Ned Tijdschr Tandheelkd 1991;98:98100
1. van der Heijde D, van Riel P, Oosterhof J, Fillekens A. Koude lucht en ijstherapie. Een prospectief vergelijkend onderzoek bij patiënten met reumatoïde arthritis.
Ned T Fysiotherapie 1989;99:402

6. Editor

5. Ankylosing Spondylitis and the Spondyloarthropathies. Weisman MH, Reveille JD, van der Heijde D. (editors)
Mosby Elsevier 2006 Philadelphia.
4. Spondyloarthropathies. Braun J, van der Heijde D (editors).
Best Practice Clinical Rheumatology 2006;20(3)
3. Feldtkeller E, van der Heijde D. (editors). Morbus Bechterew Messwerte für den Krankheitsverlauf Klassifikations- und Diagnose-Kriterien. Schriftenreihe der Deutschen Vereinigung Morbus Bechterew e.V, Heft 13, Schweinfurt, 2005.

2. Fast Facts - Ankylosing Spondylitis. Dougados M, van der Heijde D (editors), Health Press Limited, Oxford, 2004

1. Innovative therapies for the spondyloarthritides. Braun J, van der Heijde D, Pincus T (eds) Clinical and Experimental Rheumatology 2002; 20: Supplement 28; pp1-187